id	sid	tid	token	lemma	pos
ecj-11349	1	1	hrev_master	hrev_master	NOUN
ecj-11349	2	1	[	[	NOUN
ecj-11349	2	2	page	page	NOUN
ecj-11349	2	3	88	88	NUM
ecj-11349	2	4	]	]	PUNCT
ecj-11349	3	1	[	[	X
ecj-11349	3	2	emergency	emergency	NOUN
ecj-11349	3	3	care	care	NOUN
ecj-11349	3	4	journal	journal	NOUN
ecj-11349	3	5	2023	2023	NUM
ecj-11349	3	6	;	;	PUNCT
ecj-11349	3	7	19:11349	19:11349	NUM
ecj-11349	3	8	]	]	X
ecj-11349	3	9	emergency	emergency	NOUN
ecj-11349	3	10	care	care	NOUN
ecj-11349	3	11	journal	journal	PROPN
ecj-11349	3	12	2023	2023	NUM
ecj-11349	3	13	;	;	PUNCT
ecj-11349	3	14	volume	volume	NOUN
ecj-11349	3	15	19:11349	19:11349	NUM
ecj-11349	3	16	abstract	abstract	ADJ
ecj-11349	3	17	gastrointestinal	gastrointestinal	ADJ
ecj-11349	3	18	bleedings	bleeding	NOUN
ecj-11349	3	19	are	be	AUX
ecj-11349	3	20	relevant	relevant	ADJ
ecj-11349	3	21	side	side	NOUN
ecj-11349	3	22	effects	effect	NOUN
ecj-11349	3	23	in	in	ADP
ecj-11349	3	24	patients	patient	NOUN
ecj-11349	3	25	during	during	ADP
ecj-11349	3	26	anticoagulant	anticoagulant	NOUN
ecj-11349	3	27	therapy	therapy	NOUN
ecj-11349	3	28	for	for	ADP
ecj-11349	3	29	atrial	atrial	ADJ
ecj-11349	3	30	fibrillation	fibrillation	NOUN
ecj-11349	3	31	.	.	PUNCT
ecj-11349	4	1	direct	direct	ADJ
ecj-11349	4	2	oral	oral	ADJ
ecj-11349	4	3	anticoagulants	anticoagulant	NOUN
ecj-11349	4	4	(	(	PUNCT
ecj-11349	4	5	doacs	doac	NOUN
ecj-11349	4	6	)	)	PUNCT
ecj-11349	4	7	are	be	AUX
ecj-11349	4	8	less	less	ADV
ecj-11349	4	9	correlated	correlate	VERB
ecj-11349	4	10	with	with	ADP
ecj-11349	4	11	major	major	ADJ
ecj-11349	4	12	bleeding	bleeding	NOUN
ecj-11349	4	13	events	event	NOUN
ecj-11349	4	14	than	than	ADP
ecj-11349	4	15	vitamin	vitamin	NOUN
ecj-11349	4	16	k	k	PROPN
ecj-11349	4	17	antagonists	antagonist	NOUN
ecj-11349	4	18	(	(	PUNCT
ecj-11349	4	19	vkas	vkas	PROPN
ecj-11349	4	20	)	)	PUNCT
ecj-11349	4	21	,	,	PUNCT
ecj-11349	4	22	but	but	CCONJ
ecj-11349	4	23	concerns	concern	NOUN
ecj-11349	4	24	are	be	AUX
ecj-11349	4	25	present	present	ADJ
ecj-11349	4	26	about	about	ADP
ecj-11349	4	27	the	the	DET
ecj-11349	4	28	relative	relative	ADJ
ecj-11349	4	29	risk	risk	NOUN
ecj-11349	4	30	of	of	ADP
ecj-11349	4	31	gastrointestinal	gastrointestinal	ADJ
ecj-11349	4	32	bleeding	bleeding	NOUN
ecj-11349	4	33	.	.	PUNCT
ecj-11349	5	1	here	here	ADV
ecj-11349	5	2	we	we	PRON
ecj-11349	5	3	report	report	VERB
ecj-11349	5	4	the	the	DET
ecj-11349	5	5	case	case	NOUN
ecj-11349	5	6	of	of	ADP
ecj-11349	5	7	a	a	DET
ecj-11349	5	8	patient	patient	NOUN
ecj-11349	5	9	with	with	ADP
ecj-11349	5	10	atrial	atrial	ADJ
ecj-11349	5	11	fibrillation	fibrillation	NOUN
ecj-11349	5	12	and	and	CCONJ
ecj-11349	5	13	dementia	dementia	NOUN
ecj-11349	5	14	on	on	ADP
ecj-11349	5	15	doac	doac	ADJ
ecj-11349	5	16	treatment	treatment	NOUN
ecj-11349	5	17	who	who	PRON
ecj-11349	5	18	developed	develop	VERB
ecj-11349	5	19	a	a	DET
ecj-11349	5	20	ssri	ssri	ADV
ecj-11349	5	21	-	-	PUNCT
ecj-11349	5	22	associated	associate	VERB
ecj-11349	5	23	thrombocytopenia	thrombocytopenia	NOUN
ecj-11349	5	24	with	with	ADP
ecj-11349	5	25	subsequent	subsequent	ADJ
ecj-11349	5	26	life	life	NOUN
ecj-11349	5	27	-	-	PUNCT
ecj-11349	5	28	threatening	threaten	VERB
ecj-11349	5	29	bleeding	bleeding	NOUN
ecj-11349	5	30	.	.	PUNCT
ecj-11349	6	1	physicians	physician	NOUN
ecj-11349	6	2	should	should	AUX
ecj-11349	6	3	be	be	AUX
ecj-11349	6	4	aware	aware	ADJ
ecj-11349	6	5	of	of	ADP
ecj-11349	6	6	the	the	DET
ecj-11349	6	7	possible	possible	ADJ
ecj-11349	6	8	correlation	correlation	NOUN
ecj-11349	6	9	between	between	ADP
ecj-11349	6	10	ssri	ssri	PROPN
ecj-11349	6	11	-	-	PUNCT
ecj-11349	6	12	induced	induce	VERB
ecj-11349	6	13	thrombocytopenia	thrombocytopenia	NOUN
ecj-11349	6	14	and	and	CCONJ
ecj-11349	6	15	concomitant	concomitant	ADJ
ecj-11349	6	16	use	use	NOUN
ecj-11349	6	17	of	of	ADP
ecj-11349	6	18	anticoagulant	anticoagulant	NOUN
ecj-11349	6	19	and/or	and/or	CCONJ
ecj-11349	6	20	antiplatelet	antiplatelet	VERB
ecj-11349	6	21	drugs	drug	NOUN
ecj-11349	6	22	,	,	PUNCT
ecj-11349	6	23	thus	thus	ADV
ecj-11349	6	24	preventing	prevent	VERB
ecj-11349	6	25	life	life	NOUN
ecj-11349	6	26	-	-	PUNCT
ecj-11349	6	27	threatening	threaten	VERB
ecj-11349	6	28	bleedings	bleeding	NOUN
ecj-11349	6	29	.	.	PUNCT
ecj-11349	7	1	introduction	introduction	NOUN
ecj-11349	7	2	some	some	DET
ecj-11349	7	3	data	datum	NOUN
ecj-11349	7	4	in	in	ADP
ecj-11349	7	5	literature	literature	NOUN
ecj-11349	7	6	reported	report	VERB
ecj-11349	7	7	that	that	SCONJ
ecj-11349	7	8	the	the	DET
ecj-11349	7	9	use	use	NOUN
ecj-11349	7	10	of	of	ADP
ecj-11349	7	11	selective	selective	ADJ
ecj-11349	7	12	serotonin	serotonin	NOUN
ecj-11349	7	13	reuptake	reuptake	NOUN
ecj-11349	7	14	inhibitors	inhibitor	NOUN
ecj-11349	7	15	(	(	PUNCT
ecj-11349	7	16	ssris	ssris	NOUN
ecj-11349	7	17	)	)	PUNCT
ecj-11349	7	18	can	can	AUX
ecj-11349	7	19	be	be	AUX
ecj-11349	7	20	related	relate	VERB
ecj-11349	7	21	to	to	ADP
ecj-11349	7	22	an	an	DET
ecj-11349	7	23	increase	increase	NOUN
ecj-11349	7	24	risk	risk	NOUN
ecj-11349	7	25	of	of	ADP
ecj-11349	7	26	bleeding.1,2	bleeding.1,2	ADJ
ecj-11349	7	27	bleedings	bleeding	NOUN
ecj-11349	7	28	correlated	correlate	VERB
ecj-11349	7	29	with	with	ADP
ecj-11349	7	30	ssri	ssri	ADJ
ecj-11349	7	31	use	use	NOUN
ecj-11349	7	32	have	have	AUX
ecj-11349	7	33	been	be	AUX
ecj-11349	7	34	showed	show	VERB
ecj-11349	7	35	to	to	PART
ecj-11349	7	36	occur	occur	VERB
ecj-11349	7	37	mostly	mostly	ADV
ecj-11349	7	38	in	in	ADP
ecj-11349	7	39	the	the	DET
ecj-11349	7	40	upper	upper	ADJ
ecj-11349	7	41	gastrointestinal	gastrointestinal	ADJ
ecj-11349	7	42	tract	tract	NOUN
ecj-11349	8	1	and	and	CCONJ
ecj-11349	8	2	then	then	ADV
ecj-11349	8	3	intracranially.3	intracranially.3	PROPN
ecj-11349	8	4	patients	patient	NOUN
ecj-11349	8	5	taking	take	VERB
ecj-11349	8	6	those	those	DET
ecj-11349	8	7	drugs	drug	NOUN
ecj-11349	8	8	suffering	suffer	VERB
ecj-11349	8	9	from	from	ADP
ecj-11349	8	10	depression	depression	NOUN
ecj-11349	8	11	often	often	ADV
ecj-11349	8	12	display	display	VERB
ecj-11349	8	13	comorbidities	comorbiditie	NOUN
ecj-11349	8	14	needing	need	VERB
ecj-11349	8	15	the	the	DET
ecj-11349	8	16	use	use	NOUN
ecj-11349	8	17	of	of	ADP
ecj-11349	8	18	antithrombotic	antithrombotic	ADJ
ecj-11349	8	19	drugs	drug	NOUN
ecj-11349	8	20	.	.	PUNCT
ecj-11349	9	1	indeed	indeed	ADV
ecj-11349	9	2	,	,	PUNCT
ecj-11349	9	3	patients	patient	NOUN
ecj-11349	9	4	affected	affect	VERB
ecj-11349	9	5	by	by	ADP
ecj-11349	9	6	atrial	atrial	ADJ
ecj-11349	9	7	fibrillation	fibrillation	NOUN
ecj-11349	9	8	(	(	PUNCT
ecj-11349	9	9	af	af	NOUN
ecj-11349	9	10	)	)	PUNCT
ecj-11349	9	11	display	display	VERB
ecj-11349	9	12	a	a	DET
ecj-11349	9	13	higher	high	ADJ
ecj-11349	9	14	incidence	incidence	NOUN
ecj-11349	9	15	of	of	ADP
ecj-11349	9	16	affective	affective	ADJ
ecj-11349	9	17	disorders	disorder	NOUN
ecj-11349	9	18	,	,	PUNCT
ecj-11349	9	19	and	and	CCONJ
ecj-11349	9	20	antidepressant	antidepressant	ADJ
ecj-11349	9	21	use	use	NOUN
ecj-11349	9	22	are	be	AUX
ecj-11349	9	23	correlated	correlate	VERB
ecj-11349	9	24	with	with	ADP
ecj-11349	9	25	a	a	DET
ecj-11349	9	26	34	34	NUM
ecj-11349	9	27	%	%	NOUN
ecj-11349	9	28	and	and	CCONJ
ecj-11349	9	29	36	36	NUM
ecj-11349	9	30	%	%	NOUN
ecj-11349	9	31	higher	high	ADJ
ecj-11349	9	32	risk	risk	NOUN
ecj-11349	9	33	of	of	ADP
ecj-11349	9	34	af.4,5	af.4,5	NOUN
ecj-11349	9	35	here	here	ADV
ecj-11349	9	36	we	we	PRON
ecj-11349	9	37	report	report	VERB
ecj-11349	9	38	the	the	DET
ecj-11349	9	39	case	case	NOUN
ecj-11349	9	40	of	of	ADP
ecj-11349	9	41	a	a	DET
ecj-11349	9	42	life	life	NOUN
ecj-11349	9	43	-	-	PUNCT
ecj-11349	9	44	threatening	threaten	VERB
ecj-11349	9	45	gastrointestinal	gastrointestinal	ADJ
ecj-11349	9	46	bleeding	bleeding	NOUN
ecj-11349	9	47	linked	link	VERB
ecj-11349	9	48	to	to	ADP
ecj-11349	9	49	escitalopram	escitalopram	PROPN
ecj-11349	9	50	therapy	therapy	NOUN
ecj-11349	9	51	in	in	ADP
ecj-11349	9	52	the	the	DET
ecj-11349	9	53	setting	setting	NOUN
ecj-11349	9	54	of	of	ADP
ecj-11349	9	55	direct	direct	ADJ
ecj-11349	9	56	oral	oral	ADJ
ecj-11349	9	57	anticoagulant	anticoagulant	NOUN
ecj-11349	9	58	(	(	PUNCT
ecj-11349	9	59	doac	doac	ADJ
ecj-11349	9	60	)	)	PUNCT
ecj-11349	9	61	ongoing	ongoing	ADJ
ecj-11349	9	62	treatment	treatment	NOUN
ecj-11349	9	63	.	.	PUNCT
ecj-11349	10	1	case	case	NOUN
ecj-11349	10	2	report	report	VERB
ecj-11349	10	3	a	a	DET
ecj-11349	10	4	84	84	NUM
ecj-11349	10	5	-	-	PUNCT
ecj-11349	10	6	year	year	NOUN
ecj-11349	10	7	-	-	PUNCT
ecj-11349	10	8	old	old	ADJ
ecj-11349	10	9	caucasian	caucasian	ADJ
ecj-11349	10	10	man	man	NOUN
ecj-11349	10	11	was	be	AUX
ecj-11349	10	12	referred	refer	VERB
ecj-11349	10	13	to	to	ADP
ecj-11349	10	14	our	our	PRON
ecj-11349	10	15	ward	ward	NOUN
ecj-11349	10	16	for	for	ADP
ecj-11349	10	17	melena	melena	NOUN
ecj-11349	10	18	,	,	PUNCT
ecj-11349	10	19	loss	loss	NOUN
ecj-11349	10	20	of	of	ADP
ecj-11349	10	21	fluids	fluid	NOUN
ecj-11349	10	22	and	and	CCONJ
ecj-11349	10	23	worsening	worsening	NOUN
ecj-11349	10	24	of	of	ADP
ecj-11349	10	25	general	general	ADJ
ecj-11349	10	26	conditions	condition	NOUN
ecj-11349	10	27	.	.	PUNCT
ecj-11349	11	1	his	his	PRON
ecj-11349	11	2	past	past	ADJ
ecj-11349	11	3	medical	medical	ADJ
ecj-11349	11	4	history	history	NOUN
ecj-11349	11	5	was	be	AUX
ecj-11349	11	6	characterized	characterize	VERB
ecj-11349	11	7	by	by	ADP
ecj-11349	11	8	severe	severe	ADJ
ecj-11349	11	9	cognitive	cognitive	ADJ
ecj-11349	11	10	impairment	impairment	NOUN
ecj-11349	11	11	due	due	ADP
ecj-11349	11	12	to	to	ADP
ecj-11349	11	13	alzheimer	alzheimer	PROPN
ecj-11349	11	14	’s	’s	PART
ecj-11349	11	15	disease	disease	NOUN
ecj-11349	11	16	,	,	PUNCT
ecj-11349	11	17	permanent	permanent	ADJ
ecj-11349	11	18	atrial	atrial	ADJ
ecj-11349	11	19	fibrillation	fibrillation	NOUN
ecj-11349	11	20	on	on	ADP
ecj-11349	11	21	doac	doac	ADJ
ecj-11349	11	22	therapy	therapy	NOUN
ecj-11349	11	23	and	and	CCONJ
ecj-11349	11	24	benign	benign	ADJ
ecj-11349	11	25	prostatic	prostatic	ADJ
ecj-11349	11	26	hypertrophy	hypertrophy	NOUN
ecj-11349	11	27	.	.	PUNCT
ecj-11349	12	1	the	the	DET
ecj-11349	12	2	patient	patient	NOUN
ecj-11349	12	3	was	be	AUX
ecj-11349	12	4	taking	take	VERB
ecj-11349	12	5	home	home	NOUN
ecj-11349	12	6	therapy	therapy	NOUN
ecj-11349	12	7	with	with	ADP
ecj-11349	12	8	escitalopram	escitalopram	PROPN
ecj-11349	12	9	,	,	PUNCT
ecj-11349	12	10	apixaban	apixaban	ADJ
ecj-11349	12	11	5	5	NUM
ecj-11349	12	12	mg	mg	NUM
ecj-11349	12	13	1	1	NUM
ecj-11349	12	14	tablet	tablet	NOUN
ecj-11349	12	15	twice	twice	DET
ecj-11349	12	16	a	a	DET
ecj-11349	12	17	day	day	NOUN
ecj-11349	12	18	and	and	CCONJ
ecj-11349	12	19	alfuzosin	alfuzosin	NOUN
ecj-11349	12	20	.	.	PUNCT
ecj-11349	13	1	peripheral	peripheral	ADJ
ecj-11349	13	2	heart	heart	NOUN
ecj-11349	13	3	rate	rate	NOUN
ecj-11349	13	4	was	be	AUX
ecj-11349	13	5	82	82	NUM
ecj-11349	13	6	beats	beat	NOUN
ecj-11349	13	7	per	per	ADP
ecj-11349	13	8	minute	minute	NOUN
ecj-11349	13	9	(	(	PUNCT
ecj-11349	13	10	bpm	bpm	NOUN
ecj-11349	13	11	)	)	PUNCT
ecj-11349	13	12	,	,	PUNCT
ecj-11349	13	13	while	while	SCONJ
ecj-11349	13	14	central	central	ADJ
ecj-11349	13	15	heart	heart	NOUN
ecj-11349	13	16	rate	rate	NOUN
ecj-11349	13	17	was	be	AUX
ecj-11349	13	18	76	76	NUM
ecj-11349	13	19	bpm	bpm	NOUN
ecj-11349	13	20	and	and	CCONJ
ecj-11349	13	21	blood	blood	NOUN
ecj-11349	13	22	pressure	pressure	NOUN
ecj-11349	13	23	110/70	110/70	NUM
ecj-11349	13	24	mmhg	mmhg	NOUN
ecj-11349	13	25	.	.	PUNCT
ecj-11349	14	1	his	his	PRON
ecj-11349	14	2	electrocardiogram	electrocardiogram	NOUN
ecj-11349	14	3	showed	show	VERB
ecj-11349	14	4	atrial	atrial	ADJ
ecj-11349	14	5	fibrillacorrespondence	fibrillacorrespondence	NOUN
ecj-11349	14	6	:	:	PUNCT
ecj-11349	14	7	andrea	andrea	PROPN
ecj-11349	14	8	boccatonda	boccatonda	PROPN
ecj-11349	14	9	,	,	PUNCT
ecj-11349	14	10	bentivoglio	bentivoglio	PROPN
ecj-11349	14	11	hospital	hospital	NOUN
ecj-11349	14	12	,	,	PUNCT
ecj-11349	14	13	via	via	ADP
ecj-11349	14	14	marconi	marconi	NOUN
ecj-11349	14	15	35	35	NUM
ecj-11349	14	16	,	,	PUNCT
ecj-11349	14	17	40010	40010	NUM
ecj-11349	14	18	,	,	PUNCT
ecj-11349	14	19	bologna	bologna	PROPN
ecj-11349	14	20	,	,	PUNCT
ecj-11349	14	21	italy	italy	PROPN
ecj-11349	14	22	.	.	PUNCT
ecj-11349	15	1	tel	tel	PROPN
ecj-11349	15	2	.	.	PUNCT
ecj-11349	15	3	:	:	PUNCT
ecj-11349	16	1	+39.051.664459	+39.051.664459	NOUN
ecj-11349	16	2	-	-	PUNCT
ecj-11349	16	3	fax	fax	NOUN
ecj-11349	16	4	:	:	PUNCT
ecj-11349	16	5	+39.051.6644361	+39.051.6644361	NUM
ecj-11349	16	6	e	e	NOUN
ecj-11349	16	7	-	-	NOUN
ecj-11349	16	8	mail	mail	NOUN
ecj-11349	16	9	:	:	PUNCT
ecj-11349	16	10	andrea.boccatonda@ausl.bo.it	andrea.boccatonda@ausl.bo.it	NUM
ecj-11349	16	11	key	key	ADJ
ecj-11349	16	12	words	word	NOUN
ecj-11349	16	13	:	:	PUNCT
ecj-11349	16	14	ssri	ssri	ADJ
ecj-11349	16	15	;	;	PUNCT
ecj-11349	16	16	bleeding	bleed	VERB
ecj-11349	16	17	;	;	PUNCT
ecj-11349	16	18	platelet	platelet	NOUN
ecj-11349	16	19	;	;	PUNCT
ecj-11349	16	20	thrombocytopenia	thrombocytopenia	PROPN
ecj-11349	16	21	.	.	PUNCT
ecj-11349	17	1	contributions	contribution	NOUN
ecj-11349	17	2	:	:	PUNCT
ecj-11349	17	3	ab	ab	PROPN
ecj-11349	17	4	and	and	CCONJ
ecj-11349	17	5	dd	dd	VERB
ecj-11349	17	6	writing	writing	NOUN
ecj-11349	17	7	and	and	CCONJ
ecj-11349	17	8	conceptualization	conceptualization	NOUN
ecj-11349	17	9	;	;	PUNCT
ecj-11349	17	10	mtg	mtg	NOUN
ecj-11349	17	11	supervision	supervision	NOUN
ecj-11349	17	12	;	;	PUNCT
ecj-11349	17	13	fc	fc	PROPN
ecj-11349	17	14	and	and	CCONJ
ecj-11349	17	15	fs	fs	ADP
ecj-11349	17	16	expert	expert	NOUN
ecj-11349	17	17	opinion	opinion	NOUN
ecj-11349	17	18	.	.	PUNCT
ecj-11349	18	1	conflict	conflict	NOUN
ecj-11349	18	2	of	of	ADP
ecj-11349	18	3	interest	interest	NOUN
ecj-11349	18	4	:	:	PUNCT
ecj-11349	18	5	the	the	DET
ecj-11349	18	6	authors	author	NOUN
ecj-11349	18	7	declare	declare	VERB
ecj-11349	18	8	no	no	DET
ecj-11349	18	9	potential	potential	ADJ
ecj-11349	18	10	conflict	conflict	NOUN
ecj-11349	18	11	of	of	ADP
ecj-11349	18	12	interest	interest	NOUN
ecj-11349	18	13	,	,	PUNCT
ecj-11349	18	14	and	and	CCONJ
ecj-11349	18	15	all	all	DET
ecj-11349	18	16	authors	author	NOUN
ecj-11349	18	17	confirm	confirm	VERB
ecj-11349	18	18	accuracy	accuracy	NOUN
ecj-11349	18	19	.	.	PUNCT
ecj-11349	19	1	ethics	ethic	NOUN
ecj-11349	19	2	approval	approval	NOUN
ecj-11349	19	3	and	and	CCONJ
ecj-11349	19	4	consent	consent	NOUN
ecj-11349	19	5	to	to	PART
ecj-11349	19	6	participate	participate	VERB
ecj-11349	19	7	:	:	PUNCT
ecj-11349	19	8	no	no	DET
ecj-11349	19	9	ethical	ethical	ADJ
ecj-11349	19	10	committee	committee	NOUN
ecj-11349	19	11	approval	approval	NOUN
ecj-11349	19	12	was	be	AUX
ecj-11349	19	13	required	require	VERB
ecj-11349	19	14	for	for	ADP
ecj-11349	19	15	this	this	DET
ecj-11349	19	16	case	case	NOUN
ecj-11349	19	17	report	report	NOUN
ecj-11349	19	18	by	by	ADP
ecj-11349	19	19	the	the	DET
ecj-11349	19	20	department	department	NOUN
ecj-11349	19	21	,	,	PUNCT
ecj-11349	19	22	because	because	SCONJ
ecj-11349	19	23	this	this	DET
ecj-11349	19	24	article	article	NOUN
ecj-11349	19	25	does	do	AUX
ecj-11349	19	26	not	not	PART
ecj-11349	19	27	contain	contain	VERB
ecj-11349	19	28	any	any	DET
ecj-11349	19	29	studies	study	NOUN
ecj-11349	19	30	with	with	ADP
ecj-11349	19	31	human	human	ADJ
ecj-11349	19	32	participants	participant	NOUN
ecj-11349	19	33	or	or	CCONJ
ecj-11349	19	34	animals	animal	NOUN
ecj-11349	19	35	.	.	PUNCT
ecj-11349	20	1	informed	inform	VERB
ecj-11349	20	2	consent	consent	NOUN
ecj-11349	20	3	was	be	AUX
ecj-11349	20	4	obtained	obtain	VERB
ecj-11349	20	5	from	from	ADP
ecj-11349	20	6	the	the	DET
ecj-11349	20	7	patient	patient	NOUN
ecj-11349	20	8	included	include	VERB
ecj-11349	20	9	in	in	ADP
ecj-11349	20	10	this	this	DET
ecj-11349	20	11	study	study	NOUN
ecj-11349	20	12	.	.	PUNCT
ecj-11349	21	1	patient	patient	ADJ
ecj-11349	21	2	consent	consent	NOUN
ecj-11349	21	3	for	for	ADP
ecj-11349	21	4	publication	publication	NOUN
ecj-11349	21	5	:	:	PUNCT
ecj-11349	21	6	the	the	DET
ecj-11349	21	7	patient	patient	NOUN
ecj-11349	21	8	gave	give	VERB
ecj-11349	21	9	his	his	PRON
ecj-11349	21	10	written	write	VERB
ecj-11349	21	11	consent	consent	NOUN
ecj-11349	21	12	to	to	PART
ecj-11349	21	13	use	use	VERB
ecj-11349	21	14	his	his	PRON
ecj-11349	21	15	personal	personal	ADJ
ecj-11349	21	16	data	datum	NOUN
ecj-11349	21	17	for	for	ADP
ecj-11349	21	18	the	the	DET
ecj-11349	21	19	publication	publication	NOUN
ecj-11349	21	20	of	of	ADP
ecj-11349	21	21	this	this	DET
ecj-11349	21	22	case	case	NOUN
ecj-11349	21	23	report	report	NOUN
ecj-11349	21	24	and	and	CCONJ
ecj-11349	21	25	any	any	DET
ecj-11349	21	26	accompanying	accompanying	ADJ
ecj-11349	21	27	images	image	NOUN
ecj-11349	21	28	.	.	PUNCT
ecj-11349	22	1	availability	availability	NOUN
ecj-11349	22	2	of	of	ADP
ecj-11349	22	3	data	datum	NOUN
ecj-11349	22	4	and	and	CCONJ
ecj-11349	22	5	materials	material	NOUN
ecj-11349	22	6	:	:	PUNCT
ecj-11349	22	7	all	all	DET
ecj-11349	22	8	data	datum	NOUN
ecj-11349	22	9	underlying	underlie	VERB
ecj-11349	22	10	the	the	DET
ecj-11349	22	11	findings	finding	NOUN
ecj-11349	22	12	are	be	AUX
ecj-11349	22	13	fully	fully	ADV
ecj-11349	22	14	available	available	ADJ
ecj-11349	22	15	.	.	PUNCT
ecj-11349	23	1	received	receive	VERB
ecj-11349	23	2	:	:	PUNCT
ecj-11349	23	3	1	1	NUM
ecj-11349	23	4	april	april	PROPN
ecj-11349	23	5	2023	2023	NUM
ecj-11349	23	6	.	.	PUNCT
ecj-11349	24	1	accepted	accept	VERB
ecj-11349	24	2	:	:	PUNCT
ecj-11349	24	3	27	27	NUM
ecj-11349	24	4	july	july	PROPN
ecj-11349	24	5	2023	2023	NUM
ecj-11349	24	6	.	.	PUNCT
ecj-11349	25	1	early	early	ADJ
ecj-11349	25	2	view	view	NOUN
ecj-11349	25	3	:	:	PUNCT
ecj-11349	25	4	8	8	NUM
ecj-11349	25	5	august	august	PROPN
ecj-11349	25	6	2023	2023	NUM
ecj-11349	25	7	.	.	PUNCT
ecj-11349	26	1	this	this	DET
ecj-11349	26	2	work	work	NOUN
ecj-11349	26	3	is	be	AUX
ecj-11349	26	4	licensed	license	VERB
ecj-11349	26	5	under	under	ADP
ecj-11349	26	6	a	a	DET
ecj-11349	26	7	creative	creative	ADJ
ecj-11349	26	8	commons	common	NOUN
ecj-11349	26	9	attribution	attribution	NOUN
ecj-11349	26	10	4.0	4.0	NUM
ecj-11349	26	11	license	license	NOUN
ecj-11349	26	12	(	(	PUNCT
ecj-11349	26	13	by	by	ADP
ecj-11349	26	14	-	-	PUNCT
ecj-11349	26	15	nc	nc	PROPN
ecj-11349	26	16	4.0	4.0	NUM
ecj-11349	26	17	)	)	PUNCT
ecj-11349	26	18	.	.	PUNCT
ecj-11349	27	1	©	©	PROPN
ecj-11349	27	2	copyright	copyright	NOUN
ecj-11349	27	3	:	:	PUNCT
ecj-11349	27	4	the	the	DET
ecj-11349	27	5	author(s	author(s	PROPN
ecj-11349	27	6	)	)	PUNCT
ecj-11349	27	7	,	,	PUNCT
ecj-11349	27	8	2023	2023	NUM
ecj-11349	27	9	licensee	licensee	NOUN
ecj-11349	27	10	pagepress	pagepress	NOUN
ecj-11349	27	11	,	,	PUNCT
ecj-11349	27	12	italy	italy	PROPN
ecj-11349	27	13	emergency	emergency	PROPN
ecj-11349	27	14	care	care	PROPN
ecj-11349	27	15	journal	journal	PROPN
ecj-11349	27	16	2023	2023	NUM
ecj-11349	27	17	;	;	PUNCT
ecj-11349	27	18	19:11349	19:11349	NUM
ecj-11349	27	19	doi:10.4081	doi:10.4081	NOUN
ecj-11349	27	20	/	/	SYM
ecj-11349	27	21	ecj.2023.11349	ecj.2023.11349	PROPN
ecj-11349	27	22	publisher	publisher	NOUN
ecj-11349	27	23	's	's	PART
ecj-11349	27	24	note	note	NOUN
ecj-11349	27	25	:	:	PUNCT
ecj-11349	27	26	all	all	DET
ecj-11349	27	27	claims	claim	NOUN
ecj-11349	27	28	expressed	express	VERB
ecj-11349	27	29	in	in	ADP
ecj-11349	27	30	this	this	DET
ecj-11349	27	31	article	article	NOUN
ecj-11349	27	32	are	be	AUX
ecj-11349	27	33	solely	solely	ADV
ecj-11349	27	34	those	those	PRON
ecj-11349	27	35	of	of	ADP
ecj-11349	27	36	the	the	DET
ecj-11349	27	37	authors	author	NOUN
ecj-11349	27	38	and	and	CCONJ
ecj-11349	27	39	do	do	AUX
ecj-11349	27	40	not	not	PART
ecj-11349	27	41	necessarily	necessarily	ADV
ecj-11349	27	42	represent	represent	VERB
ecj-11349	27	43	those	those	PRON
ecj-11349	27	44	of	of	ADP
ecj-11349	27	45	their	their	PRON
ecj-11349	27	46	affiliated	affiliated	ADJ
ecj-11349	27	47	organizations	organization	NOUN
ecj-11349	27	48	,	,	PUNCT
ecj-11349	27	49	or	or	CCONJ
ecj-11349	27	50	those	those	PRON
ecj-11349	27	51	of	of	ADP
ecj-11349	27	52	the	the	DET
ecj-11349	27	53	publisher	publisher	NOUN
ecj-11349	27	54	,	,	PUNCT
ecj-11349	27	55	the	the	DET
ecj-11349	27	56	editors	editor	NOUN
ecj-11349	27	57	and	and	CCONJ
ecj-11349	27	58	the	the	DET
ecj-11349	27	59	reviewers	reviewer	NOUN
ecj-11349	27	60	.	.	PUNCT
ecj-11349	28	1	any	any	DET
ecj-11349	28	2	product	product	NOUN
ecj-11349	28	3	that	that	PRON
ecj-11349	28	4	may	may	AUX
ecj-11349	28	5	be	be	AUX
ecj-11349	28	6	evaluated	evaluate	VERB
ecj-11349	28	7	in	in	ADP
ecj-11349	28	8	this	this	DET
ecj-11349	28	9	article	article	NOUN
ecj-11349	28	10	or	or	CCONJ
ecj-11349	28	11	claim	claim	NOUN
ecj-11349	28	12	that	that	PRON
ecj-11349	28	13	may	may	AUX
ecj-11349	28	14	be	be	AUX
ecj-11349	28	15	made	make	VERB
ecj-11349	28	16	by	by	ADP
ecj-11349	28	17	its	its	PRON
ecj-11349	28	18	manufacturer	manufacturer	NOUN
ecj-11349	28	19	is	be	AUX
ecj-11349	28	20	not	not	PART
ecj-11349	28	21	guaranteed	guarantee	VERB
ecj-11349	28	22	or	or	CCONJ
ecj-11349	28	23	endorsed	endorse	VERB
ecj-11349	28	24	by	by	ADP
ecj-11349	28	25	the	the	DET
ecj-11349	28	26	publisher	publisher	NOUN
ecj-11349	28	27	.	.	PUNCT
ecj-11349	29	1	selective	selective	ADJ
ecj-11349	29	2	serotonin	serotonin	NOUN
ecj-11349	29	3	reuptake	reuptake	NOUN
ecj-11349	29	4	inhibitors	inhibitor	NOUN
ecj-11349	29	5	related	relate	VERB
ecj-11349	29	6	bleeding	bleeding	NOUN
ecj-11349	29	7	risk	risk	NOUN
ecj-11349	29	8	:	:	PUNCT
ecj-11349	29	9	case	case	NOUN
ecj-11349	29	10	report	report	NOUN
ecj-11349	29	11	and	and	CCONJ
ecj-11349	29	12	review	review	NOUN
ecj-11349	29	13	of	of	ADP
ecj-11349	29	14	literature	literature	PROPN
ecj-11349	29	15	andrea	andrea	PROPN
ecj-11349	29	16	boccatonda,1	boccatonda,1	PROPN
ecj-11349	29	17	damiano	damiano	PROPN
ecj-11349	29	18	d’ardes,2	d’ardes,2	PROPN
ecj-11349	29	19	maria	maria	PROPN
ecj-11349	29	20	teresa	teresa	PROPN
ecj-11349	29	21	guagnano,2	guagnano,2	PROPN
ecj-11349	29	22	francesco	francesco	PROPN
ecj-11349	29	23	cipollone	cipollone	NOUN
ecj-11349	29	24	,	,	PUNCT
ecj-11349	29	25	2	2	NUM
ecj-11349	29	26	francesca	francesca	NOUN
ecj-11349	29	27	santilli	santilli	VERB
ecj-11349	29	28	2	2	NUM
ecj-11349	29	29	1internal	1internal	NUM
ecj-11349	29	30	medicine	medicine	NOUN
ecj-11349	29	31	,	,	PUNCT
ecj-11349	29	32	bentivoglio	bentivoglio	PROPN
ecj-11349	29	33	hospital	hospital	PROPN
ecj-11349	29	34	,	,	PUNCT
ecj-11349	29	35	ausl	ausl	PROPN
ecj-11349	29	36	bologna	bologna	PROPN
ecj-11349	29	37	,	,	PUNCT
ecj-11349	29	38	bentivoglio	bentivoglio	PROPN
ecj-11349	29	39	(	(	PUNCT
ecj-11349	29	40	bo	bo	PROPN
ecj-11349	29	41	)	)	PUNCT
ecj-11349	29	42	;	;	PUNCT
ecj-11349	30	1	2department	2department	NUM
ecj-11349	30	2	of	of	ADP
ecj-11349	30	3	medicine	medicine	NOUN
ecj-11349	30	4	and	and	CCONJ
ecj-11349	30	5	aging	aging	NOUN
ecj-11349	30	6	,	,	PUNCT
ecj-11349	30	7	center	center	NOUN
ecj-11349	30	8	of	of	ADP
ecj-11349	30	9	aging	age	VERB
ecj-11349	30	10	science	science	NOUN
ecj-11349	30	11	and	and	CCONJ
ecj-11349	30	12	translational	translational	ADJ
ecj-11349	30	13	medicine	medicine	NOUN
ecj-11349	30	14	(	(	PUNCT
ecj-11349	30	15	cesi	cesi	PROPN
ecj-11349	30	16	-	-	PUNCT
ecj-11349	30	17	met	meet	VERB
ecj-11349	30	18	)	)	PUNCT
ecj-11349	30	19	,	,	PUNCT
ecj-11349	30	20	chieti	chieti	PROPN
ecj-11349	30	21	,	,	PUNCT
ecj-11349	30	22	italy	italy	PROPN
ecj-11349	30	23	highlights	highlight	VERB
ecj-11349	30	24	selective	selective	ADJ
ecj-11349	30	25	serotonin	serotonin	NOUN
ecj-11349	30	26	reuptake	reuptake	NOUN
ecj-11349	30	27	inhibitors	inhibitor	NOUN
ecj-11349	30	28	(	(	PUNCT
ecj-11349	30	29	ssris	ssris	NOUN
ecj-11349	30	30	)	)	PUNCT
ecj-11349	30	31	can	can	AUX
ecj-11349	30	32	interfere	interfere	VERB
ecj-11349	30	33	with	with	ADP
ecj-11349	30	34	platelet	platelet	NOUN
ecj-11349	30	35	adhesion	adhesion	NOUN
ecj-11349	30	36	by	by	ADP
ecj-11349	30	37	approximately	approximately	ADV
ecj-11349	30	38	50	50	NUM
ecj-11349	30	39	%	%	NOUN
ecj-11349	30	40	or	or	CCONJ
ecj-11349	30	41	more	more	ADJ
ecj-11349	30	42	at	at	ADP
ecj-11349	30	43	the	the	DET
ecj-11349	30	44	highest	high	ADJ
ecj-11349	30	45	concentration	concentration	NOUN
ecj-11349	30	46	;	;	PUNCT
ecj-11349	30	47	ssris	ssris	PROPN
ecj-11349	30	48	,	,	PUNCT
ecj-11349	30	49	in	in	ADP
ecj-11349	30	50	particular	particular	ADJ
ecj-11349	30	51	escitalopram	escitalopram	NOUN
ecj-11349	30	52	,	,	PUNCT
ecj-11349	30	53	can	can	AUX
ecj-11349	30	54	induce	induce	VERB
ecj-11349	30	55	and/or	and/or	CCONJ
ecj-11349	30	56	worsen	worsen	VERB
ecj-11349	30	57	thrombocytopenia	thrombocytopenia	NOUN
ecj-11349	30	58	as	as	ADP
ecj-11349	30	59	a	a	DET
ecj-11349	30	60	major	major	ADJ
ecj-11349	30	61	side	side	NOUN
ecj-11349	30	62	effect	effect	NOUN
ecj-11349	30	63	,	,	PUNCT
ecj-11349	30	64	thus	thus	ADV
ecj-11349	30	65	leading	lead	VERB
ecj-11349	30	66	to	to	ADP
ecj-11349	30	67	an	an	DET
ecj-11349	30	68	increased	increase	VERB
ecj-11349	30	69	bleeding	bleeding	NOUN
ecj-11349	30	70	risk	risk	NOUN
ecj-11349	30	71	;	;	PUNCT
ecj-11349	30	72	ssri	ssri	ADJ
ecj-11349	30	73	prescription	prescription	NOUN
ecj-11349	30	74	during	during	ADP
ecj-11349	30	75	hospitalization	hospitalization	NOUN
ecj-11349	30	76	for	for	ADP
ecj-11349	30	77	an	an	DET
ecj-11349	30	78	acute	acute	ADJ
ecj-11349	30	79	coronary	coronary	ADJ
ecj-11349	30	80	syndrome	syndrome	NOUN
ecj-11349	30	81	is	be	AUX
ecj-11349	30	82	related	relate	VERB
ecj-11349	30	83	to	to	ADP
ecj-11349	30	84	lower	low	ADJ
ecj-11349	30	85	incidence	incidence	NOUN
ecj-11349	30	86	of	of	ADP
ecj-11349	30	87	recurrent	recurrent	ADJ
ecj-11349	30	88	ischemia	ischemia	NOUN
ecj-11349	30	89	,	,	PUNCT
ecj-11349	30	90	heart	heart	NOUN
ecj-11349	30	91	failure	failure	NOUN
ecj-11349	30	92	or	or	CCONJ
ecj-11349	30	93	cardiac	cardiac	ADJ
ecj-11349	30	94	enzyme	enzyme	NOUN
ecj-11349	30	95	elevation	elevation	NOUN
ecj-11349	30	96	;	;	PUNCT
ecj-11349	30	97	physicians	physician	NOUN
ecj-11349	30	98	should	should	AUX
ecj-11349	30	99	be	be	AUX
ecj-11349	30	100	aware	aware	ADJ
ecj-11349	30	101	of	of	ADP
ecj-11349	30	102	the	the	DET
ecj-11349	30	103	possible	possible	ADJ
ecj-11349	30	104	correlation	correlation	NOUN
ecj-11349	30	105	between	between	ADP
ecj-11349	30	106	ssri	ssri	PROPN
ecj-11349	30	107	-	-	PUNCT
ecj-11349	30	108	linked	link	VERB
ecj-11349	30	109	thrombocytopenia	thrombocytopenia	NOUN
ecj-11349	30	110	and	and	CCONJ
ecj-11349	30	111	use	use	NOUN
ecj-11349	30	112	of	of	ADP
ecj-11349	30	113	anticoagulant	anticoagulant	NOUN
ecj-11349	30	114	and/or	and/or	CCONJ
ecj-11349	30	115	antiplatelet	antiplatelet	VERB
ecj-11349	30	116	drugs	drug	NOUN
ecj-11349	30	117	,	,	PUNCT
ecj-11349	30	118	thus	thus	ADV
ecj-11349	30	119	preventing	prevent	VERB
ecj-11349	30	120	life	life	NOUN
ecj-11349	30	121	threatening	threaten	VERB
ecj-11349	30	122	bleedings	bleeding	NOUN
ecj-11349	30	123	.	.	PUNCT
ecj-11349	31	1	non	non	ADJ
ecj-11349	31	2	-co	-co	PROPN
ecj-11349	31	3	mmerc	mmerc	PROPN
ecj-11349	31	4	ial	ial	PROPN
ecj-11349	31	5	us	us	PROPN
ecj-11349	31	6	e	e	NOUN
ecj-11349	31	7	o	o	NOUN
ecj-11349	31	8	nly	nly	ADV
ecj-11349	31	9	tion	tion	NOUN
ecj-11349	31	10	,	,	PUNCT
ecj-11349	31	11	left	leave	VERB
ecj-11349	31	12	axis	axis	NOUN
ecj-11349	31	13	deviation	deviation	NOUN
ecj-11349	31	14	,	,	PUNCT
ecj-11349	31	15	intraventricular	intraventricular	ADJ
ecj-11349	31	16	block	block	NOUN
ecj-11349	31	17	and	and	CCONJ
ecj-11349	31	18	abnormalities	abnormality	NOUN
ecj-11349	31	19	of	of	ADP
ecj-11349	31	20	qrs	qrs	PROPN
ecj-11349	31	21	profile	profile	NOUN
ecj-11349	31	22	.	.	PUNCT
ecj-11349	32	1	on	on	ADP
ecj-11349	32	2	physical	physical	ADJ
ecj-11349	32	3	examination	examination	NOUN
ecj-11349	32	4	,	,	PUNCT
ecj-11349	32	5	patient	patient	NOUN
ecj-11349	32	6	was	be	AUX
ecj-11349	32	7	stuporous	stuporous	ADJ
ecj-11349	32	8	with	with	ADP
ecj-11349	32	9	no	no	DET
ecj-11349	32	10	neurologic	neurologic	ADJ
ecj-11349	32	11	deficits	deficit	NOUN
ecj-11349	32	12	.	.	PUNCT
ecj-11349	33	1	skin	skin	NOUN
ecj-11349	33	2	and	and	CCONJ
ecj-11349	33	3	mucous	mucous	ADJ
ecj-11349	33	4	were	be	AUX
ecj-11349	33	5	dry	dry	ADJ
ecj-11349	33	6	and	and	CCONJ
ecj-11349	33	7	dehydrated	dehydrate	VERB
ecj-11349	33	8	.	.	PUNCT
ecj-11349	34	1	vesicular	vesicular	ADJ
ecj-11349	34	2	murmur	murmur	NOUN
ecj-11349	34	3	was	be	AUX
ecj-11349	34	4	diffusely	diffusely	ADV
ecj-11349	34	5	reduced	reduce	VERB
ecj-11349	34	6	.	.	PUNCT
ecj-11349	35	1	heart	heart	NOUN
ecj-11349	35	2	rate	rate	NOUN
ecj-11349	35	3	was	be	AUX
ecj-11349	35	4	arrhythmic	arrhythmic	ADJ
ecj-11349	35	5	.	.	PUNCT
ecj-11349	36	1	no	no	DET
ecj-11349	36	2	peripheral	peripheral	ADJ
ecj-11349	36	3	edema	edema	NOUN
ecj-11349	36	4	was	be	AUX
ecj-11349	36	5	present	present	ADJ
ecj-11349	36	6	.	.	PUNCT
ecj-11349	37	1	abdomen	abdomen	NOUN
ecj-11349	37	2	examination	examination	NOUN
ecj-11349	37	3	was	be	AUX
ecj-11349	37	4	normal	normal	ADJ
ecj-11349	37	5	,	,	PUNCT
ecj-11349	37	6	apparently	apparently	ADV
ecj-11349	37	7	painless	painless	ADJ
ecj-11349	37	8	.	.	PUNCT
ecj-11349	38	1	at	at	ADP
ecj-11349	38	2	digital	digital	ADJ
ecj-11349	38	3	rectal	rectal	ADJ
ecj-11349	38	4	examination	examination	NOUN
ecj-11349	38	5	there	there	PRON
ecj-11349	38	6	were	be	VERB
ecj-11349	38	7	soft	soft	ADJ
ecj-11349	38	8	stool	stool	NOUN
ecj-11349	38	9	black	black	ADJ
ecj-11349	38	10	in	in	ADP
ecj-11349	38	11	color	color	NOUN
ecj-11349	38	12	.	.	PUNCT
ecj-11349	39	1	abdomen	abdomen	PROPN
ecj-11349	39	2	x	x	NOUN
ecj-11349	39	3	-	-	NOUN
ecj-11349	39	4	ray	ray	NOUN
ecj-11349	39	5	did	do	AUX
ecj-11349	39	6	not	not	PART
ecj-11349	39	7	show	show	VERB
ecj-11349	39	8	intestinal	intestinal	ADJ
ecj-11349	39	9	perforation	perforation	NOUN
ecj-11349	39	10	signs	sign	NOUN
ecj-11349	39	11	.	.	PUNCT
ecj-11349	40	1	no	no	DET
ecj-11349	40	2	inflammatory	inflammatory	ADJ
ecj-11349	40	3	parenchymal	parenchymal	ADJ
ecj-11349	40	4	and	and	CCONJ
ecj-11349	40	5	pleural	pleural	ADJ
ecj-11349	40	6	alterations	alteration	NOUN
ecj-11349	40	7	were	be	AUX
ecj-11349	40	8	present	present	ADJ
ecj-11349	40	9	on	on	ADP
ecj-11349	40	10	chest	chest	NOUN
ecj-11349	40	11	x	x	NOUN
ecj-11349	40	12	-	-	NOUN
ecj-11349	40	13	ray	ray	NOUN
ecj-11349	40	14	.	.	PUNCT
ecj-11349	41	1	brain	brain	PROPN
ecj-11349	41	2	computed	compute	VERB
ecj-11349	41	3	tomography	tomography	NOUN
ecj-11349	41	4	demonstrated	demonstrate	VERB
ecj-11349	41	5	no	no	DET
ecj-11349	41	6	bleeding	bleed	VERB
ecj-11349	41	7	lesions	lesion	NOUN
ecj-11349	41	8	or	or	CCONJ
ecj-11349	41	9	edema	edema	NOUN
ecj-11349	41	10	,	,	PUNCT
ecj-11349	41	11	and	and	CCONJ
ecj-11349	41	12	no	no	DET
ecj-11349	41	13	indirect	indirect	ADJ
ecj-11349	41	14	signs	sign	NOUN
ecj-11349	41	15	of	of	ADP
ecj-11349	41	16	intra	intra	ADJ
ecj-11349	41	17	-	-	ADJ
ecj-11349	41	18	cranial	cranial	ADJ
ecj-11349	41	19	expansive	expansive	ADJ
ecj-11349	41	20	lesions	lesion	NOUN
ecj-11349	41	21	.	.	PUNCT
ecj-11349	42	1	anemia	anemia	NOUN
ecj-11349	42	2	and	and	CCONJ
ecj-11349	42	3	thrombocytopenia	thrombocytopenia	PROPN
ecj-11349	42	4	(	(	PUNCT
ecj-11349	42	5	haemoglobin	haemoglobin	NOUN
ecj-11349	42	6	:	:	PUNCT
ecj-11349	42	7	8.7	8.7	NUM
ecj-11349	42	8	g	g	NOUN
ecj-11349	42	9	/	/	SYM
ecj-11349	42	10	dl	dl	PROPN
ecj-11349	42	11	;	;	PUNCT
ecj-11349	42	12	platelet	platelet	NOUN
ecj-11349	42	13	count	count	NOUN
ecj-11349	42	14	:	:	PUNCT
ecj-11349	42	15	66x103	66x103	PROPN
ecj-11349	42	16	/	/	SYM
ecj-11349	42	17	mmc	mmc	PROPN
ecj-11349	42	18	,	,	PUNCT
ecj-11349	42	19	table	table	NOUN
ecj-11349	42	20	1	1	NUM
ecj-11349	42	21	)	)	PUNCT
ecj-11349	42	22	were	be	AUX
ecj-11349	42	23	evident	evident	ADJ
ecj-11349	42	24	on	on	ADP
ecj-11349	42	25	blood	blood	NOUN
ecj-11349	42	26	exams	exam	NOUN
ecj-11349	42	27	.	.	PUNCT
ecj-11349	43	1	reticulocyte	reticulocyte	NOUN
ecj-11349	43	2	absolute	absolute	ADJ
ecj-11349	43	3	count	count	NOUN
ecj-11349	43	4	(	(	PUNCT
ecj-11349	43	5	reticulocytes	reticulocyte	NOUN
ecj-11349	43	6	%	%	NOUN
ecj-11349	43	7	:	:	PUNCT
ecj-11349	43	8	2.62	2.62	NUM
ecj-11349	43	9	)	)	PUNCT
ecj-11349	43	10	and	and	CCONJ
ecj-11349	43	11	reticulocyte	reticulocyte	NOUN
ecj-11349	43	12	index	index	NOUN
ecj-11349	43	13	(	(	PUNCT
ecj-11349	43	14	2.56	2.56	NUM
ecj-11349	43	15	)	)	PUNCT
ecj-11349	43	16	were	be	AUX
ecj-11349	43	17	required	require	VERB
ecj-11349	43	18	to	to	PART
ecj-11349	43	19	ascertain	ascertain	VERB
ecj-11349	43	20	the	the	DET
ecj-11349	43	21	cause	cause	NOUN
ecj-11349	43	22	of	of	ADP
ecj-11349	43	23	anemia	anemia	NOUN
ecj-11349	43	24	and	and	CCONJ
ecj-11349	43	25	thrombocytopenia	thrombocytopenia	PROPN
ecj-11349	43	26	;	;	PUNCT
ecj-11349	43	27	the	the	DET
ecj-11349	43	28	results	result	NOUN
ecj-11349	43	29	did	do	AUX
ecj-11349	43	30	not	not	PART
ecj-11349	43	31	support	support	VERB
ecj-11349	43	32	a	a	DET
ecj-11349	43	33	possible	possible	ADJ
ecj-11349	43	34	hyporegenerative	hyporegenerative	ADJ
ecj-11349	43	35	medullar	medullar	ADJ
ecj-11349	43	36	disease	disease	NOUN
ecj-11349	43	37	.	.	PUNCT
ecj-11349	44	1	during	during	ADP
ecj-11349	44	2	hospitalization	hospitalization	NOUN
ecj-11349	44	3	no	no	DET
ecj-11349	44	4	platelet	platelet	NOUN
ecj-11349	44	5	aggregation	aggregation	NOUN
ecj-11349	44	6	tests	test	NOUN
ecj-11349	44	7	were	be	AUX
ecj-11349	44	8	performed	perform	VERB
ecj-11349	44	9	due	due	ADP
ecj-11349	44	10	to	to	ADP
ecj-11349	44	11	their	their	PRON
ecj-11349	44	12	unavailability	unavailability	NOUN
ecj-11349	44	13	.	.	PUNCT
ecj-11349	45	1	all	all	DET
ecj-11349	45	2	the	the	DET
ecj-11349	45	3	remaining	remain	VERB
ecj-11349	45	4	causes	cause	NOUN
ecj-11349	45	5	of	of	ADP
ecj-11349	45	6	thrombocytopenia	thrombocytopenia	PROPN
ecj-11349	45	7	,	,	PUNCT
ecj-11349	45	8	including	include	VERB
ecj-11349	45	9	those	those	PRON
ecj-11349	45	10	related	relate	VERB
ecj-11349	45	11	to	to	ADP
ecj-11349	45	12	drugs	drug	NOUN
ecj-11349	45	13	,	,	PUNCT
ecj-11349	45	14	were	be	AUX
ecj-11349	45	15	considered	consider	VERB
ecj-11349	45	16	.	.	PUNCT
ecj-11349	46	1	by	by	ADP
ecj-11349	46	2	reconsidering	reconsider	VERB
ecj-11349	46	3	patient	patient	ADJ
ecj-11349	46	4	medical	medical	ADJ
ecj-11349	46	5	history	history	NOUN
ecj-11349	46	6	,	,	PUNCT
ecj-11349	46	7	escitalopram	escitalopram	PROPN
ecj-11349	46	8	treatment	treatment	NOUN
ecj-11349	46	9	had	have	AUX
ecj-11349	46	10	been	be	AUX
ecj-11349	46	11	introduced	introduce	VERB
ecj-11349	46	12	for	for	ADP
ecj-11349	46	13	about	about	ADV
ecj-11349	46	14	a	a	PRON
ecj-11349	46	15	month	month	NOUN
ecj-11349	46	16	,	,	PUNCT
ecj-11349	46	17	due	due	ADP
ecj-11349	46	18	to	to	ADP
ecj-11349	46	19	a	a	DET
ecj-11349	46	20	form	form	NOUN
ecj-11349	46	21	of	of	ADP
ecj-11349	46	22	depression	depression	NOUN
ecj-11349	46	23	linked	link	VERB
ecj-11349	46	24	to	to	ADP
ecj-11349	46	25	dementia	dementia	NOUN
ecj-11349	46	26	.	.	PUNCT
ecj-11349	47	1	some	some	DET
ecj-11349	47	2	previous	previous	ADJ
ecj-11349	47	3	reports	report	NOUN
ecj-11349	47	4	demonstrated	demonstrate	VERB
ecj-11349	47	5	ssris	ssris	NOUN
ecj-11349	47	6	to	to	PART
ecj-11349	47	7	be	be	AUX
ecj-11349	47	8	correlated	correlate	VERB
ecj-11349	47	9	with	with	ADP
ecj-11349	47	10	thrombocytopenia	thrombocytopenia	PROPN
ecj-11349	47	11	,	,	PUNCT
ecj-11349	47	12	as	as	ADP
ecj-11349	47	13	a	a	DET
ecj-11349	47	14	side	side	NOUN
ecj-11349	47	15	effect	effect	NOUN
ecj-11349	47	16	.	.	PUNCT
ecj-11349	48	1	subsequently	subsequently	ADV
ecj-11349	48	2	,	,	PUNCT
ecj-11349	48	3	escitalopram	escitalopram	PROPN
ecj-11349	48	4	was	be	AUX
ecj-11349	48	5	withdrawn	withdraw	VERB
ecj-11349	48	6	with	with	ADP
ecj-11349	48	7	a	a	DET
ecj-11349	48	8	progressive	progressive	ADJ
ecj-11349	48	9	increase	increase	NOUN
ecj-11349	48	10	of	of	ADP
ecj-11349	48	11	platelet	platelet	NOUN
ecj-11349	48	12	count	count	NOUN
ecj-11349	48	13	,	,	PUNCT
ecj-11349	48	14	and	and	CCONJ
ecj-11349	48	15	the	the	DET
ecj-11349	48	16	concurrent	concurrent	ADJ
ecj-11349	48	17	resolution	resolution	NOUN
ecj-11349	48	18	of	of	ADP
ecj-11349	48	19	the	the	DET
ecj-11349	48	20	gastrointestinal	gastrointestinal	ADJ
ecj-11349	48	21	(	(	PUNCT
ecj-11349	48	22	gi	gi	INTJ
ecj-11349	48	23	)	)	PUNCT
ecj-11349	48	24	bleeding	bleeding	NOUN
ecj-11349	48	25	.	.	PUNCT
ecj-11349	49	1	once	once	SCONJ
ecj-11349	49	2	the	the	DET
ecj-11349	49	3	blood	blood	NOUN
ecj-11349	49	4	pressure	pressure	NOUN
ecj-11349	49	5	was	be	AUX
ecj-11349	49	6	restored	restore	VERB
ecj-11349	49	7	to	to	ADP
ecj-11349	49	8	normal	normal	ADJ
ecj-11349	49	9	level	level	NOUN
ecj-11349	49	10	,	,	PUNCT
ecj-11349	49	11	a	a	DET
ecj-11349	49	12	gastroscopy	gastroscopy	NOUN
ecj-11349	49	13	was	be	AUX
ecj-11349	49	14	performed	perform	VERB
ecj-11349	49	15	showing	show	VERB
ecj-11349	49	16	a	a	DET
ecj-11349	49	17	diffuse	diffuse	ADJ
ecj-11349	49	18	inflammation	inflammation	NOUN
ecj-11349	49	19	of	of	ADP
ecj-11349	49	20	the	the	DET
ecj-11349	49	21	gastric	gastric	ADJ
ecj-11349	49	22	mucosa	mucosa	NOUN
ecj-11349	49	23	and	and	CCONJ
ecj-11349	49	24	hemorrhagic	hemorrhagic	NOUN
ecj-11349	49	25	suffusions	suffusion	NOUN
ecj-11349	49	26	.	.	PUNCT
ecj-11349	50	1	the	the	DET
ecj-11349	50	2	patient	patient	NOUN
ecj-11349	50	3	was	be	AUX
ecj-11349	50	4	discharged	discharge	VERB
ecj-11349	50	5	on	on	ADP
ecj-11349	50	6	the	the	DET
ecj-11349	50	7	sixth	sixth	ADJ
ecj-11349	50	8	day	day	NOUN
ecj-11349	50	9	in	in	ADP
ecj-11349	50	10	good	good	ADJ
ecj-11349	50	11	clinical	clinical	ADJ
ecj-11349	50	12	conditions	condition	NOUN
ecj-11349	50	13	.	.	PUNCT
ecj-11349	51	1	the	the	DET
ecj-11349	51	2	same	same	ADJ
ecj-11349	51	3	home	home	NOUN
ecj-11349	51	4	therapy	therapy	NOUN
ecj-11349	51	5	was	be	AUX
ecj-11349	51	6	reintroduced	reintroduce	VERB
ecj-11349	51	7	,	,	PUNCT
ecj-11349	51	8	but	but	CCONJ
ecj-11349	51	9	with	with	ADP
ecj-11349	51	10	a	a	DET
ecj-11349	51	11	halved	halve	VERB
ecj-11349	51	12	dosage	dosage	NOUN
ecj-11349	51	13	of	of	ADP
ecj-11349	51	14	apixaban	apixaban	NOUN
ecj-11349	51	15	and	and	CCONJ
ecj-11349	51	16	a	a	DET
ecj-11349	51	17	standard	standard	ADJ
ecj-11349	51	18	dose	dose	NOUN
ecj-11349	51	19	of	of	ADP
ecj-11349	51	20	proton	proton	NOUN
ecj-11349	51	21	-	-	PUNCT
ecj-11349	51	22	pump	pump	NOUN
ecj-11349	51	23	inhibitor	inhibitor	NOUN
ecj-11349	51	24	.	.	PUNCT
ecj-11349	52	1	no	no	DET
ecj-11349	52	2	antidepressant	antidepressant	ADJ
ecj-11349	52	3	drugs	drug	NOUN
ecj-11349	52	4	were	be	AUX
ecj-11349	52	5	prescribed	prescribe	VERB
ecj-11349	52	6	at	at	ADP
ecj-11349	52	7	discharge	discharge	NOUN
ecj-11349	52	8	.	.	PUNCT
ecj-11349	53	1	therefore	therefore	ADV
ecj-11349	53	2	,	,	PUNCT
ecj-11349	53	3	a	a	DET
ecj-11349	53	4	clinical	clinical	ADJ
ecj-11349	53	5	and	and	CCONJ
ecj-11349	53	6	laboratory	laboratory	NOUN
ecj-11349	53	7	follow	follow	NOUN
ecj-11349	53	8	-	-	PUNCT
ecj-11349	53	9	up	up	NOUN
ecj-11349	53	10	was	be	AUX
ecj-11349	53	11	set	set	VERB
ecj-11349	53	12	up	up	ADP
ecj-11349	53	13	for	for	ADP
ecj-11349	53	14	the	the	DET
ecj-11349	53	15	prescription	prescription	NOUN
ecj-11349	53	16	of	of	ADP
ecj-11349	53	17	doac	doac	NOUN
ecj-11349	53	18	for	for	ADP
ecj-11349	53	19	atrial	atrial	ADJ
ecj-11349	53	20	fibrillation	fibrillation	NOUN
ecj-11349	53	21	.	.	PUNCT
ecj-11349	54	1	informed	inform	VERB
ecj-11349	54	2	consent	consent	NOUN
ecj-11349	54	3	was	be	AUX
ecj-11349	54	4	obtained	obtain	VERB
ecj-11349	54	5	from	from	ADP
ecj-11349	54	6	the	the	DET
ecj-11349	54	7	patient	patient	NOUN
ecj-11349	54	8	regarding	regard	VERB
ecj-11349	54	9	the	the	DET
ecj-11349	54	10	reporting	reporting	NOUN
ecj-11349	54	11	and	and	CCONJ
ecj-11349	54	12	publication	publication	NOUN
ecj-11349	54	13	of	of	ADP
ecj-11349	54	14	this	this	DET
ecj-11349	54	15	case	case	NOUN
ecj-11349	54	16	report	report	NOUN
ecj-11349	54	17	.	.	PUNCT
ecj-11349	55	1	discussion	discussion	NOUN
ecj-11349	55	2	and	and	CCONJ
ecj-11349	55	3	review	review	NOUN
ecj-11349	55	4	of	of	ADP
ecj-11349	55	5	literature	literature	NOUN
ecj-11349	55	6	ssris	ssris	NOUN
ecj-11349	55	7	effects	effect	NOUN
ecj-11349	55	8	on	on	ADP
ecj-11349	55	9	platelet	platelet	NOUN
ecj-11349	55	10	aggregation	aggregation	NOUN
ecj-11349	55	11	and	and	CCONJ
ecj-11349	55	12	platelet	platelet	NOUN
ecj-11349	55	13	count	count	NOUN
ecj-11349	55	14	ssris	ssris	NOUN
ecj-11349	55	15	(	(	PUNCT
ecj-11349	55	16	e.g.	e.g.	ADV
ecj-11349	55	17	citalopram	citalopram	PROPN
ecj-11349	55	18	and	and	CCONJ
ecj-11349	55	19	sertraline	sertraline	PROPN
ecj-11349	55	20	)	)	PUNCT
ecj-11349	55	21	do	do	AUX
ecj-11349	55	22	not	not	PART
ecj-11349	55	23	significantly	significantly	ADV
ecj-11349	55	24	change	change	VERB
ecj-11349	55	25	plasma	plasma	NOUN
ecj-11349	55	26	coagulation	coagulation	NOUN
ecj-11349	55	27	but	but	CCONJ
ecj-11349	55	28	can	can	AUX
ecj-11349	55	29	interfere	interfere	VERB
ecj-11349	55	30	with	with	ADP
ecj-11349	55	31	platelet	platelet	NOUN
ecj-11349	55	32	adhesion	adhesion	NOUN
ecj-11349	55	33	by	by	ADP
ecj-11349	55	34	approximately	approximately	ADV
ecj-11349	55	35	50	50	NUM
ecj-11349	55	36	%	%	NOUN
ecj-11349	55	37	or	or	CCONJ
ecj-11349	55	38	more	more	ADJ
ecj-11349	55	39	at	at	ADP
ecj-11349	55	40	the	the	DET
ecj-11349	55	41	highest	high	ADJ
ecj-11349	55	42	concentration.6	concentration.6	NOUN
ecj-11349	55	43	mini	mini	ADJ
ecj-11349	55	44	review	review	NOUN
ecj-11349	55	45	[	[	X
ecj-11349	55	46	emergency	emergency	NOUN
ecj-11349	55	47	care	care	NOUN
ecj-11349	55	48	journal	journal	NOUN
ecj-11349	55	49	2023	2023	NUM
ecj-11349	55	50	;	;	PUNCT
ecj-11349	56	1	19:11349	19:11349	NUM
ecj-11349	56	2	]	]	X
ecj-11349	57	1	[	[	X
ecj-11349	57	2	page	page	NOUN
ecj-11349	57	3	89	89	NUM
ecj-11349	57	4	]	]	PUNCT
ecj-11349	57	5	table	table	NOUN
ecj-11349	57	6	1	1	NUM
ecj-11349	57	7	.	.	PUNCT
ecj-11349	58	1	blood	blood	NOUN
ecj-11349	58	2	tests	test	NOUN
ecj-11349	58	3	of	of	ADP
ecj-11349	58	4	the	the	DET
ecj-11349	58	5	patient	patient	NOUN
ecj-11349	58	6	on	on	ADP
ecj-11349	58	7	admission	admission	NOUN
ecj-11349	58	8	and	and	CCONJ
ecj-11349	58	9	discharge	discharge	NOUN
ecj-11349	58	10	.	.	PUNCT
ecj-11349	59	1	laboratory	laboratory	NOUN
ecj-11349	59	2	test	test	NOUN
ecj-11349	59	3	mu	mu	PROPN
ecj-11349	59	4	normal	normal	ADJ
ecj-11349	59	5	reference	reference	NOUN
ecj-11349	59	6	values	value	NOUN
ecj-11349	59	7	admission	admission	NOUN
ecj-11349	59	8	discharge	discharge	VERB
ecj-11349	59	9	folic	folic	NOUN
ecj-11349	59	10	acid	acid	NOUN
ecj-11349	59	11	ng	ng	PROPN
ecj-11349	59	12	/	/	SYM
ecj-11349	59	13	ml	ml	PROPN
ecj-11349	59	14	3	3	NUM
ecj-11349	59	15	-	-	SYM
ecj-11349	59	16	17	17	NUM
ecj-11349	59	17	2.8	2.8	NUM
ecj-11349	59	18	b12	b12	NOUN
ecj-11349	59	19	vitamin	vitamin	NOUN
ecj-11349	59	20	pg	pg	NOUN
ecj-11349	59	21	/	/	SYM
ecj-11349	59	22	ml	ml	VERB
ecj-11349	59	23	200	200	NUM
ecj-11349	59	24	-	-	SYM
ecj-11349	59	25	950	950	NUM
ecj-11349	59	26	1886.0	1886.0	NUM
ecj-11349	59	27	ferritin	ferritin	PROPN
ecj-11349	59	28	ng	ng	PROPN
ecj-11349	59	29	/	/	SYM
ecj-11349	59	30	ml	ml	PROPN
ecj-11349	59	31	15	15	NUM
ecj-11349	59	32	-	-	SYM
ecj-11349	59	33	300	300	NUM
ecj-11349	59	34	486.8	486.8	NUM
ecj-11349	59	35	esr	esr	PROPN
ecj-11349	59	36	mm	mm	PROPN
ecj-11349	59	37	/	/	SYM
ecj-11349	59	38	h	h	NOUN
ecj-11349	59	39	0	0	NUM
ecj-11349	59	40	-	-	SYM
ecj-11349	59	41	19	19	NUM
ecj-11349	59	42	40	40	NUM
ecj-11349	59	43	38	38	NUM
ecj-11349	59	44	bilirubin	bilirubin	NOUN
ecj-11349	59	45	total	total	NOUN
ecj-11349	59	46	mg	mg	PROPN
ecj-11349	59	47	/	/	SYM
ecj-11349	59	48	dl	dl	PROPN
ecj-11349	59	49	0	0	NUM
ecj-11349	59	50	-	-	SYM
ecj-11349	59	51	1.2	1.2	NUM
ecj-11349	59	52	0.9	0.9	NUM
ecj-11349	59	53	0.8	0.8	NUM
ecj-11349	59	54	inr	inr	PROPN
ecj-11349	59	55	0.9	0.9	NUM
ecj-11349	59	56	-	-	SYM
ecj-11349	59	57	1.2	1.2	NUM
ecj-11349	59	58	1.8	1.8	NUM
ecj-11349	59	59	1.29	1.29	NUM
ecj-11349	59	60	aptt	aptt	NOUN
ecj-11349	59	61	sec	sec	PROPN
ecj-11349	59	62	28	28	NUM
ecj-11349	59	63	-	-	SYM
ecj-11349	59	64	40	40	NUM
ecj-11349	59	65	111	111	NUM
ecj-11349	59	66	108	108	NUM
ecj-11349	59	67	crp	crp	NOUN
ecj-11349	59	68	mg	mg	PROPN
ecj-11349	59	69	/	/	SYM
ecj-11349	59	70	dl	dl	PROPN
ecj-11349	59	71	0,5	0,5	PROPN
ecj-11349	59	72	-	-	PUNCT
ecj-11349	59	73	1	1	NUM
ecj-11349	59	74	2.98	2.98	NUM
ecj-11349	59	75	1.03	1.03	NUM
ecj-11349	59	76	rbc	rbc	PROPN
ecj-11349	59	77	x	x	X
ecj-11349	59	78	106	106	NUM
ecj-11349	59	79	/	/	SYM
ecj-11349	59	80	mmc	mmc	X
ecj-11349	59	81	4.7	4.7	NUM
ecj-11349	59	82	-	-	SYM
ecj-11349	59	83	6.1	6.1	NUM
ecj-11349	59	84	(	(	PUNCT
ecj-11349	59	85	m	m	NOUN
ecj-11349	59	86	)	)	PUNCT
ecj-11349	59	87	4.2	4.2	NUM
ecj-11349	59	88	-	-	SYM
ecj-11349	59	89	5.4	5.4	NUM
ecj-11349	59	90	(	(	PUNCT
ecj-11349	59	91	f	f	X
ecj-11349	59	92	)	)	PUNCT
ecj-11349	59	93	3.03	3.03	NUM
ecj-11349	59	94	2.99	2.99	NUM
ecj-11349	59	95	hgb	hgb	NOUN
ecj-11349	59	96	g	g	PROPN
ecj-11349	59	97	/	/	SYM
ecj-11349	59	98	dl	dl	PROPN
ecj-11349	59	99	14.0	14.0	NUM
ecj-11349	59	100	-	-	SYM
ecj-11349	59	101	17.5	17.5	NUM
ecj-11349	59	102	(	(	PUNCT
ecj-11349	59	103	m	m	NOUN
ecj-11349	59	104	)	)	PUNCT
ecj-11349	59	105	12.3	12.3	NUM
ecj-11349	59	106	-	-	SYM
ecj-11349	59	107	15.3	15.3	NUM
ecj-11349	59	108	(	(	PUNCT
ecj-11349	59	109	f	f	X
ecj-11349	59	110	)	)	PUNCT
ecj-11349	59	111	8.7	8.7	NUM
ecj-11349	59	112	8.8	8.8	NUM
ecj-11349	59	113	hct	hct	NOUN
ecj-11349	59	114	%	%	NOUN
ecj-11349	59	115	40	40	NUM
ecj-11349	59	116	-	-	SYM
ecj-11349	59	117	54	54	NUM
ecj-11349	59	118	43.9	43.9	NUM
ecj-11349	59	119	39.8	39.8	NUM
ecj-11349	59	120	mcv	mcv	PROPN
ecj-11349	59	121	fl	fl	NUM
ecj-11349	59	122	78	78	NUM
ecj-11349	59	123	-	-	SYM
ecj-11349	59	124	98	98	NUM
ecj-11349	59	125	85.5	85.5	NUM
ecj-11349	59	126	87.6	87.6	NUM
ecj-11349	59	127	mch	mch	PROPN
ecj-11349	59	128	pg	pg	PROPN
ecj-11349	59	129	26.0	26.0	NUM
ecj-11349	59	130	-	-	SYM
ecj-11349	59	131	34.0	34.0	NUM
ecj-11349	59	132	28.7	28.7	NUM
ecj-11349	59	133	29.4	29.4	NUM
ecj-11349	59	134	mchc	mchc	NOUN
ecj-11349	59	135	g	g	PROPN
ecj-11349	59	136	/	/	SYM
ecj-11349	59	137	dl	dl	PROPN
ecj-11349	59	138	30.0	30.0	NUM
ecj-11349	59	139	-	-	SYM
ecj-11349	59	140	36.0	36.0	NUM
ecj-11349	59	141	33.6	33.6	NUM
ecj-11349	59	142	33.6	33.6	NUM
ecj-11349	59	143	wbc	wbc	NOUN
ecj-11349	59	144	x	x	X
ecj-11349	59	145	103	103	NUM
ecj-11349	59	146	/	/	SYM
ecj-11349	59	147	ul	ul	NOUN
ecj-11349	59	148	4.5	4.5	NUM
ecj-11349	59	149	-	-	SYM
ecj-11349	59	150	10.0	10.0	NUM
ecj-11349	59	151	5.50	5.50	NUM
ecj-11349	59	152	5.43	5.43	NUM
ecj-11349	59	153	plt	plt	NOUN
ecj-11349	59	154	x	x	SYM
ecj-11349	59	155	103	103	NUM
ecj-11349	59	156	/	/	SYM
ecj-11349	59	157	mmc	mmc	NOUN
ecj-11349	59	158	150	150	NUM
ecj-11349	59	159	-	-	SYM
ecj-11349	59	160	400	400	NUM
ecj-11349	59	161	66	66	NUM
ecj-11349	59	162	144	144	NUM
ecj-11349	59	163	basophils	basophil	NOUN
ecj-11349	59	164	x103	x103	PROPN
ecj-11349	59	165	/	/	SYM
ecj-11349	59	166	ul	ul	NOUN
ecj-11349	59	167	0.00	0.00	NUM
ecj-11349	59	168	-	-	SYM
ecj-11349	59	169	0.27	0.27	NUM
ecj-11349	59	170	0.01	0.01	NUM
ecj-11349	59	171	0.03	0.03	NUM
ecj-11349	59	172	neutrophils	neutrophil	NOUN
ecj-11349	59	173	x103	x103	PROPN
ecj-11349	59	174	/	/	SYM
ecj-11349	59	175	ul	ul	NOUN
ecj-11349	59	176	1.35	1.35	NUM
ecj-11349	59	177	-	-	SYM
ecj-11349	59	178	8.10	8.10	NUM
ecj-11349	59	179	4.06	4.06	NUM
ecj-11349	59	180	4.10	4.10	NUM
ecj-11349	59	181	lymphocytes	lymphocyte	VERB
ecj-11349	59	182	x103	x103	PROPN
ecj-11349	59	183	/	/	SYM
ecj-11349	59	184	ul	ul	NOUN
ecj-11349	59	185	1.57	1.57	NUM
ecj-11349	59	186	-	-	SYM
ecj-11349	59	187	7.43	7.43	NUM
ecj-11349	59	188	0.88	0.88	NUM
ecj-11349	59	189	0.99	0.99	NUM
ecj-11349	59	190	monocytes	monocyte	VERB
ecj-11349	59	191	x103	x103	PROPN
ecj-11349	59	192	/	/	SYM
ecj-11349	59	193	ul	ul	NOUN
ecj-11349	59	194	0.05	0.05	NUM
ecj-11349	59	195	-	-	SYM
ecj-11349	59	196	1.62	1.62	NUM
ecj-11349	59	197	0.43	0.43	NUM
ecj-11349	59	198	0.67	0.67	NUM
ecj-11349	59	199	eosinophils	eosinophil	NOUN
ecj-11349	59	200	x103	x103	NUM
ecj-11349	59	201	/	/	SYM
ecj-11349	59	202	ul	ul	NOUN
ecj-11349	59	203	0.05	0.05	NUM
ecj-11349	59	204	-	-	SYM
ecj-11349	59	205	1.21	1.21	NUM
ecj-11349	59	206	0.11	0.11	NUM
ecj-11349	59	207	0.02	0.02	NUM
ecj-11349	59	208	reticulocytes	reticulocyte	NOUN
ecj-11349	59	209	%	%	NOUN
ecj-11349	59	210	0.5	0.5	NUM
ecj-11349	59	211	-	-	SYM
ecj-11349	59	212	2.5	2.5	NUM
ecj-11349	59	213	2.62	2.62	NUM
ecj-11349	59	214	2.59	2.59	NUM
ecj-11349	59	215	fibrinogen	fibrinogen	NOUN
ecj-11349	59	216	mg	mg	PROPN
ecj-11349	59	217	/	/	SYM
ecj-11349	59	218	dl	dl	PROPN
ecj-11349	59	219	150	150	NUM
ecj-11349	59	220	-	-	SYM
ecj-11349	59	221	400	400	NUM
ecj-11349	59	222	310	310	NUM
ecj-11349	59	223	410	410	NUM
ecj-11349	59	224	creatinin	creatinin	NOUN
ecj-11349	59	225	mg	mg	PROPN
ecj-11349	59	226	/	/	SYM
ecj-11349	59	227	dl	dl	PROPN
ecj-11349	59	228	0.50	0.50	NUM
ecj-11349	59	229	-	-	SYM
ecj-11349	59	230	1.40	1.40	NUM
ecj-11349	59	231	0.8	0.8	NUM
ecj-11349	59	232	0.8	0.8	NUM
ecj-11349	59	233	aptoglobin	aptoglobin	ADV
ecj-11349	59	234	mg	mg	PROPN
ecj-11349	59	235	/	/	SYM
ecj-11349	59	236	dl	dl	PROPN
ecj-11349	59	237	30	30	NUM
ecj-11349	59	238	-	-	SYM
ecj-11349	59	239	200	200	NUM
ecj-11349	59	240	47	47	NUM
ecj-11349	59	241	ldh	ldh	PROPN
ecj-11349	59	242	u	u	PROPN
ecj-11349	59	243	/	/	SYM
ecj-11349	59	244	l	l	NOUN
ecj-11349	59	245	80	80	NUM
ecj-11349	59	246	-	-	SYM
ecj-11349	59	247	300	300	NUM
ecj-11349	59	248	711	711	NUM
ecj-11349	59	249	tsh	tsh	NOUN
ecj-11349	59	250	ui	ui	PROPN
ecj-11349	59	251	/	/	SYM
ecj-11349	59	252	ml	ml	NOUN
ecj-11349	59	253	0.35	0.35	NUM
ecj-11349	59	254	-	-	SYM
ecj-11349	59	255	4.50	4.50	NUM
ecj-11349	59	256	2.42	2.42	NUM
ecj-11349	59	257	abbreviations	abbreviation	NOUN
ecj-11349	59	258	:	:	PUNCT
ecj-11349	59	259	esr	esr	NOUN
ecj-11349	59	260	,	,	PUNCT
ecj-11349	59	261	erythrocyte	erythrocyte	PROPN
ecj-11349	59	262	sedimentation	sedimentation	NOUN
ecj-11349	59	263	rate	rate	NOUN
ecj-11349	59	264	;	;	PUNCT
ecj-11349	59	265	inr	inr	PROPN
ecj-11349	59	266	,	,	PUNCT
ecj-11349	59	267	international	international	ADJ
ecj-11349	59	268	normalized	normalize	VERB
ecj-11349	59	269	ratio	ratio	NOUN
ecj-11349	59	270	;	;	PUNCT
ecj-11349	59	271	aptt	aptt	ADJ
ecj-11349	59	272	,	,	PUNCT
ecj-11349	59	273	activated	activate	VERB
ecj-11349	59	274	partial	partial	ADJ
ecj-11349	59	275	thromboplastin	thromboplastin	NOUN
ecj-11349	59	276	time	time	NOUN
ecj-11349	59	277	;	;	PUNCT
ecj-11349	59	278	crp	crp	PROPN
ecj-11349	59	279	,	,	PUNCT
ecj-11349	59	280	c	c	PROPN
ecj-11349	59	281	reactive	reactive	ADJ
ecj-11349	59	282	protein	protein	NOUN
ecj-11349	59	283	;	;	PUNCT
ecj-11349	59	284	rbc	rbc	PROPN
ecj-11349	59	285	,	,	PUNCT
ecj-11349	59	286	red	red	ADJ
ecj-11349	59	287	blood	blood	NOUN
ecj-11349	59	288	cells	cell	NOUN
ecj-11349	59	289	;	;	PUNCT
ecj-11349	60	1	hgb	hgb	PROPN
ecj-11349	60	2	,	,	PUNCT
ecj-11349	60	3	haemoglobin	haemoglobin	PROPN
ecj-11349	60	4	;	;	PUNCT
ecj-11349	60	5	hct	hct	PROPN
ecj-11349	60	6	,	,	PUNCT
ecj-11349	60	7	hematocrit	hematocrit	PROPN
ecj-11349	60	8	;	;	PUNCT
ecj-11349	60	9	mcv	mcv	PROPN
ecj-11349	60	10	,	,	PUNCT
ecj-11349	60	11	mean	mean	ADJ
ecj-11349	60	12	corpuscular	corpuscular	NOUN
ecj-11349	60	13	volume	volume	NOUN
ecj-11349	60	14	;	;	PUNCT
ecj-11349	60	15	mch	mch	PROPN
ecj-11349	60	16	,	,	PUNCT
ecj-11349	60	17	mean	mean	VERB
ecj-11349	60	18	corpuscolar	corpuscolar	ADJ
ecj-11349	60	19	hemoglobin	hemoglobin	NOUN
ecj-11349	60	20	;	;	PUNCT
ecj-11349	60	21	mchc	mchc	NOUN
ecj-11349	60	22	,	,	PUNCT
ecj-11349	60	23	mean	mean	ADJ
ecj-11349	60	24	corpuscular	corpuscular	ADJ
ecj-11349	60	25	hemoglobin	hemoglobin	NOUN
ecj-11349	60	26	concentration	concentration	NOUN
ecj-11349	60	27	;	;	PUNCT
ecj-11349	60	28	wbc	wbc	PROPN
ecj-11349	60	29	,	,	PUNCT
ecj-11349	60	30	white	white	ADJ
ecj-11349	60	31	blood	blood	NOUN
ecj-11349	60	32	cells	cell	NOUN
ecj-11349	60	33	;	;	PUNCT
ecj-11349	60	34	plt	plt	NOUN
ecj-11349	60	35	,	,	PUNCT
ecj-11349	60	36	platelets	platelet	NOUN
ecj-11349	60	37	;	;	PUNCT
ecj-11349	60	38	ldh	ldh	X
ecj-11349	60	39	,	,	PUNCT
ecj-11349	60	40	lactate	lactate	NOUN
ecj-11349	60	41	dehydrogenase	dehydrogenase	NOUN
ecj-11349	60	42	;	;	PUNCT
ecj-11349	60	43	tsh	tsh	NOUN
ecj-11349	60	44	,	,	PUNCT
ecj-11349	60	45	thyroidstimulating	thyroidstimulating	ADJ
ecj-11349	60	46	hormone	hormone	NOUN
ecj-11349	60	47	.	.	PUNCT
ecj-11349	61	1	non	non	ADJ
ecj-11349	62	1	-co	-co	PROPN
ecj-11349	62	2	mmerc	mmerc	PROPN
ecj-11349	62	3	ial	ial	PROPN
ecj-11349	62	4	us	us	PROPN
ecj-11349	62	5	e	e	NOUN
ecj-11349	62	6	o	o	X
ecj-11349	62	7	nly	nly	ADV
ecj-11349	62	8	ssris	ssris	ADJ
ecj-11349	62	9	,	,	PUNCT
ecj-11349	62	10	in	in	ADP
ecj-11349	62	11	particular	particular	ADJ
ecj-11349	62	12	escitalopram	escitalopram	NOUN
ecj-11349	62	13	,	,	PUNCT
ecj-11349	62	14	can	can	AUX
ecj-11349	62	15	induce	induce	VERB
ecj-11349	62	16	and/or	and/or	CCONJ
ecj-11349	62	17	worsen	worsen	VERB
ecj-11349	62	18	thrombocytopenia	thrombocytopenia	NOUN
ecj-11349	62	19	as	as	ADP
ecj-11349	62	20	a	a	DET
ecj-11349	62	21	major	major	ADJ
ecj-11349	62	22	side	side	NOUN
ecj-11349	62	23	effect7	effect7	PROPN
ecj-11349	63	1	and	and	CCONJ
ecj-11349	63	2	are	be	AUX
ecj-11349	63	3	associated	associate	VERB
ecj-11349	63	4	with	with	ADP
ecj-11349	63	5	bleeding	bleed	VERB
ecj-11349	63	6	risk.3,8	risk.3,8	NUM
ecj-11349	63	7	in	in	ADP
ecj-11349	63	8	the	the	DET
ecj-11349	63	9	work	work	NOUN
ecj-11349	63	10	of	of	ADP
ecj-11349	63	11	ataoglu	ataoglu	PROPN
ecj-11349	63	12	et	et	PROPN
ecj-11349	63	13	al	al	PROPN
ecj-11349	63	14	.	.	PROPN
ecj-11349	63	15	,	,	PUNCT
ecj-11349	63	16	patients	patient	NOUN
ecj-11349	63	17	with	with	ADP
ecj-11349	63	18	depression	depression	NOUN
ecj-11349	63	19	on	on	ADP
ecj-11349	63	20	escitalopram	escitalopram	PROPN
ecj-11349	63	21	treatment	treatment	NOUN
ecj-11349	63	22	exhibited	exhibit	VERB
ecj-11349	63	23	significant	significant	ADJ
ecj-11349	63	24	reduction	reduction	NOUN
ecj-11349	63	25	in	in	ADP
ecj-11349	63	26	mean	mean	ADJ
ecj-11349	63	27	platelet	platelet	NOUN
ecj-11349	63	28	volume	volume	NOUN
ecj-11349	63	29	(	(	PUNCT
ecj-11349	63	30	mpv	mpv	PROPN
ecj-11349	63	31	)	)	PUNCT
ecj-11349	63	32	and	and	CCONJ
ecj-11349	63	33	a	a	DET
ecj-11349	63	34	significant	significant	ADJ
ecj-11349	63	35	decline	decline	NOUN
ecj-11349	63	36	in	in	ADP
ecj-11349	63	37	platelet	platelet	NOUN
ecj-11349	63	38	count.9	count.9	NOUN
ecj-11349	63	39	moreover	moreover	ADV
ecj-11349	63	40	,	,	PUNCT
ecj-11349	63	41	a	a	DET
ecj-11349	63	42	subsequent	subsequent	ADJ
ecj-11349	63	43	study	study	NOUN
ecj-11349	63	44	enrolling	enrol	VERB
ecj-11349	63	45	131	131	NUM
ecj-11349	63	46	patients	patient	NOUN
ecj-11349	63	47	with	with	ADP
ecj-11349	63	48	depression	depression	NOUN
ecj-11349	63	49	showed	show	VERB
ecj-11349	63	50	a	a	DET
ecj-11349	63	51	decrease	decrease	NOUN
ecj-11349	63	52	in	in	ADP
ecj-11349	63	53	platelet	platelet	NOUN
ecj-11349	63	54	count	count	NOUN
ecj-11349	63	55	on	on	ADP
ecj-11349	63	56	escitalopram	escitalopram	PROPN
ecj-11349	63	57	,	,	PUNCT
ecj-11349	63	58	while	while	SCONJ
ecj-11349	63	59	other	other	ADJ
ecj-11349	63	60	antidepressants	antidepressant	NOUN
ecj-11349	63	61	such	such	ADJ
ecj-11349	63	62	as	as	ADP
ecj-11349	63	63	venlafaxine	venlafaxine	NOUN
ecj-11349	63	64	and	and	CCONJ
ecj-11349	63	65	bupropion	bupropion	NOUN
ecj-11349	63	66	did	do	AUX
ecj-11349	63	67	not	not	PART
ecj-11349	63	68	exert	exert	VERB
ecj-11349	63	69	the	the	DET
ecj-11349	63	70	same	same	ADJ
ecj-11349	63	71	effect.10	effect.10	ADP
ecj-11349	63	72	a	a	DET
ecj-11349	63	73	work	work	NOUN
ecj-11349	63	74	by	by	ADP
ecj-11349	63	75	lopez	lopez	NOUN
ecj-11349	63	76	-	-	PUNCT
ecj-11349	63	77	vilchez	vilchez	PROPN
ecj-11349	63	78	demonstrated	demonstrate	VERB
ecj-11349	63	79	that	that	SCONJ
ecj-11349	63	80	escitalopram	escitalopram	PROPN
ecj-11349	63	81	can	can	AUX
ecj-11349	63	82	inhibit	inhibit	VERB
ecj-11349	63	83	platelet	platelet	NOUN
ecj-11349	63	84	response	response	NOUN
ecj-11349	63	85	to	to	ADP
ecj-11349	63	86	thrombin	thrombin	NOUN
ecj-11349	63	87	,	,	PUNCT
ecj-11349	63	88	measured	measure	VERB
ecj-11349	63	89	as	as	ADP
ecj-11349	63	90	platelet	platelet	NOUN
ecj-11349	63	91	aggregation	aggregation	NOUN
ecj-11349	63	92	and	and	CCONJ
ecj-11349	63	93	expression	expression	NOUN
ecj-11349	63	94	of	of	ADP
ecj-11349	63	95	activation	activation	NOUN
ecj-11349	63	96	markers	marker	VERB
ecj-11349	63	97	cd62	cd62	PROPN
ecj-11349	63	98	-	-	PUNCT
ecj-11349	63	99	p	p	PROPN
ecj-11349	63	100	and	and	CCONJ
ecj-11349	63	101	cd63	cd63	PROPN
ecj-11349	63	102	from	from	ADP
ecj-11349	63	103	platelet	platelet	NOUN
ecj-11349	63	104	granules	granule	NOUN
ecj-11349	63	105	,	,	PUNCT
ecj-11349	63	106	and	and	CCONJ
ecj-11349	63	107	interfer	interfer	VERB
ecj-11349	63	108	with	with	ADP
ecj-11349	63	109	signalling	signal	VERB
ecj-11349	63	110	pathways	pathway	NOUN
ecj-11349	63	111	mediated	mediate	VERB
ecj-11349	63	112	by	by	ADP
ecj-11349	63	113	thrombin	thrombin	NOUN
ecj-11349	63	114	(	(	PUNCT
ecj-11349	63	115	rhoa	rhoa	PROPN
ecj-11349	63	116	,	,	PUNCT
ecj-11349	63	117	pkc	pkc	PROPN
ecj-11349	63	118	,	,	PUNCT
ecj-11349	63	119	erk1/2	erk1/2	PROPN
ecj-11349	63	120	and	and	CCONJ
ecj-11349	63	121	pi3k	pi3k	PROPN
ecj-11349	63	122	/	/	SYM
ecj-11349	63	123	akt	akt	PROPN
ecj-11349	63	124	)	)	PUNCT
ecj-11349	63	125	.	.	PUNCT
ecj-11349	64	1	escitalopram	escitalopram	PROPN
ecj-11349	64	2	can	can	AUX
ecj-11349	64	3	dysregulate	dysregulate	VERB
ecj-11349	64	4	the	the	DET
ecj-11349	64	5	polymerization	polymerization	NOUN
ecj-11349	64	6	of	of	ADP
ecj-11349	64	7	the	the	DET
ecj-11349	64	8	actin	actin	NOUN
ecj-11349	64	9	cytoskeleton	cytoskeleton	PROPN
ecj-11349	64	10	and	and	CCONJ
ecj-11349	64	11	association	association	NOUN
ecj-11349	64	12	of	of	ADP
ecj-11349	64	13	contractile	contractile	ADJ
ecj-11349	64	14	proteins	protein	NOUN
ecj-11349	64	15	during	during	ADP
ecj-11349	64	16	activation	activation	NOUN
ecj-11349	64	17	with	with	ADP
ecj-11349	64	18	thrombin	thrombin	NOUN
ecj-11349	64	19	.	.	PUNCT
ecj-11349	65	1	resting	rest	VERB
ecj-11349	65	2	platelets	platelet	NOUN
ecj-11349	65	3	incubated	incubate	VERB
ecj-11349	65	4	with	with	ADP
ecj-11349	65	5	escitalopram	escitalopram	PROPN
ecj-11349	65	6	became	become	VERB
ecj-11349	65	7	most	most	ADV
ecj-11349	65	8	spherical.11	spherical.11	NOUN
ecj-11349	65	9	moreover	moreover	ADV
ecj-11349	65	10	,	,	PUNCT
ecj-11349	65	11	an	an	DET
ecj-11349	65	12	in	in	ADP
ecj-11349	65	13	vitro	vitro	X
ecj-11349	65	14	study	study	NOUN
ecj-11349	65	15	showed	show	VERB
ecj-11349	65	16	how	how	SCONJ
ecj-11349	65	17	medium	medium	ADJ
ecj-11349	65	18	or	or	CCONJ
ecj-11349	65	19	high	high	ADJ
ecj-11349	65	20	amount	amount	NOUN
ecj-11349	65	21	of	of	ADP
ecj-11349	65	22	escitalopram	escitalopram	PROPN
ecj-11349	65	23	can	can	AUX
ecj-11349	65	24	significantly	significantly	ADV
ecj-11349	65	25	inhibit	inhibit	VERB
ecj-11349	65	26	platelet	platelet	NOUN
ecj-11349	65	27	aggregation	aggregation	NOUN
ecj-11349	65	28	induced	induce	VERB
ecj-11349	65	29	by	by	ADP
ecj-11349	65	30	adp	adp	PROPN
ecj-11349	65	31	and	and	CCONJ
ecj-11349	65	32	by	by	ADP
ecj-11349	65	33	collagen	collagen	NOUN
ecj-11349	65	34	,	,	PUNCT
ecj-11349	65	35	together	together	ADV
ecj-11349	65	36	with	with	ADP
ecj-11349	65	37	a	a	DET
ecj-11349	65	38	reduced	reduced	ADJ
ecj-11349	65	39	expression	expression	NOUN
ecj-11349	65	40	of	of	ADP
ecj-11349	65	41	glycoprotein	glycoprotein	NOUN
ecj-11349	65	42	(	(	PUNCT
ecj-11349	65	43	gp)ib	gp)ib	X
ecj-11349	65	44	,	,	PUNCT
ecj-11349	65	45	lysosome	lysosome	NOUN
ecj-11349	65	46	-	-	PUNCT
ecj-11349	65	47	associated	associate	VERB
ecj-11349	65	48	membrane	membrane	NOUN
ecj-11349	65	49	glycoprotein	glycoprotein	NOUN
ecj-11349	65	50	3	3	NUM
ecj-11349	65	51	(	(	PUNCT
ecj-11349	65	52	lamp-3	lamp-3	NOUN
ecj-11349	65	53	)	)	PUNCT
ecj-11349	65	54	and	and	CCONJ
ecj-11349	65	55	gp37	gp37	PROPN
ecj-11349	65	56	on	on	ADP
ecj-11349	65	57	platelet	platelet	NOUN
ecj-11349	65	58	surface.12	surface.12	PROPN
ecj-11349	65	59	-	-	NUM
ecj-11349	65	60	15	15	NUM
ecj-11349	65	61	some	some	DET
ecj-11349	65	62	ssris	ssris	NOUN
ecj-11349	65	63	(	(	PUNCT
ecj-11349	65	64	e.g.	e.g.	ADV
ecj-11349	65	65	,	,	PUNCT
ecj-11349	65	66	fluoxetine	fluoxetine	NOUN
ecj-11349	65	67	,	,	PUNCT
ecj-11349	65	68	paroxetine	paroxetine	NOUN
ecj-11349	65	69	or	or	CCONJ
ecj-11349	65	70	citalopram	citalopram	NOUN
ecj-11349	65	71	)	)	PUNCT
ecj-11349	65	72	may	may	AUX
ecj-11349	65	73	decrease	decrease	VERB
ecj-11349	65	74	the	the	DET
ecj-11349	65	75	secondary	secondary	ADJ
ecj-11349	65	76	phase	phase	NOUN
ecj-11349	65	77	of	of	ADP
ecj-11349	65	78	aggregation	aggregation	NOUN
ecj-11349	65	79	in	in	ADP
ecj-11349	65	80	response	response	NOUN
ecj-11349	65	81	to	to	ADP
ecj-11349	65	82	adp	adp	PROPN
ecj-11349	65	83	,	,	PUNCT
ecj-11349	65	84	and	and	CCONJ
ecj-11349	65	85	significantly	significantly	ADV
ecj-11349	65	86	lower	low	ADJ
ecj-11349	65	87	adenosine	adenosine	ADJ
ecj-11349	65	88	triphosphate16	triphosphate16	NOUN
ecj-11349	65	89	and	and	CCONJ
ecj-11349	65	90	serotonin	serotonin	VERB
ecj-11349	65	91	release	release	NOUN
ecj-11349	65	92	in	in	ADP
ecj-11349	65	93	normal	normal	ADJ
ecj-11349	65	94	platelet	platelet	NOUN
ecj-11349	65	95	rich	rich	ADJ
ecj-11349	65	96	plasma.13,14	plasma.13,14	ADJ
ecj-11349	65	97	ssris	ssris	PROPN
ecj-11349	65	98	can	can	AUX
ecj-11349	65	99	block	block	VERB
ecj-11349	65	100	serotonin	serotonin	NOUN
ecj-11349	65	101	release	release	NOUN
ecj-11349	65	102	from	from	ADP
ecj-11349	65	103	dense	dense	ADJ
ecj-11349	65	104	granule	granule	NOUN
ecj-11349	65	105	during	during	ADP
ecj-11349	65	106	platelet	platelet	NOUN
ecj-11349	65	107	aggregation.17	aggregation.17	PROPN
ecj-11349	65	108	tseng	tseng	PROPN
ecj-11349	65	109	et	et	PROPN
ecj-11349	65	110	al	al	PROPN
ecj-11349	65	111	.	.	PROPN
ecj-11349	65	112	demonstrated	demonstrate	VERB
ecj-11349	65	113	that	that	SCONJ
ecj-11349	65	114	ssris	ssris	PROPN
ecj-11349	65	115	can	can	AUX
ecj-11349	65	116	decrease	decrease	VERB
ecj-11349	65	117	the	the	DET
ecj-11349	65	118	amplification	amplification	NOUN
ecj-11349	65	119	of	of	ADP
ecj-11349	65	120	platelet	platelet	NOUN
ecj-11349	65	121	aggregation	aggregation	NOUN
ecj-11349	65	122	secondary	secondary	ADJ
ecj-11349	65	123	to	to	ADP
ecj-11349	65	124	the	the	DET
ecj-11349	65	125	activation	activation	NOUN
ecj-11349	65	126	of	of	ADP
ecj-11349	65	127	purinergic	purinergic	NOUN
ecj-11349	65	128	receptor	receptor	NOUN
ecj-11349	65	129	p2y12	p2y12	NOUN
ecj-11349	65	130	,	,	PUNCT
ecj-11349	65	131	thus	thus	ADV
ecj-11349	65	132	reducing	reduce	VERB
ecj-11349	65	133	the	the	DET
ecj-11349	65	134	activation	activation	NOUN
ecj-11349	65	135	of	of	ADP
ecj-11349	65	136	the	the	DET
ecj-11349	65	137	downstream	downstream	ADJ
ecj-11349	65	138	molecules	molecule	NOUN
ecj-11349	65	139	of	of	ADP
ecj-11349	65	140	the	the	DET
ecj-11349	65	141	adp	adp	PROPN
ecj-11349	65	142	signaling	signal	VERB
ecj-11349	65	143	pathways.13	pathways.13	ADP
ecj-11349	65	144	differences	difference	NOUN
ecj-11349	65	145	between	between	ADP
ecj-11349	65	146	citalopram	citalopram	PROPN
ecj-11349	65	147	and	and	CCONJ
ecj-11349	65	148	other	other	ADJ
ecj-11349	65	149	ssri	ssri	PROPN
ecj-11349	65	150	citalopram	citalopram	PROPN
ecj-11349	65	151	displays	display	VERB
ecj-11349	65	152	a	a	DET
ecj-11349	65	153	greater	great	ADJ
ecj-11349	65	154	effect	effect	NOUN
ecj-11349	65	155	to	to	PART
ecj-11349	65	156	inhibit	inhibit	VERB
ecj-11349	65	157	platelet	platelet	NOUN
ecj-11349	65	158	adhesion	adhesion	NOUN
ecj-11349	65	159	to	to	ADP
ecj-11349	65	160	both	both	DET
ecj-11349	65	161	collagen	collagen	NOUN
ecj-11349	65	162	and	and	CCONJ
ecj-11349	65	163	fibrinogen	fibrinogen	NOUN
ecj-11349	65	164	surfaces	surface	NOUN
ecj-11349	65	165	than	than	ADP
ecj-11349	65	166	sertraline.6	sertraline.6	PROPN
ecj-11349	65	167	moreover	moreover	ADV
ecj-11349	65	168	,	,	PUNCT
ecj-11349	65	169	citalopram	citalopram	PROPN
ecj-11349	65	170	,	,	PUNCT
ecj-11349	65	171	but	but	CCONJ
ecj-11349	65	172	not	not	PART
ecj-11349	65	173	paroxetine	paroxetine	NOUN
ecj-11349	65	174	,	,	PUNCT
ecj-11349	65	175	may	may	AUX
ecj-11349	65	176	significantly	significantly	ADV
ecj-11349	65	177	decrease	decrease	VERB
ecj-11349	65	178	p	p	NOUN
ecj-11349	65	179	-	-	PUNCT
ecj-11349	65	180	selectin	selectin	ADJ
ecj-11349	65	181	expression	expression	NOUN
ecj-11349	65	182	on	on	ADP
ecj-11349	65	183	platelets	platelet	NOUN
ecj-11349	65	184	after	after	ADP
ecj-11349	65	185	adp	adp	PROPN
ecj-11349	65	186	activation	activation	NOUN
ecj-11349	65	187	,	,	PUNCT
ecj-11349	65	188	thrombin	thrombin	NOUN
ecj-11349	65	189	receptor	receptor	NOUN
ecj-11349	65	190	-	-	PUNCT
ecj-11349	65	191	activating	activate	VERB
ecj-11349	65	192	peptides	peptide	NOUN
ecj-11349	65	193	(	(	PUNCT
ecj-11349	65	194	trap	trap	NOUN
ecj-11349	65	195	)	)	PUNCT
ecj-11349	65	196	and	and	CCONJ
ecj-11349	65	197	cross	cross	ADJ
ecj-11349	65	198	-	-	ADJ
ecj-11349	65	199	linked	link	VERB
ecj-11349	65	200	collagen	collagen	NOUN
ecj-11349	65	201	-	-	PUNCT
ecj-11349	65	202	related	relate	VERB
ecj-11349	65	203	peptide	peptide	NOUN
ecj-11349	65	204	(	(	PUNCT
ecj-11349	65	205	crp	crp	PROPN
ecj-11349	65	206	-	-	PROPN
ecj-11349	65	207	xl).18	xl).18	PROPN
ecj-11349	65	208	a	a	DET
ecj-11349	65	209	recent	recent	ADJ
ecj-11349	65	210	in	in	ADP
ecj-11349	65	211	vitro	vitro	X
ecj-11349	65	212	study	study	NOUN
ecj-11349	65	213	demonstrated	demonstrate	VERB
ecj-11349	65	214	two	two	NUM
ecj-11349	65	215	distinct	distinct	ADJ
ecj-11349	65	216	inhibitory	inhibitory	ADJ
ecj-11349	65	217	mechanisms	mechanism	NOUN
ecj-11349	65	218	on	on	ADP
ecj-11349	65	219	platelet	platelet	NOUN
ecj-11349	65	220	for	for	ADP
ecj-11349	65	221	citalopram	citalopram	NOUN
ecj-11349	65	222	:	:	PUNCT
ecj-11349	65	223	i	i	NOUN
ecj-11349	65	224	)	)	PUNCT
ecj-11349	65	225	inhibition	inhibition	NOUN
ecj-11349	65	226	of	of	ADP
ecj-11349	65	227	caldag	caldag	NOUN
ecj-11349	65	228	-	-	PUNCT
ecj-11349	65	229	gefi	gefi	PROPN
ecj-11349	65	230	/	/	SYM
ecj-11349	65	231	rap1	rap1	PROPN
ecj-11349	65	232	signaling	signal	VERB
ecj-11349	65	233	,	,	PUNCT
ecj-11349	65	234	and	and	CCONJ
ecj-11349	65	235	ii	ii	X
ecj-11349	65	236	)	)	PUNCT
ecj-11349	65	237	competitive	competitive	ADJ
ecj-11349	65	238	antagonism	antagonism	NOUN
ecj-11349	65	239	of	of	ADP
ecj-11349	65	240	glycoprotein	glycoprotein	ADJ
ecj-11349	65	241	vi	vi	PROPN
ecj-11349	65	242	(	(	PUNCT
ecj-11349	65	243	gpvi	gpvi	PROPN
ecj-11349	65	244	)	)	PUNCT
ecj-11349	65	245	in	in	ADP
ecj-11349	65	246	platelets.19	platelets.19	NOUN
ecj-11349	65	247	citalopram	citalopram	NOUN
ecj-11349	65	248	-	-	PUNCT
ecj-11349	65	249	related	relate	VERB
ecj-11349	65	250	inhibition	inhibition	NOUN
ecj-11349	65	251	of	of	ADP
ecj-11349	65	252	gpvi	gpvi	NOUN
ecj-11349	65	253	-	-	PUNCT
ecj-11349	65	254	mediated	mediate	VERB
ecj-11349	65	255	platelet	platelet	NOUN
ecj-11349	65	256	aggregation	aggregation	NOUN
ecj-11349	65	257	was	be	AUX
ecj-11349	65	258	instantaneous	instantaneous	ADJ
ecj-11349	65	259	,	,	PUNCT
ecj-11349	65	260	reversible	reversible	ADJ
ecj-11349	65	261	and	and	CCONJ
ecj-11349	65	262	displayed	display	VERB
ecj-11349	65	263	competitive	competitive	ADJ
ecj-11349	65	264	characteristics	characteristic	NOUN
ecj-11349	65	265	,	,	PUNCT
ecj-11349	65	266	thus	thus	ADV
ecj-11349	65	267	showing	show	VERB
ecj-11349	65	268	that	that	SCONJ
ecj-11349	65	269	those	those	DET
ecj-11349	65	270	effects	effect	NOUN
ecj-11349	65	271	were	be	AUX
ecj-11349	65	272	not	not	PART
ecj-11349	65	273	induced	induce	VERB
ecj-11349	65	274	by	by	ADP
ecj-11349	65	275	gpvi	gpvi	PROPN
ecj-11349	65	276	decrease	decrease	NOUN
ecj-11349	65	277	in	in	ADP
ecj-11349	65	278	surface	surface	NOUN
ecj-11349	65	279	expression	expression	NOUN
ecj-11349	65	280	,	,	PUNCT
ecj-11349	65	281	but	but	CCONJ
ecj-11349	65	282	by	by	ADP
ecj-11349	65	283	competitive	competitive	ADJ
ecj-11349	65	284	binding.19	binding.19	NOUN
ecj-11349	65	285	ssris	ssris	NOUN
ecj-11349	65	286	-	-	PUNCT
ecj-11349	65	287	induced	induce	VERB
ecj-11349	65	288	bleeding	bleeding	NOUN
ecj-11349	65	289	risk	risk	NOUN
ecj-11349	65	290	in	in	ADP
ecj-11349	65	291	patients	patient	NOUN
ecj-11349	65	292	undergoing	undergo	VERB
ecj-11349	65	293	anticoagulant	anticoagulant	NOUN
ecj-11349	65	294	therapy	therapy	NOUN
ecj-11349	65	295	as	as	SCONJ
ecj-11349	65	296	mentioned	mention	VERB
ecj-11349	65	297	earlier	early	ADV
ecj-11349	65	298	in	in	ADP
ecj-11349	65	299	the	the	DET
ecj-11349	65	300	background	background	NOUN
ecj-11349	65	301	,	,	PUNCT
ecj-11349	65	302	ssri	ssri	PROPN
ecj-11349	65	303	treatment	treatment	NOUN
ecj-11349	65	304	is	be	AUX
ecj-11349	65	305	related	relate	VERB
ecj-11349	65	306	to	to	ADP
ecj-11349	65	307	a	a	DET
ecj-11349	65	308	higher	high	ADJ
ecj-11349	65	309	risk	risk	NOUN
ecj-11349	65	310	of	of	ADP
ecj-11349	65	311	upper	upper	ADJ
ecj-11349	65	312	gi	gi	NOUN
ecj-11349	65	313	bleeding	bleeding	NOUN
ecj-11349	65	314	,	,	PUNCT
ecj-11349	65	315	probably	probably	ADV
ecj-11349	65	316	due	due	ADJ
ecj-11349	65	317	to	to	ADP
ecj-11349	65	318	ssri	ssri	ADV
ecj-11349	65	319	-	-	PUNCT
ecj-11349	65	320	induced	induce	VERB
ecj-11349	65	321	increase	increase	NOUN
ecj-11349	65	322	in	in	ADP
ecj-11349	65	323	gastric	gastric	ADJ
ecj-11349	65	324	acid	acid	NOUN
ecj-11349	65	325	secretion.20,21	secretion.20,21	VERB
ecj-11349	65	326	ssri	ssri	PROPN
ecj-11349	65	327	-	-	PUNCT
ecj-11349	65	328	associated	associate	VERB
ecj-11349	65	329	gastrointestinal	gastrointestinal	ADJ
ecj-11349	65	330	bleeding	bleed	VERB
ecj-11349	65	331	incidence	incidence	NOUN
ecj-11349	65	332	can	can	AUX
ecj-11349	65	333	be	be	AUX
ecj-11349	65	334	also	also	ADV
ecj-11349	65	335	increased	increase	VERB
ecj-11349	65	336	by	by	ADP
ecj-11349	65	337	the	the	DET
ecj-11349	65	338	concurrent	concurrent	ADJ
ecj-11349	65	339	use	use	NOUN
ecj-11349	65	340	of	of	ADP
ecj-11349	65	341	nonsteroidal	nonsteroidal	NOUN
ecj-11349	65	342	anti	anti	ADJ
ecj-11349	65	343	-	-	ADJ
ecj-11349	65	344	inflammatory	inflammatory	ADJ
ecj-11349	65	345	drug	drug	NOUN
ecj-11349	65	346	(	(	PUNCT
ecj-11349	65	347	nsaid)s	nsaid)s	PROPN
ecj-11349	65	348	,	,	PUNCT
ecj-11349	65	349	anticoagulants	anticoagulant	NOUN
ecj-11349	65	350	and	and	CCONJ
ecj-11349	65	351	antiplatelet	antiplatelet	VERB
ecj-11349	65	352	agents.20,22	agents.20,22	NOUN
ecj-11349	65	353	in	in	ADP
ecj-11349	65	354	our	our	PRON
ecj-11349	65	355	case	case	NOUN
ecj-11349	65	356	,	,	PUNCT
ecj-11349	65	357	patient	patient	NOUN
ecj-11349	65	358	was	be	AUX
ecj-11349	65	359	on	on	ADP
ecj-11349	65	360	treatment	treatment	NOUN
ecj-11349	65	361	with	with	ADP
ecj-11349	65	362	doac	doac	NOUN
ecj-11349	65	363	for	for	ADP
ecj-11349	65	364	a	a	DET
ecj-11349	65	365	permanent	permanent	ADJ
ecj-11349	65	366	af	af	NOUN
ecj-11349	65	367	,	,	PUNCT
ecj-11349	65	368	and	and	CCONJ
ecj-11349	65	369	the	the	DET
ecj-11349	65	370	association	association	NOUN
ecj-11349	65	371	between	between	ADP
ecj-11349	65	372	escitalopram	escitalopram	NOUN
ecj-11349	65	373	-	-	PUNCT
ecj-11349	65	374	induced	induce	VERB
ecj-11349	65	375	thrombocytopenia	thrombocytopenia	NOUN
ecj-11349	65	376	and	and	CCONJ
ecj-11349	65	377	anticoagulation	anticoagulation	NOUN
ecj-11349	65	378	may	may	AUX
ecj-11349	65	379	have	have	AUX
ecj-11349	65	380	exacerbated	exacerbate	VERB
ecj-11349	65	381	the	the	DET
ecj-11349	65	382	gastrointestinal	gastrointestinal	ADJ
ecj-11349	65	383	bleeding	bleeding	NOUN
ecj-11349	65	384	.	.	PUNCT
ecj-11349	66	1	moreover	moreover	ADV
ecj-11349	66	2	,	,	PUNCT
ecj-11349	66	3	doacs	doac	NOUN
ecj-11349	66	4	are	be	AUX
ecj-11349	66	5	known	know	VERB
ecj-11349	66	6	to	to	PART
ecj-11349	66	7	increase	increase	VERB
ecj-11349	66	8	the	the	DET
ecj-11349	66	9	potential	potential	ADJ
ecj-11349	66	10	risk	risk	NOUN
ecj-11349	66	11	for	for	ADP
ecj-11349	66	12	upper	upper	ADJ
ecj-11349	66	13	gi	gi	NOUN
ecj-11349	66	14	tract	tract	NOUN
ecj-11349	66	15	bleeding.23	bleeding.23	NOUN
ecj-11349	66	16	in	in	ADP
ecj-11349	66	17	the	the	DET
ecj-11349	66	18	work	work	NOUN
ecj-11349	66	19	of	of	ADP
ecj-11349	66	20	wallerstedt	wallerstedt	PROPN
ecj-11349	66	21	et	et	PROPN
ecj-11349	66	22	al	al	PROPN
ecj-11349	66	23	,	,	PUNCT
ecj-11349	66	24	the	the	DET
ecj-11349	66	25	addition	addition	NOUN
ecj-11349	66	26	of	of	ADP
ecj-11349	66	27	ssri	ssri	PROPN
ecj-11349	66	28	to	to	ADP
ecj-11349	66	29	warfarin	warfarin	NOUN
ecj-11349	66	30	-	-	PUNCT
ecj-11349	66	31	treated	treat	VERB
ecj-11349	66	32	patients	patient	NOUN
ecj-11349	66	33	was	be	AUX
ecj-11349	66	34	correlated	correlate	VERB
ecj-11349	66	35	with	with	ADP
ecj-11349	66	36	an	an	DET
ecj-11349	66	37	increased	increase	VERB
ecj-11349	66	38	risk	risk	NOUN
ecj-11349	66	39	of	of	ADP
ecj-11349	66	40	clinically	clinically	ADV
ecj-11349	66	41	relevant	relevant	ADJ
ecj-11349	66	42	bleeding.24	bleeding.24	NOUN
ecj-11349	66	43	these	these	DET
ecj-11349	66	44	findings	finding	NOUN
ecj-11349	66	45	have	have	AUX
ecj-11349	66	46	been	be	AUX
ecj-11349	66	47	reinforced	reinforce	VERB
ecj-11349	66	48	by	by	ADP
ecj-11349	66	49	a	a	DET
ecj-11349	66	50	recent	recent	ADJ
ecj-11349	66	51	work	work	NOUN
ecj-11349	66	52	by	by	ADP
ecj-11349	66	53	quinn	quinn	PROPN
ecj-11349	66	54	et	et	PROPN
ecj-11349	66	55	al	al	PROPN
ecj-11349	66	56	analyzing	analyze	VERB
ecj-11349	66	57	a	a	DET
ecj-11349	66	58	cohort	cohort	NOUN
ecj-11349	66	59	of	of	ADP
ecj-11349	66	60	9,186	9,186	NUM
ecj-11349	66	61	patients	patient	NOUN
ecj-11349	66	62	adults	adult	NOUN
ecj-11349	66	63	with	with	ADP
ecj-11349	66	64	atrial	atrial	ADJ
ecj-11349	66	65	fibrillation.25	fibrillation.25	NOUN
ecj-11349	66	66	ssri	ssri	NOUN
ecj-11349	66	67	utilization	utilization	NOUN
ecj-11349	66	68	was	be	AUX
ecj-11349	66	69	related	relate	VERB
ecj-11349	66	70	to	to	ADP
ecj-11349	66	71	higher	high	ADJ
ecj-11349	66	72	incidence	incidence	NOUN
ecj-11349	66	73	of	of	ADP
ecj-11349	66	74	bleedings	bleeding	NOUN
ecj-11349	66	75	in	in	ADP
ecj-11349	66	76	comparison	comparison	NOUN
ecj-11349	66	77	with	with	ADP
ecj-11349	66	78	no	no	DET
ecj-11349	66	79	antidepressants	antidepressant	NOUN
ecj-11349	66	80	,	,	PUNCT
ecj-11349	66	81	and	and	CCONJ
ecj-11349	66	82	bleeding	bleeding	NOUN
ecj-11349	66	83	was	be	AUX
ecj-11349	66	84	more	more	ADV
ecj-11349	66	85	detected	detect	VERB
ecj-11349	66	86	during	during	ADP
ecj-11349	66	87	periods	period	NOUN
ecj-11349	66	88	of	of	ADP
ecj-11349	66	89	ssri	ssri	ADJ
ecj-11349	66	90	exposure	exposure	NOUN
ecj-11349	66	91	than	than	SCONJ
ecj-11349	66	92	no	no	DET
ecj-11349	66	93	antidepressants	antidepressant	NOUN
ecj-11349	66	94	ones.25	ones.25	VERB
ecj-11349	66	95	a	a	DET
ecj-11349	66	96	recent	recent	ADJ
ecj-11349	66	97	work	work	NOUN
ecj-11349	66	98	by	by	ADP
ecj-11349	66	99	bakker	bakker	PROPN
ecj-11349	66	100	et	et	PROPN
ecj-11349	66	101	al	al	PROPN
ecj-11349	66	102	.	.	PROPN
ecj-11349	66	103	reinforced	reinforce	VERB
ecj-11349	66	104	the	the	DET
ecj-11349	66	105	concept	concept	NOUN
ecj-11349	66	106	that	that	SCONJ
ecj-11349	66	107	ssris	ssris	PROPN
ecj-11349	66	108	are	be	AUX
ecj-11349	66	109	related	relate	VERB
ecj-11349	66	110	to	to	ADP
ecj-11349	66	111	an	an	DET
ecj-11349	66	112	increased	increase	VERB
ecj-11349	66	113	risk	risk	NOUN
ecj-11349	66	114	of	of	ADP
ecj-11349	66	115	high	high	ADJ
ecj-11349	66	116	inr	inr	PROPN
ecj-11349	66	117	and	and	CCONJ
ecj-11349	66	118	major	major	ADJ
ecj-11349	66	119	bleeding	bleeding	NOUN
ecj-11349	66	120	in	in	ADP
ecj-11349	66	121	patients	patient	NOUN
ecj-11349	66	122	taking	take	VERB
ecj-11349	66	123	vitamin	vitamin	NOUN
ecj-11349	66	124	k	k	PROPN
ecj-11349	66	125	antagonist	antagonist	NOUN
ecj-11349	66	126	therapy.2,26	therapy.2,26	PROPN
ecj-11349	66	127	indeed	indeed	ADV
ecj-11349	66	128	,	,	PUNCT
ecj-11349	66	129	ssri	ssri	PROPN
ecj-11349	66	130	therapy	therapy	NOUN
ecj-11349	66	131	versus	versus	ADP
ecj-11349	66	132	non	non	ADJ
ecj-11349	66	133	-	-	ADJ
ecj-11349	66	134	use	use	NOUN
ecj-11349	66	135	was	be	AUX
ecj-11349	66	136	related	relate	VERB
ecj-11349	66	137	to	to	ADP
ecj-11349	66	138	a	a	DET
ecj-11349	66	139	2.41	2.41	NUM
ecj-11349	66	140	-	-	NUM
ecj-11349	66	141	fold	fold	ADJ
ecj-11349	66	142	(	(	PUNCT
ecj-11349	66	143	95	95	NUM
ecj-11349	66	144	%	%	NOUN
ecj-11349	66	145	ci	ci	NOUN
ecj-11349	66	146	:	:	PUNCT
ecj-11349	66	147	2.01	2.01	NUM
ecj-11349	66	148	-	-	SYM
ecj-11349	66	149	2.89	2.89	NUM
ecj-11349	66	150	)	)	PUNCT
ecj-11349	66	151	increased	increase	VERB
ecj-11349	66	152	risk	risk	NOUN
ecj-11349	66	153	for	for	ADP
ecj-11349	66	154	a	a	DET
ecj-11349	66	155	high	high	ADJ
ecj-11349	66	156	inr	inr	NOUN
ecj-11349	66	157	,	,	PUNCT
ecj-11349	66	158	which	which	PRON
ecj-11349	66	159	was	be	AUX
ecj-11349	66	160	3.14	3.14	NUM
ecj-11349	66	161	-	-	ADJ
ecj-11349	66	162	fold	fold	ADJ
ecj-11349	66	163	(	(	PUNCT
ecj-11349	66	164	95	95	NUM
ecj-11349	66	165	%	%	NOUN
ecj-11349	66	166	ci	ci	NOUN
ecj-11349	66	167	:	:	PUNCT
ecj-11349	66	168	1.33	1.33	NUM
ecj-11349	66	169	-	-	SYM
ecj-11349	66	170	7.43	7.43	NUM
ecj-11349	66	171	)	)	PUNCT
ecj-11349	66	172	among	among	ADP
ecj-11349	66	173	cyp2c9	cyp2c9	NOUN
ecj-11349	66	174	-	-	PUNCT
ecj-11349	66	175	inhibiting	inhibit	VERB
ecj-11349	66	176	ssri	ssri	NOUN
ecj-11349	66	177	users.2	users.2	ADP
ecj-11349	66	178	the	the	DET
ecj-11349	66	179	adjusted	adjust	VERB
ecj-11349	66	180	hr	hr	NOUN
ecj-11349	66	181	of	of	ADP
ecj-11349	66	182	major	major	ADJ
ecj-11349	66	183	bleeding	bleeding	NOUN
ecj-11349	66	184	was	be	AUX
ecj-11349	66	185	1.22	1.22	NUM
ecj-11349	66	186	(	(	PUNCT
ecj-11349	66	187	95	95	NUM
ecj-11349	66	188	%	%	NOUN
ecj-11349	66	189	ci	ci	NOUN
ecj-11349	66	190	:	:	PUNCT
ecj-11349	66	191	0.99	0.99	NUM
ecj-11349	66	192	-	-	SYM
ecj-11349	66	193	1.50	1.50	NUM
ecj-11349	66	194	)	)	PUNCT
ecj-11349	66	195	in	in	ADP
ecj-11349	66	196	all	all	DET
ecj-11349	66	197	ssri	ssri	ADJ
ecj-11349	66	198	users	user	NOUN
ecj-11349	66	199	and	and	CCONJ
ecj-11349	66	200	1.31	1.31	NUM
ecj-11349	66	201	(	(	PUNCT
ecj-11349	66	202	95	95	NUM
ecj-11349	66	203	%	%	NOUN
ecj-11349	66	204	ci	ci	NOUN
ecj-11349	66	205	:	:	PUNCT
ecj-11349	66	206	0.62	0.62	NUM
ecj-11349	66	207	-	-	SYM
ecj-11349	66	208	2.72	2.72	NUM
ecj-11349	66	209	)	)	PUNCT
ecj-11349	66	210	in	in	ADP
ecj-11349	66	211	cyp2c9	cyp2c9	NOUN
ecj-11349	66	212	-	-	PUNCT
ecj-11349	66	213	inhibiting	inhibit	VERB
ecj-11349	66	214	ssri	ssri	NOUN
ecj-11349	66	215	users	user	NOUN
ecj-11349	66	216	compared	compare	VERB
ecj-11349	66	217	with	with	ADP
ecj-11349	66	218	non	non	ADJ
ecj-11349	66	219	-	-	ADJ
ecj-11349	66	220	users.2	users.2	ADJ
ecj-11349	66	221	therefore	therefore	ADV
ecj-11349	66	222	,	,	PUNCT
ecj-11349	66	223	ssris	ssris	PROPN
ecj-11349	66	224	can	can	AUX
ecj-11349	66	225	increase	increase	VERB
ecj-11349	66	226	the	the	DET
ecj-11349	66	227	risk	risk	NOUN
ecj-11349	66	228	of	of	ADP
ecj-11349	66	229	major	major	ADJ
ecj-11349	66	230	bleeding	bleeding	NOUN
ecj-11349	66	231	in	in	ADP
ecj-11349	66	232	patients	patient	NOUN
ecj-11349	66	233	on	on	ADP
ecj-11349	66	234	vka	vka	NOUN
ecj-11349	66	235	therapy	therapy	NOUN
ecj-11349	66	236	not	not	PART
ecj-11349	66	237	only	only	ADV
ecj-11349	66	238	by	by	ADP
ecj-11349	66	239	decreasing	decrease	VERB
ecj-11349	66	240	platelet	platelet	NOUN
ecj-11349	66	241	function	function	NOUN
ecj-11349	66	242	but	but	CCONJ
ecj-11349	66	243	decreasing	decrease	VERB
ecj-11349	66	244	vka	vka	NOUN
ecj-11349	66	245	metabolism	metabolism	NOUN
ecj-11349	66	246	through	through	ADP
ecj-11349	66	247	cytochrome	cytochrome	NOUN
ecj-11349	66	248	cyp2c9	cyp2c9	NOUN
ecj-11349	66	249	inhibition	inhibition	NOUN
ecj-11349	66	250	.	.	PUNCT
ecj-11349	67	1	some	some	DET
ecj-11349	67	2	guidelines	guideline	NOUN
ecj-11349	67	3	recommended	recommend	VERB
ecj-11349	67	4	to	to	PART
ecj-11349	67	5	avoid	avoid	VERB
ecj-11349	67	6	ssris	ssris	NOUN
ecj-11349	67	7	in	in	ADP
ecj-11349	67	8	doac	doac	ADJ
ecj-11349	67	9	users.27,28	users.27,28	NOUN
ecj-11349	67	10	however	however	ADV
ecj-11349	67	11	,	,	PUNCT
ecj-11349	67	12	a	a	DET
ecj-11349	67	13	work	work	NOUN
ecj-11349	67	14	by	by	ADP
ecj-11349	67	15	bezabhe	bezabhe	PROPN
ecj-11349	67	16	et	et	PROPN
ecj-11349	67	17	al	al	PROPN
ecj-11349	67	18	.	.	PROPN
ecj-11349	68	1	analyzing	analyze	VERB
ecj-11349	68	2	data	datum	NOUN
ecj-11349	68	3	during	during	ADP
ecj-11349	68	4	2018	2018	NUM
ecj-11349	68	5	demonstrated	demonstrate	VERB
ecj-11349	68	6	that	that	SCONJ
ecj-11349	68	7	ssris	ssris	PROPN
ecj-11349	68	8	were	be	AUX
ecj-11349	68	9	co	co	VERB
ecj-11349	68	10	-	-	VERB
ecj-11349	68	11	prescribed	prescribe	VERB
ecj-11349	68	12	with	with	ADP
ecj-11349	68	13	doacs	doac	NOUN
ecj-11349	68	14	in	in	ADP
ecj-11349	68	15	14.8	14.8	NUM
ecj-11349	68	16	%	%	NOUN
ecj-11349	68	17	of	of	ADP
ecj-11349	68	18	users.29	users.29	NOUN
ecj-11349	68	19	high	high	ADJ
ecj-11349	68	20	rate	rate	NOUN
ecj-11349	68	21	of	of	ADP
ecj-11349	68	22	concomitant	concomitant	ADJ
ecj-11349	68	23	ssris	ssris	NOUN
ecj-11349	68	24	and	and	CCONJ
ecj-11349	68	25	doac	doac	ADJ
ecj-11349	68	26	prescribing	prescribing	NOUN
ecj-11349	68	27	(	(	PUNCT
ecj-11349	68	28	22.9	22.9	NUM
ecj-11349	68	29	%	%	NOUN
ecj-11349	68	30	)	)	PUNCT
ecj-11349	68	31	was	be	AUX
ecj-11349	68	32	also	also	ADV
ecj-11349	68	33	reported	report	VERB
ecj-11349	68	34	in	in	ADP
ecj-11349	68	35	an	an	DET
ecj-11349	68	36	australian	australian	ADJ
ecj-11349	68	37	study	study	NOUN
ecj-11349	68	38	of	of	ADP
ecj-11349	68	39	elderly	elderly	ADJ
ecj-11349	68	40	hospitalized	hospitalize	VERB
ecj-11349	68	41	patients.30	patients.30	NOUN
ecj-11349	68	42	a	a	DET
ecj-11349	68	43	recent	recent	ADJ
ecj-11349	68	44	study	study	NOUN
ecj-11349	68	45	by	by	ADP
ecj-11349	68	46	zhang	zhang	PROPN
ecj-11349	68	47	et	et	PROPN
ecj-11349	68	48	al	al	PROPN
ecj-11349	68	49	.	.	PROPN
ecj-11349	68	50	,	,	PUNCT
ecj-11349	68	51	involving	involve	VERB
ecj-11349	68	52	almost	almost	ADV
ecj-11349	68	53	24,000	24,000	NUM
ecj-11349	68	54	new	new	ADJ
ecj-11349	68	55	users	user	NOUN
ecj-11349	68	56	of	of	ADP
ecj-11349	68	57	doacs	doac	NOUN
ecj-11349	68	58	in	in	ADP
ecj-11349	68	59	the	the	DET
ecj-11349	68	60	uk	uk	PROPN
ecj-11349	68	61	clinical	clinical	ADJ
ecj-11349	68	62	practice	practice	NOUN
ecj-11349	68	63	research	research	NOUN
ecj-11349	68	64	datalink	datalink	NOUN
ecj-11349	68	65	,	,	PUNCT
ecj-11349	68	66	found	find	VERB
ecj-11349	68	67	a	a	DET
ecj-11349	68	68	significant	significant	ADJ
ecj-11349	68	69	increase	increase	NOUN
ecj-11349	68	70	in	in	ADP
ecj-11349	68	71	the	the	DET
ecj-11349	68	72	risk	risk	NOUN
ecj-11349	68	73	of	of	ADP
ecj-11349	68	74	major	major	ADJ
ecj-11349	68	75	bleeding	bleeding	NOUN
ecj-11349	68	76	in	in	ADP
ecj-11349	68	77	patients	patient	NOUN
ecj-11349	68	78	co	co	ADJ
ecj-11349	68	79	-	-	VERB
ecj-11349	68	80	prescribed	prescribe	VERB
ecj-11349	68	81	an	an	DET
ecj-11349	68	82	ssri	ssri	NOUN
ecj-11349	68	83	/	/	SYM
ecj-11349	68	84	snri	snri	NOUN
ecj-11349	68	85	(	(	PUNCT
ecj-11349	68	86	or	or	CCONJ
ecj-11349	68	87	1.68	1.68	NUM
ecj-11349	68	88	95	95	NUM
ecj-11349	68	89	%	%	NOUN
ecj-11349	68	90	ci	ci	NOUN
ecj-11349	68	91	,	,	PUNCT
ecj-11349	68	92	1.10	1.10	NUM
ecj-11349	68	93	-	-	PUNCT
ecj-11349	68	94	2.59).31	2.59).31	NUM
ecj-11349	68	95	a	a	DET
ecj-11349	68	96	sub	sub	NOUN
ecj-11349	68	97	-	-	NOUN
ecj-11349	68	98	analysis	analysis	NOUN
ecj-11349	68	99	of	of	ADP
ecj-11349	68	100	the	the	DET
ecj-11349	68	101	rocket	rocket	NOUN
ecj-11349	68	102	af	af	PROPN
ecj-11349	68	103	trial	trial	NOUN
ecj-11349	68	104	was	be	AUX
ecj-11349	68	105	performed	perform	VERB
ecj-11349	68	106	on	on	ADP
ecj-11349	68	107	737	737	NUM
ecj-11349	68	108	patients	patient	NOUN
ecj-11349	68	109	taking	take	VERB
ecj-11349	68	110	ssris.32	ssris.32	ADJ
ecj-11349	68	111	authors	author	NOUN
ecj-11349	68	112	found	find	VERB
ecj-11349	68	113	no	no	DET
ecj-11349	68	114	significant	significant	ADJ
ecj-11349	68	115	increase	increase	NOUN
ecj-11349	68	116	in	in	ADP
ecj-11349	68	117	bleeding	bleed	VERB
ecj-11349	68	118	risk	risk	NOUN
ecj-11349	68	119	when	when	SCONJ
ecj-11349	68	120	ssri	ssri	PROPN
ecj-11349	68	121	s	s	VERB
ecj-11349	68	122	were	be	AUX
ecj-11349	68	123	combined	combine	VERB
ecj-11349	68	124	with	with	ADP
ecj-11349	68	125	anticoagulant	anticoagulant	ADJ
ecj-11349	68	126	therapy	therapy	NOUN
ecj-11349	68	127	,	,	PUNCT
ecj-11349	68	128	although	although	SCONJ
ecj-11349	68	129	there	there	PRON
ecj-11349	68	130	was	be	VERB
ecj-11349	68	131	a	a	DET
ecj-11349	68	132	suggestion	suggestion	NOUN
ecj-11349	68	133	of	of	ADP
ecj-11349	68	134	increased	increase	VERB
ecj-11349	68	135	bleeding	bleeding	NOUN
ecj-11349	68	136	risk	risk	NOUN
ecj-11349	68	137	with	with	ADP
ecj-11349	68	138	ssri	ssri	PROPN
ecj-11349	68	139	s	s	AUX
ecj-11349	68	140	added	add	VERB
ecj-11349	68	141	to	to	ADP
ecj-11349	68	142	warfarin	warfarin	NOUN
ecj-11349	68	143	than	than	ADP
ecj-11349	68	144	rivaroxaban	rivaroxaban	NOUN
ecj-11349	68	145	(	(	PUNCT
ecj-11349	68	146	hr	hr	NOUN
ecj-11349	68	147	1.58	1.58	NUM
ecj-11349	68	148	vs.	vs.	ADP
ecj-11349	68	149	1.13).32	1.13).32	NUM
ecj-11349	68	150	furthermore	furthermore	ADV
ecj-11349	68	151	,	,	PUNCT
ecj-11349	68	152	ssris	ssris	PROPN
ecj-11349	68	153	are	be	AUX
ecj-11349	68	154	more	more	ADV
ecj-11349	68	155	related	related	ADJ
ecj-11349	68	156	to	to	ADP
ecj-11349	68	157	non	non	ADJ
ecj-11349	68	158	-	-	ADJ
ecj-11349	68	159	ulcer	ulcer	ADJ
ecj-11349	68	160	gastrointestinal	gastrointestinal	ADJ
ecj-11349	68	161	bleeding	bleeding	NOUN
ecj-11349	68	162	after	after	ADP
ecj-11349	68	163	adjusting	adjust	VERB
ecj-11349	68	164	for	for	ADP
ecj-11349	68	165	age	age	NOUN
ecj-11349	68	166	,	,	PUNCT
ecj-11349	68	167	gender	gender	NOUN
ecj-11349	68	168	and	and	CCONJ
ecj-11349	68	169	co	co	NOUN
ecj-11349	68	170	-	-	NOUN
ecj-11349	68	171	morbidity	morbidity	NOUN
ecj-11349	68	172	in	in	ADP
ecj-11349	68	173	comparison	comparison	NOUN
ecj-11349	68	174	with	with	ADP
ecj-11349	68	175	aspirin.33	aspirin.33	NOUN
ecj-11349	68	176	the	the	DET
ecj-11349	68	177	prescription	prescription	NOUN
ecj-11349	68	178	of	of	ADP
ecj-11349	68	179	concurrent	concurrent	ADJ
ecj-11349	68	180	proton	proton	NOUN
ecj-11349	68	181	pump	pump	NOUN
ecj-11349	68	182	inhibitors	inhibitor	NOUN
ecj-11349	68	183	therapy	therapy	NOUN
ecj-11349	68	184	can	can	AUX
ecj-11349	68	185	be	be	AUX
ecj-11349	68	186	beneficial	beneficial	ADJ
ecj-11349	68	187	.	.	PUNCT
ecj-11349	69	1	bleedings	bleeding	NOUN
ecj-11349	69	2	have	have	AUX
ecj-11349	69	3	been	be	AUX
ecj-11349	69	4	less	less	ADV
ecj-11349	69	5	commonly	commonly	ADV
ecj-11349	69	6	reported	report	VERB
ecj-11349	69	7	at	at	ADP
ecj-11349	69	8	other	other	ADJ
ecj-11349	69	9	sites	site	NOUN
ecj-11349	69	10	,	,	PUNCT
ecj-11349	69	11	especially	especially	ADV
ecj-11349	69	12	those	those	PRON
ecj-11349	69	13	associated	associate	VERB
ecj-11349	69	14	with	with	ADP
ecj-11349	69	15	surgical	surgical	ADJ
ecj-11349	69	16	procedures.20	procedures.20	NOUN
ecj-11349	69	17	a	a	DET
ecj-11349	69	18	more	more	ADV
ecj-11349	69	19	recent	recent	ADJ
ecj-11349	69	20	work	work	NOUN
ecj-11349	69	21	performed	perform	VERB
ecj-11349	69	22	on	on	ADP
ecj-11349	69	23	98863	98863	NUM
ecj-11349	69	24	patients	patient	NOUN
ecj-11349	69	25	with	with	ADP
ecj-11349	69	26	af	af	PROPN
ecj-11349	69	27	,	,	PUNCT
ecj-11349	69	28	demonstrated	demonstrate	VERB
ecj-11349	69	29	an	an	DET
ecj-11349	69	30	increased	increased	ADJ
ecj-11349	69	31	risk	risk	NOUN
ecj-11349	69	32	of	of	ADP
ecj-11349	69	33	intracerebral	intracerebral	ADJ
ecj-11349	69	34	hemorrhage	hemorrhage	NOUN
ecj-11349	69	35	(	(	PUNCT
ecj-11349	69	36	ich	ich	NOUN
ecj-11349	69	37	)	)	PUNCT
ecj-11349	69	38	was	be	AUX
ecj-11349	69	39	associated	associate	VERB
ecj-11349	69	40	with	with	ADP
ecj-11349	69	41	the	the	DET
ecj-11349	69	42	combinations	combination	NOUN
ecj-11349	69	43	of	of	ADP
ecj-11349	69	44	doacs	doac	NOUN
ecj-11349	69	45	with	with	ADP
ecj-11349	69	46	ssris	ssris	NOUN
ecj-11349	69	47	(	(	PUNCT
ecj-11349	69	48	rr	rr	NOUN
ecj-11349	69	49	:	:	PUNCT
ecj-11349	69	50	1.38	1.38	NUM
ecj-11349	69	51	,	,	PUNCT
ecj-11349	69	52	95	95	NUM
ecj-11349	69	53	%	%	NOUN
ecj-11349	69	54	ci	ci	NOUN
ecj-11349	69	55	:	:	PUNCT
ecj-11349	69	56	1.08	1.08	NUM
ecj-11349	69	57	-	-	SYM
ecj-11349	69	58	1.76	1.76	NUM
ecj-11349	69	59	)	)	PUNCT
ecj-11349	69	60	.	.	PUNCT
ecj-11349	70	1	in	in	ADP
ecj-11349	70	2	subgroup	subgroup	NOUN
ecj-11349	70	3	analyses	analysis	NOUN
ecj-11349	70	4	stratified	stratify	VERB
ecj-11349	70	5	by	by	ADP
ecj-11349	70	6	individual	individual	ADJ
ecj-11349	70	7	doacs	doac	NOUN
ecj-11349	70	8	,	,	PUNCT
ecj-11349	70	9	ssris	ssris	PROPN
ecj-11349	70	10	increased	increase	VERB
ecj-11349	70	11	the	the	DET
ecj-11349	70	12	risk	risk	NOUN
ecj-11349	70	13	of	of	ADP
ecj-11349	70	14	ich	ich	NOUN
ecj-11349	70	15	in	in	ADP
ecj-11349	70	16	the	the	DET
ecj-11349	70	17	dabigatran	dabigatran	ADV
ecj-11349	70	18	-	-	PUNCT
ecj-11349	70	19	treated	treat	VERB
ecj-11349	70	20	patients	patient	NOUN
ecj-11349	70	21	(	(	PUNCT
ecj-11349	70	22	rr	rr	NOUN
ecj-11349	70	23	:	:	PUNCT
ecj-11349	70	24	1.55	1.55	NUM
ecj-11349	70	25	,	,	PUNCT
ecj-11349	70	26	95	95	NUM
ecj-11349	70	27	%	%	NOUN
ecj-11349	70	28	ci	ci	NOUN
ecj-11349	70	29	:	:	PUNCT
ecj-11349	70	30	1.042.33	1.042.33	NUM
ecj-11349	70	31	)	)	PUNCT
ecj-11349	70	32	.	.	PUNCT
ecj-11349	71	1	in	in	ADP
ecj-11349	71	2	our	our	PRON
ecj-11349	71	3	clinical	clinical	ADJ
ecj-11349	71	4	case	case	NOUN
ecj-11349	71	5	,	,	PUNCT
ecj-11349	71	6	time	time	NOUN
ecj-11349	71	7	latency	latency	NOUN
ecj-11349	71	8	from	from	ADP
ecj-11349	71	9	ssris	ssris	PROPN
ecj-11349	71	10	starting	starting	NOUN
ecj-11349	71	11	and	and	CCONJ
ecj-11349	71	12	bleeding	bleed	VERB
ecj-11349	71	13	event	event	NOUN
ecj-11349	71	14	could	could	AUX
ecj-11349	71	15	confirm	confirm	VERB
ecj-11349	71	16	the	the	DET
ecj-11349	71	17	possible	possible	ADJ
ecj-11349	71	18	association	association	NOUN
ecj-11349	71	19	with	with	ADP
ecj-11349	71	20	ssri	ssri	PROPN
ecj-11349	71	21	and	and	CCONJ
ecj-11349	71	22	the	the	DET
ecj-11349	71	23	involved	involved	ADJ
ecj-11349	71	24	mechanism	mechanism	NOUN
ecj-11349	71	25	related	relate	VERB
ecj-11349	71	26	to	to	ADP
ecj-11349	71	27	impairment	impairment	NOUN
ecj-11349	71	28	of	of	ADP
ecj-11349	71	29	platelet	platelet	NOUN
ecj-11349	71	30	adhesion	adhesion	NOUN
ecj-11349	71	31	.	.	PUNCT
ecj-11349	72	1	the	the	DET
ecj-11349	72	2	‘	'	PUNCT
ecj-11349	72	3	beneficial	beneficial	ADJ
ecj-11349	72	4	’	'	PUNCT
ecj-11349	72	5	effect	effect	NOUN
ecj-11349	72	6	of	of	ADP
ecj-11349	72	7	ssris	ssris	NOUN
ecj-11349	72	8	on	on	ADP
ecj-11349	72	9	cardiovascular	cardiovascular	ADJ
ecj-11349	72	10	disease	disease	NOUN
ecj-11349	72	11	an	an	DET
ecj-11349	72	12	increasing	increase	VERB
ecj-11349	72	13	body	body	NOUN
ecj-11349	72	14	of	of	ADP
ecj-11349	72	15	evidence	evidence	NOUN
ecj-11349	72	16	is	be	AUX
ecj-11349	72	17	available	available	ADJ
ecj-11349	72	18	about	about	ADP
ecj-11349	72	19	ssris	ssris	NOUN
ecj-11349	72	20	and	and	CCONJ
ecj-11349	72	21	their	their	PRON
ecj-11349	72	22	possible	possible	ADJ
ecj-11349	72	23	protective	protective	ADJ
ecj-11349	72	24	effects	effect	NOUN
ecj-11349	72	25	against	against	ADP
ecj-11349	72	26	cardiovascular	cardiovascular	ADJ
ecj-11349	72	27	and	and	CCONJ
ecj-11349	72	28	ischemic	ischemic	ADJ
ecj-11349	72	29	heart	heart	NOUN
ecj-11349	72	30	disease	disease	NOUN
ecj-11349	72	31	events	event	NOUN
ecj-11349	72	32	.	.	PUNCT
ecj-11349	73	1	ssri	ssri	PROPN
ecj-11349	73	2	effects	effect	NOUN
ecj-11349	73	3	on	on	ADP
ecj-11349	73	4	platelet	platelet	NOUN
ecj-11349	73	5	reactivity	reactivity	NOUN
ecj-11349	73	6	,	,	PUNCT
ecj-11349	73	7	endothelial	endothelial	ADJ
ecj-11349	73	8	reactivity	reactivity	NOUN
ecj-11349	73	9	,	,	PUNCT
ecj-11349	73	10	and	and	CCONJ
ecj-11349	73	11	inflammatory	inflammatory	ADJ
ecj-11349	73	12	molecules	molecule	NOUN
ecj-11349	73	13	can	can	AUX
ecj-11349	73	14	be	be	AUX
ecj-11349	73	15	responsible	responsible	ADJ
ecj-11349	73	16	for	for	ADP
ecj-11349	73	17	the	the	DET
ecj-11349	73	18	beneficial	beneficial	ADJ
ecj-11349	73	19	effect	effect	NOUN
ecj-11349	73	20	on	on	ADP
ecj-11349	73	21	ischemic	ischemic	ADJ
ecj-11349	73	22	heart	heart	NOUN
ecj-11349	73	23	disease.34	disease.34	NOUN
ecj-11349	73	24	-	-	PUNCT
ecj-11349	73	25	37	37	NUM
ecj-11349	73	26	a	a	DET
ecj-11349	73	27	recent	recent	ADJ
ecj-11349	73	28	systematic	systematic	ADJ
ecj-11349	73	29	review	review	NOUN
ecj-11349	73	30	performed	perform	VERB
ecj-11349	73	31	on1148	on1148	NOUN
ecj-11349	73	32	patients	patient	NOUN
ecj-11349	73	33	showed	show	VERB
ecj-11349	73	34	that	that	SCONJ
ecj-11349	73	35	ssris	ssris	NOUN
ecj-11349	73	36	were	be	AUX
ecj-11349	73	37	related	relate	VERB
ecj-11349	73	38	to	to	ADP
ecj-11349	73	39	a	a	DET
ecj-11349	73	40	significantly	significantly	ADV
ecj-11349	73	41	lower	low	ADJ
ecj-11349	73	42	risk	risk	NOUN
ecj-11349	73	43	of	of	ADP
ecj-11349	73	44	myocardial	myocardial	ADJ
ecj-11349	73	45	infarction	infarction	NOUN
ecj-11349	73	46	in	in	ADP
ecj-11349	73	47	patients	patient	NOUN
ecj-11349	73	48	with	with	ADP
ecj-11349	73	49	cad	cad	PROPN
ecj-11349	73	50	and	and	CCONJ
ecj-11349	73	51	depression	depression	NOUN
ecj-11349	73	52	(	(	PUNCT
ecj-11349	73	53	rr	rr	NOUN
ecj-11349	73	54	0.54	0.54	NUM
ecj-11349	73	55	,	,	PUNCT
ecj-11349	73	56	95	95	NUM
ecj-11349	73	57	%	%	NOUN
ecj-11349	73	58	ci	ci	NOUN
ecj-11349	73	59	0.34	0.34	NUM
ecj-11349	73	60	-	-	PUNCT
ecj-11349	73	61	0.86	0.86	NUM
ecj-11349	73	62	)	)	PUNCT
ecj-11349	73	63	,	,	PUNCT
ecj-11349	73	64	and	and	CCONJ
ecj-11349	73	65	in	in	ADP
ecj-11349	73	66	post	post	ADJ
ecj-11349	73	67	-	-	ADJ
ecj-11349	73	68	acs	acs	ADJ
ecj-11349	73	69	patients	patient	NOUN
ecj-11349	73	70	with	with	ADP
ecj-11349	73	71	depression	depression	NOUN
ecj-11349	73	72	(	(	PUNCT
ecj-11349	73	73	rr	rr	NOUN
ecj-11349	73	74	0.56	0.56	NUM
ecj-11349	73	75	,	,	PUNCT
ecj-11349	73	76	95	95	NUM
ecj-11349	73	77	%	%	NOUN
ecj-11349	73	78	ci	ci	NOUN
ecj-11349	73	79	0.35	0.35	NUM
ecj-11349	73	80	-	-	PUNCT
ecj-11349	73	81	0.90	0.90	NUM
ecj-11349	73	82	)	)	PUNCT
ecj-11349	73	83	.	.	PUNCT
ecj-11349	74	1	authors	author	NOUN
ecj-11349	74	2	found	find	VERB
ecj-11349	74	3	no	no	DET
ecj-11349	74	4	statistically	statistically	ADV
ecj-11349	74	5	significant	significant	ADJ
ecj-11349	74	6	dif	dif	X
ecj-11349	74	7	mini	mini	ADJ
ecj-11349	74	8	review	review	NOUN
ecj-11349	74	9	[	[	X
ecj-11349	74	10	page	page	NOUN
ecj-11349	74	11	90	90	NUM
ecj-11349	74	12	]	]	PUNCT
ecj-11349	75	1	[	[	X
ecj-11349	75	2	emergency	emergency	NOUN
ecj-11349	75	3	care	care	NOUN
ecj-11349	75	4	journal	journal	NOUN
ecj-11349	75	5	2023	2023	NUM
ecj-11349	75	6	;	;	PUNCT
ecj-11349	75	7	19:11349	19:11349	NUM
ecj-11349	75	8	]	]	X
ecj-11349	75	9	non	non	ADJ
ecj-11349	75	10	-co	-co	PROPN
ecj-11349	75	11	mmerc	mmerc	PROPN
ecj-11349	75	12	ial	ial	PROPN
ecj-11349	75	13	us	us	PROPN
ecj-11349	75	14	e	e	NOUN
ecj-11349	75	15	o	o	NOUN
ecj-11349	75	16	nly	nly	ADV
ecj-11349	75	17	ference	ference	VERB
ecj-11349	75	18	in	in	ADP
ecj-11349	75	19	all	all	DET
ecj-11349	75	20	-	-	PUNCT
ecj-11349	75	21	cause	cause	NOUN
ecj-11349	75	22	mortality	mortality	NOUN
ecj-11349	75	23	,	,	PUNCT
ecj-11349	75	24	cardiovascular	cardiovascular	ADJ
ecj-11349	75	25	mortality	mortality	NOUN
ecj-11349	75	26	,	,	PUNCT
ecj-11349	75	27	hospitalizations	hospitalization	NOUN
ecj-11349	75	28	,	,	PUNCT
ecj-11349	75	29	angina	angina	ADJ
ecj-11349	75	30	,	,	PUNCT
ecj-11349	75	31	congestive	congestive	ADJ
ecj-11349	75	32	heart	heart	NOUN
ecj-11349	75	33	failure	failure	NOUN
ecj-11349	75	34	,	,	PUNCT
ecj-11349	75	35	or	or	CCONJ
ecj-11349	75	36	stroke	stroke	NOUN
ecj-11349	75	37	incidence.38	incidence.38	PROPN
ecj-11349	75	38	iasella	iasella	NOUN
ecj-11349	75	39	et	et	PROPN
ecj-11349	75	40	al	al	PROPN
ecj-11349	75	41	.	.	PROPN
ecj-11349	75	42	performed	perform	VERB
ecj-11349	75	43	a	a	DET
ecj-11349	75	44	retrospective	retrospective	ADJ
ecj-11349	75	45	study	study	NOUN
ecj-11349	75	46	with	with	ADP
ecj-11349	75	47	co	co	ADJ
ecj-11349	75	48	-	-	ADJ
ecj-11349	75	49	primary	primary	ADJ
ecj-11349	75	50	endpoints	endpoint	NOUN
ecj-11349	75	51	of	of	ADP
ecj-11349	75	52	bleeding	bleeding	NOUN
ecj-11349	75	53	and	and	CCONJ
ecj-11349	75	54	mace	mace	NOUN
ecj-11349	75	55	in	in	ADP
ecj-11349	75	56	patients	patient	NOUN
ecj-11349	75	57	treated	treat	VERB
ecj-11349	75	58	with	with	ADP
ecj-11349	75	59	clopidogrel	clopidogrel	NOUN
ecj-11349	75	60	-	-	PUNCT
ecj-11349	75	61	based	base	VERB
ecj-11349	75	62	dapt	dapt	NOUN
ecj-11349	75	63	within	within	ADP
ecj-11349	75	64	1	1	NUM
ecj-11349	75	65	year	year	NOUN
ecj-11349	75	66	of	of	ADP
ecj-11349	75	67	percutaneous	percutaneous	ADJ
ecj-11349	75	68	coronary	coronary	ADJ
ecj-11349	75	69	intervention	intervention	NOUN
ecj-11349	75	70	(	(	PUNCT
ecj-11349	75	71	pci	pci	ADJ
ecj-11349	75	72	)	)	PUNCT
ecj-11349	75	73	.	.	PUNCT
ecj-11349	76	1	ssri	ssri	PROPN
ecj-11349	76	2	patients	patient	NOUN
ecj-11349	76	3	had	have	VERB
ecj-11349	76	4	lower	low	ADJ
ecj-11349	76	5	mace	mace	NOUN
ecj-11349	76	6	risk	risk	NOUN
ecj-11349	76	7	than	than	ADP
ecj-11349	76	8	mirtazapine	mirtazapine	NOUN
ecj-11349	76	9	patients	patient	NOUN
ecj-11349	76	10	(	(	PUNCT
ecj-11349	76	11	hr	hr	NOUN
ecj-11349	76	12	0.61	0.61	NUM
ecj-11349	76	13	,	,	PUNCT
ecj-11349	76	14	95	95	NUM
ecj-11349	76	15	%	%	NOUN
ecj-11349	76	16	ci	ci	NOUN
ecj-11349	76	17	0.38	0.38	NUM
ecj-11349	76	18	-	-	SYM
ecj-11349	76	19	0.97	0.97	NUM
ecj-11349	76	20	,	,	PUNCT
ecj-11349	76	21	p	p	NOUN
ecj-11349	76	22	=	=	NOUN
ecj-11349	76	23	0.036	0.036	NUM
ecj-11349	76	24	)	)	PUNCT
ecj-11349	76	25	but	but	CCONJ
ecj-11349	76	26	higher	high	ADJ
ecj-11349	76	27	mace	mace	NOUN
ecj-11349	76	28	risk	risk	NOUN
ecj-11349	76	29	than	than	ADP
ecj-11349	76	30	patients	patient	NOUN
ecj-11349	76	31	on	on	ADP
ecj-11349	76	32	neither	neither	CCONJ
ecj-11349	76	33	agent	agent	NOUN
ecj-11349	76	34	(	(	PUNCT
ecj-11349	76	35	hr	hr	NOUN
ecj-11349	76	36	1.21	1.21	NUM
ecj-11349	76	37	,	,	PUNCT
ecj-11349	76	38	95	95	NUM
ecj-11349	76	39	%	%	NOUN
ecj-11349	76	40	ci	ci	NOUN
ecj-11349	76	41	1.02	1.02	NUM
ecj-11349	76	42	-	-	SYM
ecj-11349	76	43	1.43	1.43	NUM
ecj-11349	76	44	,	,	PUNCT
ecj-11349	76	45	p	p	X
ecj-11349	76	46	=	=	NOUN
ecj-11349	76	47	0.030	0.030	NUM
ecj-11349	76	48	)	)	PUNCT
ecj-11349	76	49	in	in	ADP
ecj-11349	76	50	adjusted	adjust	VERB
ecj-11349	76	51	analyses	analysis	NOUN
ecj-11349	76	52	.	.	PUNCT
ecj-11349	77	1	no	no	DET
ecj-11349	77	2	significant	significant	ADJ
ecj-11349	77	3	differences	difference	NOUN
ecj-11349	77	4	were	be	AUX
ecj-11349	77	5	associated	associate	VERB
ecj-11349	77	6	with	with	ADP
ecj-11349	77	7	bleeding	bleed	VERB
ecj-11349	77	8	risk	risk	NOUN
ecj-11349	77	9	(	(	PUNCT
ecj-11349	77	10	ssri	ssri	X
ecj-11349	77	11	vs.	vs.	CCONJ
ecj-11349	77	12	neither	neither	CCONJ
ecj-11349	77	13	adjusted	adjust	VERB
ecj-11349	77	14	hr	hr	NOUN
ecj-11349	77	15	1.07	1.07	NUM
ecj-11349	77	16	,	,	PUNCT
ecj-11349	77	17	95	95	NUM
ecj-11349	77	18	%	%	NOUN
ecj-11349	77	19	ci	ci	NOUN
ecj-11349	77	20	0.93	0.93	NUM
ecj-11349	77	21	-	-	PUNCT
ecj-11349	77	22	1.24	1.24	NUM
ecj-11349	77	23	,	,	PUNCT
ecj-11349	77	24	p	p	NOUN
ecj-11349	77	25	=	=	PUNCT
ecj-11349	77	26	0.36).39	0.36).39	PROPN
ecj-11349	77	27	moreover	moreover	ADV
ecj-11349	77	28	,	,	PUNCT
ecj-11349	77	29	previous	previous	ADJ
ecj-11349	77	30	data	datum	NOUN
ecj-11349	77	31	demonstrated	demonstrate	VERB
ecj-11349	77	32	that	that	SCONJ
ecj-11349	77	33	sertraline	sertraline	NOUN
ecj-11349	77	34	can	can	AUX
ecj-11349	77	35	decrease	decrease	VERB
ecj-11349	77	36	inflammatory	inflammatory	ADJ
ecj-11349	77	37	molecules	molecule	NOUN
ecj-11349	77	38	,	,	PUNCT
ecj-11349	77	39	such	such	ADJ
ecj-11349	77	40	as	as	ADP
ecj-11349	77	41	c	c	NOUN
ecj-11349	77	42	-	-	PUNCT
ecj-11349	77	43	reactive	reactive	ADJ
ecj-11349	77	44	protein	protein	NOUN
ecj-11349	77	45	and	and	CCONJ
ecj-11349	77	46	interleukin-6	interleukin-6	NUM
ecj-11349	77	47	(	(	PUNCT
ecj-11349	77	48	il-6	il-6	NUM
ecj-11349	77	49	)	)	PUNCT
ecj-11349	77	50	,	,	PUNCT
ecj-11349	77	51	after	after	ADP
ecj-11349	77	52	a	a	DET
ecj-11349	77	53	20	20	NUM
ecj-11349	77	54	-	-	PUNCT
ecj-11349	77	55	week	week	NOUN
ecj-11349	77	56	administration	administration	NOUN
ecj-11349	77	57	,	,	PUNCT
ecj-11349	77	58	thus	thus	ADV
ecj-11349	77	59	improving	improve	VERB
ecj-11349	77	60	endothelium	endothelium	NOUN
ecj-11349	77	61	-	-	PUNCT
ecj-11349	77	62	mediated	mediate	VERB
ecj-11349	77	63	dilation.40	dilation.40	NOUN
ecj-11349	77	64	otherwise	otherwise	ADV
ecj-11349	77	65	,	,	PUNCT
ecj-11349	77	66	other	other	ADJ
ecj-11349	77	67	published	publish	VERB
ecj-11349	77	68	works	work	NOUN
ecj-11349	77	69	found	find	VERB
ecj-11349	77	70	no	no	DET
ecj-11349	77	71	clear	clear	ADJ
ecj-11349	77	72	data	datum	NOUN
ecj-11349	77	73	in	in	ADP
ecj-11349	77	74	favor	favor	NOUN
ecj-11349	77	75	of	of	ADP
ecj-11349	77	76	the	the	DET
ecj-11349	77	77	use	use	NOUN
ecj-11349	77	78	of	of	ADP
ecj-11349	77	79	ssris	ssris	NOUN
ecj-11349	77	80	in	in	ADP
ecj-11349	77	81	terms	term	NOUN
ecj-11349	77	82	of	of	ADP
ecj-11349	77	83	cardiovascular	cardiovascular	ADJ
ecj-11349	77	84	risk	risk	NOUN
ecj-11349	77	85	reduction.41	reduction.41	NOUN
ecj-11349	77	86	-	-	PUNCT
ecj-11349	77	87	43	43	NUM
ecj-11349	77	88	a	a	DET
ecj-11349	77	89	work	work	NOUN
ecj-11349	77	90	by	by	ADP
ecj-11349	77	91	almuwaqqat	almuwaqqat	NOUN
ecj-11349	77	92	et	et	PROPN
ecj-11349	77	93	al	al	PROPN
ecj-11349	77	94	.	.	PROPN
ecj-11349	78	1	on	on	ADP
ecj-11349	78	2	2027	2027	NUM
ecj-11349	78	3	participants	participant	NOUN
ecj-11349	78	4	treated	treat	VERB
ecj-11349	78	5	with	with	ADP
ecj-11349	78	6	antidepressants	antidepressant	NOUN
ecj-11349	78	7	at	at	ADP
ecj-11349	78	8	some	some	DET
ecj-11349	78	9	time	time	NOUN
ecj-11349	78	10	between	between	ADP
ecj-11349	78	11	1987	1987	NUM
ecj-11349	78	12	and	and	CCONJ
ecj-11349	78	13	2013	2013	NUM
ecj-11349	78	14	.	.	PUNCT
ecj-11349	79	1	cvd	cvd	PROPN
ecj-11349	79	2	risk	risk	NOUN
ecj-11349	79	3	was	be	AUX
ecj-11349	79	4	similar	similar	ADJ
ecj-11349	79	5	for	for	ADP
ecj-11349	79	6	ssri	ssri	PROPN
ecj-11349	79	7	s	s	PART
ecj-11349	79	8	and	and	CCONJ
ecj-11349	79	9	nonssri	nonssri	ADJ
ecj-11349	79	10	antidepressant	antidepressant	ADJ
ecj-11349	79	11	users	user	NOUN
ecj-11349	79	12	(	(	PUNCT
ecj-11349	79	13	hazard	hazard	NOUN
ecj-11349	79	14	ratio	ratio	NOUN
ecj-11349	79	15	,	,	PUNCT
ecj-11349	79	16	1.10	1.10	NUM
ecj-11349	79	17	;	;	PUNCT
ecj-11349	79	18	95	95	NUM
ecj-11349	79	19	%	%	NOUN
ecj-11349	79	20	ci	ci	NOUN
ecj-11349	79	21	,	,	PUNCT
ecj-11349	79	22	0.86	0.86	NUM
ecj-11349	79	23	-	-	SYM
ecj-11349	79	24	1.41	1.41	NUM
ecj-11349	79	25	for	for	ADP
ecj-11349	79	26	af	af	PROPN
ecj-11349	79	27	;	;	PUNCT
ecj-11349	79	28	hazard	hazard	NOUN
ecj-11349	79	29	ratio	ratio	NOUN
ecj-11349	79	30	,	,	PUNCT
ecj-11349	79	31	0.98	0.98	NUM
ecj-11349	79	32	;	;	PUNCT
ecj-11349	79	33	95	95	NUM
ecj-11349	79	34	%	%	NOUN
ecj-11349	79	35	ci	ci	NOUN
ecj-11349	79	36	,	,	PUNCT
ecj-11349	79	37	0.77	0.77	NUM
ecj-11349	79	38	-	-	SYM
ecj-11349	79	39	1.25	1.25	NUM
ecj-11349	79	40	for	for	ADP
ecj-11349	79	41	heart	heart	NOUN
ecj-11349	79	42	failure	failure	NOUN
ecj-11349	79	43	;	;	PUNCT
ecj-11349	79	44	hazard	hazard	NOUN
ecj-11349	79	45	ratio	ratio	NOUN
ecj-11349	79	46	,	,	PUNCT
ecj-11349	79	47	0.91	0.91	NUM
ecj-11349	79	48	;	;	PUNCT
ecj-11349	79	49	95	95	NUM
ecj-11349	79	50	%	%	NOUN
ecj-11349	79	51	ci	ci	NOUN
ecj-11349	79	52	,	,	PUNCT
ecj-11349	79	53	0.64	0.64	NUM
ecj-11349	79	54	-	-	SYM
ecj-11349	79	55	1.29	1.29	NUM
ecj-11349	79	56	for	for	ADP
ecj-11349	79	57	myocardial	myocardial	ADJ
ecj-11349	79	58	infarction	infarction	NOUN
ecj-11349	79	59	;	;	PUNCT
ecj-11349	79	60	and	and	CCONJ
ecj-11349	79	61	hazard	hazard	NOUN
ecj-11349	79	62	ratio	ratio	NOUN
ecj-11349	79	63	,	,	PUNCT
ecj-11349	79	64	1.07	1.07	NUM
ecj-11349	79	65	;	;	PUNCT
ecj-11349	79	66	95	95	NUM
ecj-11349	79	67	%	%	NOUN
ecj-11349	79	68	ci	ci	NOUN
ecj-11349	79	69	,	,	PUNCT
ecj-11349	79	70	0.701.63	0.701.63	NUM
ecj-11349	79	71	for	for	ADP
ecj-11349	79	72	ischemic	ischemic	ADJ
ecj-11349	79	73	stroke).41	stroke).41	NOUN
ecj-11349	79	74	conclusions	conclusion	NOUN
ecj-11349	79	75	since	since	SCONJ
ecj-11349	79	76	the	the	DET
ecj-11349	79	77	absolute	absolute	ADJ
ecj-11349	79	78	risk	risk	NOUN
ecj-11349	79	79	of	of	ADP
ecj-11349	79	80	gi	gi	ADJ
ecj-11349	79	81	bleedings	bleeding	NOUN
ecj-11349	79	82	due	due	ADJ
ecj-11349	79	83	to	to	ADP
ecj-11349	79	84	ssris	ssris	PROPN
ecj-11349	79	85	is	be	AUX
ecj-11349	79	86	low	low	ADJ
ecj-11349	79	87	,	,	PUNCT
ecj-11349	79	88	precautions	precaution	NOUN
ecj-11349	79	89	are	be	AUX
ecj-11349	79	90	needed	need	VERB
ecj-11349	79	91	in	in	ADP
ecj-11349	79	92	high	high	ADJ
ecj-11349	79	93	-	-	PUNCT
ecj-11349	79	94	risk	risk	NOUN
ecj-11349	79	95	subjects	subject	NOUN
ecj-11349	79	96	only	only	ADV
ecj-11349	79	97	,	,	PUNCT
ecj-11349	79	98	like	like	SCONJ
ecj-11349	79	99	those	those	PRON
ecj-11349	79	100	referring	refer	VERB
ecj-11349	79	101	peptic	peptic	ADJ
ecj-11349	79	102	acid	acid	NOUN
ecj-11349	79	103	disease	disease	NOUN
ecj-11349	79	104	and	and	CCONJ
ecj-11349	79	105	previous	previous	ADJ
ecj-11349	79	106	events	event	NOUN
ecj-11349	79	107	of	of	ADP
ecj-11349	79	108	bleeding.20	bleeding.20	PROPN
ecj-11349	79	109	further	further	ADJ
ecj-11349	79	110	studies	study	NOUN
ecj-11349	79	111	are	be	AUX
ecj-11349	79	112	needed	need	VERB
ecj-11349	79	113	to	to	PART
ecj-11349	79	114	ascertain	ascertain	VERB
ecj-11349	79	115	the	the	DET
ecj-11349	79	116	possible	possible	ADJ
ecj-11349	79	117	antiplatelet	antiplatelet	ADJ
ecj-11349	79	118	effect	effect	NOUN
ecj-11349	79	119	of	of	ADP
ecj-11349	79	120	escitalopram	escitalopram	PROPN
ecj-11349	79	121	in	in	ADP
ecj-11349	79	122	people	people	NOUN
ecj-11349	79	123	affected	affect	VERB
ecj-11349	79	124	by	by	ADP
ecj-11349	79	125	ischemic	ischemic	ADJ
ecj-11349	79	126	cardiac	cardiac	ADJ
ecj-11349	79	127	diseases	disease	NOUN
ecj-11349	79	128	.	.	PUNCT
ecj-11349	80	1	risk	risk	NOUN
ecj-11349	80	2	assessment	assessment	NOUN
ecj-11349	80	3	by	by	ADP
ecj-11349	80	4	platelet	platelet	NOUN
ecj-11349	80	5	function	function	NOUN
ecj-11349	80	6	/	/	SYM
ecj-11349	80	7	aggregation	aggregation	NOUN
ecj-11349	80	8	tests	test	NOUN
ecj-11349	80	9	in	in	ADP
ecj-11349	80	10	patients	patient	NOUN
ecj-11349	80	11	taking	take	VERB
ecj-11349	80	12	ssris	ssris	NOUN
ecj-11349	80	13	could	could	AUX
ecj-11349	80	14	direct	direct	VERB
ecj-11349	80	15	a	a	DET
ecj-11349	80	16	tailored	tailored	ADJ
ecj-11349	80	17	therapy	therapy	NOUN
ecj-11349	80	18	.	.	PUNCT
ecj-11349	81	1	proton	proton	NOUN
ecj-11349	81	2	-	-	PUNCT
ecj-11349	81	3	pump	pump	NOUN
ecj-11349	81	4	inhibitor	inhibitor	NOUN
ecj-11349	81	5	should	should	AUX
ecj-11349	81	6	be	be	AUX
ecj-11349	81	7	recommended	recommend	VERB
ecj-11349	81	8	in	in	ADP
ecj-11349	81	9	patients	patient	NOUN
ecj-11349	81	10	taking	take	VERB
ecj-11349	81	11	ssris	ssris	NOUN
ecj-11349	81	12	and	and	CCONJ
ecj-11349	81	13	concomitant	concomitant	ADJ
ecj-11349	81	14	anticoagulant	anticoagulant	NOUN
ecj-11349	81	15	therapy	therapy	NOUN
ecj-11349	81	16	.	.	PUNCT
ecj-11349	82	1	ssri	ssri	PROPN
ecj-11349	82	2	prescription	prescription	NOUN
ecj-11349	82	3	during	during	ADP
ecj-11349	82	4	hospitalization	hospitalization	NOUN
ecj-11349	82	5	for	for	ADP
ecj-11349	82	6	an	an	DET
ecj-11349	82	7	acute	acute	ADJ
ecj-11349	82	8	coronary	coronary	ADJ
ecj-11349	82	9	syndrome	syndrome	NOUN
ecj-11349	82	10	is	be	AUX
ecj-11349	82	11	related	relate	VERB
ecj-11349	82	12	to	to	ADP
ecj-11349	82	13	lower	low	ADJ
ecj-11349	82	14	incidence	incidence	NOUN
ecj-11349	82	15	of	of	ADP
ecj-11349	82	16	recurrent	recurrent	ADJ
ecj-11349	82	17	ischemia	ischemia	NOUN
ecj-11349	82	18	,	,	PUNCT
ecj-11349	82	19	heart	heart	NOUN
ecj-11349	82	20	failure	failure	NOUN
ecj-11349	82	21	or	or	CCONJ
ecj-11349	82	22	cardiac	cardiac	ADJ
ecj-11349	82	23	enzyme	enzyme	NOUN
ecj-11349	82	24	elevation	elevation	NOUN
ecj-11349	82	25	at	at	ADP
ecj-11349	82	26	the	the	DET
ecj-11349	82	27	expense	expense	NOUN
ecj-11349	82	28	of	of	ADP
ecj-11349	82	29	higher	high	ADJ
ecj-11349	82	30	bleeding	bleeding	NOUN
ecj-11349	82	31	rates	rate	NOUN
ecj-11349	82	32	in	in	ADP
ecj-11349	82	33	patients	patient	NOUN
ecj-11349	82	34	taking	take	VERB
ecj-11349	82	35	high	high	ADJ
ecj-11349	82	36	dose	dose	NOUN
ecj-11349	82	37	antiplatelet	antiplatelet	NOUN
ecj-11349	82	38	therapy	therapy	NOUN
ecj-11349	82	39	and	and	CCONJ
ecj-11349	82	40	heparin	heparin	NOUN
ecj-11349	82	41	.	.	PUNCT
ecj-11349	83	1	physicians	physician	NOUN
ecj-11349	83	2	should	should	AUX
ecj-11349	83	3	be	be	AUX
ecj-11349	83	4	aware	aware	ADJ
ecj-11349	83	5	of	of	ADP
ecj-11349	83	6	the	the	DET
ecj-11349	83	7	possible	possible	ADJ
ecj-11349	83	8	correlation	correlation	NOUN
ecj-11349	83	9	between	between	ADP
ecj-11349	83	10	ssri	ssri	PROPN
ecj-11349	83	11	-	-	PUNCT
ecj-11349	83	12	linked	link	VERB
ecj-11349	83	13	thrombocytopenia	thrombocytopenia	NOUN
ecj-11349	83	14	and	and	CCONJ
ecj-11349	83	15	use	use	NOUN
ecj-11349	83	16	of	of	ADP
ecj-11349	83	17	anticoagulant	anticoagulant	NOUN
ecj-11349	83	18	and/or	and/or	CCONJ
ecj-11349	83	19	antiplatelet	antiplatelet	VERB
ecj-11349	83	20	drugs	drug	NOUN
ecj-11349	83	21	,	,	PUNCT
ecj-11349	83	22	thus	thus	ADV
ecj-11349	83	23	preventing	prevent	VERB
ecj-11349	83	24	lifethreatening	lifethreatene	VERB
ecj-11349	83	25	bleedings	bleeding	NOUN
ecj-11349	83	26	.	.	PUNCT
ecj-11349	84	1	references	reference	NOUN
ecj-11349	84	2	1	1	NUM
ecj-11349	84	3	.	.	PUNCT
ecj-11349	85	1	alam	alam	PROPN
ecj-11349	85	2	sm	sm	PROPN
ecj-11349	85	3	,	,	PUNCT
ecj-11349	85	4	qasswal	qasswal	NOUN
ecj-11349	85	5	m	m	PROPN
ecj-11349	85	6	,	,	PUNCT
ecj-11349	85	7	ahsan	ahsan	PROPN
ecj-11349	85	8	mj	mj	PROPN
ecj-11349	85	9	,	,	PUNCT
ecj-11349	85	10	et	et	PROPN
ecj-11349	85	11	al	al	PROPN
ecj-11349	85	12	.	.	PROPN
ecj-11349	85	13	selective	selective	ADJ
ecj-11349	85	14	serotonin	serotonin	NOUN
ecj-11349	85	15	reuptake	reuptake	NOUN
ecj-11349	85	16	inhibitors	inhibitor	NOUN
ecj-11349	85	17	increase	increase	VERB
ecj-11349	85	18	risk	risk	NOUN
ecj-11349	85	19	of	of	ADP
ecj-11349	85	20	upper	upper	ADJ
ecj-11349	85	21	gastrointestinal	gastrointestinal	ADJ
ecj-11349	85	22	bleeding	bleeding	NOUN
ecj-11349	85	23	when	when	SCONJ
ecj-11349	85	24	used	use	VERB
ecj-11349	85	25	with	with	ADP
ecj-11349	85	26	nsaids	nsaid	NOUN
ecj-11349	85	27	:	:	PUNCT
ecj-11349	85	28	a	a	DET
ecj-11349	85	29	systemic	systemic	ADJ
ecj-11349	85	30	review	review	NOUN
ecj-11349	85	31	and	and	CCONJ
ecj-11349	85	32	meta	meta	NOUN
ecj-11349	85	33	-	-	PUNCT
ecj-11349	85	34	analysis	analysis	NOUN
ecj-11349	85	35	.	.	PUNCT
ecj-11349	86	1	sci	sci	PROPN
ecj-11349	86	2	rep	rep	PROPN
ecj-11349	86	3	2022;12:14452	2022;12:14452	PROPN
ecj-11349	86	4	.	.	PROPN
ecj-11349	87	1	2	2	NUM
ecj-11349	87	2	.	.	X
ecj-11349	87	3	bakker	bakker	PROPN
ecj-11349	87	4	s	s	PROPN
ecj-11349	87	5	,	,	PUNCT
ecj-11349	87	6	burggraaf	burggraaf	PROPN
ecj-11349	87	7	jli	jli	PROPN
ecj-11349	87	8	,	,	PUNCT
ecj-11349	87	9	kruip	kruip	PROPN
ecj-11349	87	10	m	m	PROPN
ecj-11349	87	11	,	,	PUNCT
ecj-11349	87	12	et	et	PROPN
ecj-11349	87	13	al	al	PROPN
ecj-11349	87	14	.	.	PROPN
ecj-11349	87	15	selective	selective	ADJ
ecj-11349	87	16	serotonin	serotonin	NOUN
ecj-11349	87	17	reuptake	reuptake	NOUN
ecj-11349	87	18	inhibitor	inhibitor	NOUN
ecj-11349	87	19	use	use	NOUN
ecj-11349	87	20	and	and	CCONJ
ecj-11349	87	21	risk	risk	NOUN
ecj-11349	87	22	of	of	ADP
ecj-11349	87	23	major	major	ADJ
ecj-11349	87	24	bleeding	bleeding	NOUN
ecj-11349	87	25	during	during	ADP
ecj-11349	87	26	treatment	treatment	NOUN
ecj-11349	87	27	with	with	ADP
ecj-11349	87	28	vitamin	vitamin	NOUN
ecj-11349	87	29	k	k	PROPN
ecj-11349	87	30	antagonists	antagonist	NOUN
ecj-11349	87	31	:	:	PUNCT
ecj-11349	87	32	results	result	NOUN
ecj-11349	87	33	of	of	ADP
ecj-11349	87	34	a	a	DET
ecj-11349	87	35	cohort	cohort	NOUN
ecj-11349	87	36	study	study	NOUN
ecj-11349	87	37	.	.	PUNCT
ecj-11349	88	1	thromb	thromb	PROPN
ecj-11349	88	2	haemost	haemost	VERB
ecj-11349	88	3	2023;123:245	2023;123:245	NUM
ecj-11349	88	4	-	-	SYM
ecj-11349	88	5	54	54	NUM
ecj-11349	88	6	.	.	PUNCT
ecj-11349	89	1	3	3	X
ecj-11349	89	2	.	.	NOUN
ecj-11349	89	3	edinoff	edinoff	PROPN
ecj-11349	89	4	an	an	PRON
ecj-11349	89	5	,	,	PUNCT
ecj-11349	89	6	raveendran	raveendran	ADJ
ecj-11349	89	7	k	k	NOUN
ecj-11349	89	8	,	,	PUNCT
ecj-11349	89	9	colon	colon	NOUN
ecj-11349	89	10	ma	ma	PROPN
ecj-11349	89	11	,	,	PUNCT
ecj-11349	89	12	et	et	PROPN
ecj-11349	89	13	al	al	PROPN
ecj-11349	89	14	.	.	PROPN
ecj-11349	89	15	selective	selective	ADJ
ecj-11349	89	16	serotonin	serotonin	NOUN
ecj-11349	89	17	reuptake	reuptake	NOUN
ecj-11349	89	18	inhibitors	inhibitor	NOUN
ecj-11349	89	19	and	and	CCONJ
ecj-11349	89	20	associated	associated	ADJ
ecj-11349	89	21	bleeding	bleeding	NOUN
ecj-11349	89	22	risks	risk	NOUN
ecj-11349	89	23	:	:	PUNCT
ecj-11349	89	24	a	a	DET
ecj-11349	89	25	narrative	narrative	NOUN
ecj-11349	89	26	and	and	CCONJ
ecj-11349	89	27	clinical	clinical	ADJ
ecj-11349	89	28	review	review	NOUN
ecj-11349	89	29	.	.	PUNCT
ecj-11349	90	1	health	health	NOUN
ecj-11349	90	2	psychol	psychol	PROPN
ecj-11349	90	3	res	re	NOUN
ecj-11349	90	4	2022;10:39580	2022;10:39580	NUM
ecj-11349	90	5	.	.	PROPN
ecj-11349	90	6	4	4	NUM
ecj-11349	90	7	.	.	X
ecj-11349	90	8	garg	garg	PROPN
ecj-11349	90	9	pk	pk	PROPN
ecj-11349	90	10	,	,	PUNCT
ecj-11349	90	11	o'neal	o'neal	PROPN
ecj-11349	90	12	wt	wt	NOUN
ecj-11349	90	13	,	,	PUNCT
ecj-11349	90	14	diez	diez	NOUN
ecj-11349	90	15	-	-	PUNCT
ecj-11349	90	16	roux	roux	NOUN
ecj-11349	90	17	av	av	PROPN
ecj-11349	90	18	,	,	PUNCT
ecj-11349	90	19	et	et	PROPN
ecj-11349	90	20	al	al	PROPN
ecj-11349	90	21	.	.	PROPN
ecj-11349	90	22	negative	negative	ADJ
ecj-11349	90	23	affect	affect	NOUN
ecj-11349	90	24	and	and	CCONJ
ecj-11349	90	25	risk	risk	NOUN
ecj-11349	90	26	of	of	ADP
ecj-11349	90	27	atrial	atrial	ADJ
ecj-11349	90	28	fibrillation	fibrillation	NOUN
ecj-11349	90	29	:	:	PUNCT
ecj-11349	90	30	mesa	mesa	PROPN
ecj-11349	90	31	.	.	PROPN
ecj-11349	91	1	j	j	PROPN
ecj-11349	91	2	am	be	AUX
ecj-11349	91	3	heart	heart	NOUN
ecj-11349	91	4	assoc	assoc	PROPN
ecj-11349	91	5	2019;8	2019;8	PROPN
ecj-11349	91	6	:	:	PUNCT
ecj-11349	91	7	e010603	e010603	NUM
ecj-11349	91	8	.	.	NOUN
ecj-11349	91	9	5	5	NUM
ecj-11349	91	10	.	.	X
ecj-11349	91	11	fu	fu	PROPN
ecj-11349	91	12	y	y	PROPN
ecj-11349	91	13	,	,	PUNCT
ecj-11349	91	14	feng	feng	PROPN
ecj-11349	91	15	s	s	PROPN
ecj-11349	91	16	,	,	PUNCT
ecj-11349	91	17	xu	xu	PROPN
ecj-11349	91	18	y	y	PROPN
ecj-11349	91	19	,	,	PUNCT
ecj-11349	91	20	et	et	PROPN
ecj-11349	92	1	al	al	PROPN
ecj-11349	92	2	.	.	PROPN
ecj-11349	92	3	association	association	PROPN
ecj-11349	92	4	of	of	ADP
ecj-11349	92	5	depression	depression	NOUN
ecj-11349	92	6	,	,	PUNCT
ecj-11349	92	7	antidepressants	antidepressant	NOUN
ecj-11349	92	8	with	with	ADP
ecj-11349	92	9	atrial	atrial	ADJ
ecj-11349	92	10	fibrillation	fibrillation	NOUN
ecj-11349	92	11	risk	risk	NOUN
ecj-11349	92	12	:	:	PUNCT
ecj-11349	92	13	a	a	DET
ecj-11349	92	14	systemic	systemic	ADJ
ecj-11349	92	15	review	review	NOUN
ecj-11349	92	16	and	and	CCONJ
ecj-11349	92	17	meta	meta	ADJ
ecj-11349	92	18	-	-	PUNCT
ecj-11349	92	19	analysis	analysis	NOUN
ecj-11349	92	20	.	.	PUNCT
ecj-11349	93	1	front	front	PROPN
ecj-11349	93	2	cardiovasc	cardiovasc	PROPN
ecj-11349	93	3	med	me	VERB
ecj-11349	93	4	2022	2022	NUM
ecj-11349	93	5	;	;	PUNCT
ecj-11349	93	6	9:897622	9:897622	NUM
ecj-11349	93	7	.	.	X
ecj-11349	94	1	6	6	NUM
ecj-11349	94	2	.	.	X
ecj-11349	94	3	hallbäck	hallbäck	PROPN
ecj-11349	94	4	i	i	PROPN
ecj-11349	94	5	,	,	PUNCT
ecj-11349	94	6	hägg	hägg	PROPN
ecj-11349	94	7	s	s	PROPN
ecj-11349	94	8	,	,	PUNCT
ecj-11349	94	9	eriksson	eriksson	PROPN
ecj-11349	94	10	ac	ac	PROPN
ecj-11349	94	11	,	,	PUNCT
ecj-11349	94	12	whiss	whiss	VERB
ecj-11349	94	13	pa	pa	PROPN
ecj-11349	94	14	.	.	PUNCT
ecj-11349	95	1	in	in	ADP
ecj-11349	95	2	vitro	vitro	X
ecj-11349	95	3	effects	effect	NOUN
ecj-11349	95	4	of	of	ADP
ecj-11349	95	5	serotonin	serotonin	NOUN
ecj-11349	95	6	and	and	CCONJ
ecj-11349	95	7	noradrenaline	noradrenaline	ADJ
ecj-11349	95	8	reuptake	reuptake	NOUN
ecj-11349	95	9	inhibitors	inhibitor	NOUN
ecj-11349	95	10	on	on	ADP
ecj-11349	95	11	human	human	ADJ
ecj-11349	95	12	platelet	platelet	NOUN
ecj-11349	95	13	adhesion	adhesion	NOUN
ecj-11349	95	14	and	and	CCONJ
ecj-11349	95	15	coagulation	coagulation	NOUN
ecj-11349	95	16	.	.	PUNCT
ecj-11349	96	1	pharmacol	pharmacol	PROPN
ecj-11349	96	2	rep	rep	PROPN
ecj-11349	96	3	2012;64:979	2012;64:979	PROPN
ecj-11349	96	4	-	-	SYM
ecj-11349	96	5	83	83	NUM
ecj-11349	96	6	.	.	PUNCT
ecj-11349	96	7	7	7	X
ecj-11349	96	8	.	.	X
ecj-11349	96	9	andersohn	andersohn	PROPN
ecj-11349	96	10	f	f	PROPN
ecj-11349	96	11	,	,	PUNCT
ecj-11349	96	12	konzen	konzen	NOUN
ecj-11349	96	13	c	c	NOUN
ecj-11349	96	14	,	,	PUNCT
ecj-11349	96	15	bronder	bronder	NOUN
ecj-11349	96	16	e	e	NOUN
ecj-11349	96	17	,	,	PUNCT
ecj-11349	96	18	et	et	PROPN
ecj-11349	96	19	al	al	PROPN
ecj-11349	96	20	.	.	PROPN
ecj-11349	96	21	citalopram	citalopram	PROPN
ecj-11349	96	22	-	-	PUNCT
ecj-11349	96	23	induced	induce	VERB
ecj-11349	96	24	bleeding	bleeding	NOUN
ecj-11349	96	25	due	due	ADP
ecj-11349	96	26	to	to	ADP
ecj-11349	96	27	severe	severe	ADJ
ecj-11349	96	28	thrombocytopenia	thrombocytopenia	PROPN
ecj-11349	96	29	.	.	PUNCT
ecj-11349	97	1	psychosomatics	psychosomatic	NOUN
ecj-11349	97	2	2009;50:297	2009;50:297	NUM
ecj-11349	97	3	-	-	SYM
ecj-11349	97	4	8	8	NUM
ecj-11349	97	5	.	.	NOUN
ecj-11349	97	6	8	8	NUM
ecj-11349	97	7	.	.	PUNCT
ecj-11349	98	1	mcfarland	mcfarland	PROPN
ecj-11349	98	2	d	d	PROPN
ecj-11349	98	3	,	,	PUNCT
ecj-11349	98	4	merchant	merchant	NOUN
ecj-11349	98	5	d	d	PROPN
ecj-11349	98	6	,	,	PUNCT
ecj-11349	98	7	khandai	khandai	PROPN
ecj-11349	98	8	a	a	PROPN
ecj-11349	98	9	,	,	PUNCT
ecj-11349	98	10	et	et	PROPN
ecj-11349	98	11	al	al	PROPN
ecj-11349	98	12	.	.	PROPN
ecj-11349	98	13	selective	selective	ADJ
ecj-11349	98	14	serotonin	serotonin	NOUN
ecj-11349	98	15	reuptake	reuptake	NOUN
ecj-11349	98	16	inhibitor	inhibitor	NOUN
ecj-11349	98	17	(	(	PUNCT
ecj-11349	98	18	ssri	ssri	PROPN
ecj-11349	98	19	)	)	PUNCT
ecj-11349	98	20	bleeding	bleed	VERB
ecj-11349	98	21	risk	risk	NOUN
ecj-11349	98	22	:	:	PUNCT
ecj-11349	98	23	considerations	consideration	NOUN
ecj-11349	98	24	for	for	ADP
ecj-11349	98	25	the	the	DET
ecj-11349	98	26	consult	consult	NOUN
ecj-11349	98	27	-	-	PUNCT
ecj-11349	98	28	liaison	liaison	NOUN
ecj-11349	98	29	psychiatrist	psychiatrist	NOUN
ecj-11349	98	30	.	.	PUNCT
ecj-11349	99	1	curr	curr	PROPN
ecj-11349	99	2	psychiatry	psychiatry	PROPN
ecj-11349	99	3	rep	rep	PROPN
ecj-11349	99	4	2023;25:113	2023;25:113	PROPN
ecj-11349	99	5	-	-	SYM
ecj-11349	99	6	24	24	NUM
ecj-11349	99	7	.	.	PUNCT
ecj-11349	100	1	9	9	NUM
ecj-11349	100	2	.	.	X
ecj-11349	100	3	ataoglu	ataoglu	PROPN
ecj-11349	100	4	a	a	PROPN
ecj-11349	100	5	,	,	PUNCT
ecj-11349	100	6	canan	canan	PROPN
ecj-11349	100	7	f.	f.	PROPN
ecj-11349	100	8	mean	mean	VERB
ecj-11349	100	9	platelet	platelet	NOUN
ecj-11349	100	10	volume	volume	NOUN
ecj-11349	100	11	in	in	ADP
ecj-11349	100	12	patients	patient	NOUN
ecj-11349	100	13	with	with	ADP
ecj-11349	100	14	major	major	ADJ
ecj-11349	100	15	depression	depression	NOUN
ecj-11349	100	16	:	:	PUNCT
ecj-11349	100	17	effect	effect	NOUN
ecj-11349	100	18	of	of	ADP
ecj-11349	100	19	escitalopram	escitalopram	PROPN
ecj-11349	100	20	treatment	treatment	NOUN
ecj-11349	100	21	.	.	PUNCT
ecj-11349	101	1	j	j	PROPN
ecj-11349	101	2	clin	clin	PROPN
ecj-11349	101	3	psychopharmacol	psychopharmacol	PROPN
ecj-11349	101	4	2009;29:368	2009;29:368	PROPN
ecj-11349	101	5	-	-	SYM
ecj-11349	101	6	71	71	NUM
ecj-11349	101	7	.	.	PUNCT
ecj-11349	101	8	10	10	NUM
ecj-11349	101	9	.	.	PUNCT
ecj-11349	101	10	song	song	PROPN
ecj-11349	101	11	hr	hr	PROPN
ecj-11349	101	12	,	,	PUNCT
ecj-11349	101	13	jung	jung	PROPN
ecj-11349	101	14	ye	ye	PROPN
ecj-11349	101	15	,	,	PUNCT
ecj-11349	101	16	wang	wang	PROPN
ecj-11349	101	17	hr	hr	PROPN
ecj-11349	101	18	,	,	PUNCT
ecj-11349	101	19	et	et	PROPN
ecj-11349	101	20	al	al	PROPN
ecj-11349	101	21	.	.	PUNCT
ecj-11349	101	22	platelet	platelet	PROPN
ecj-11349	101	23	count	count	NOUN
ecj-11349	101	24	alterations	alteration	NOUN
ecj-11349	101	25	associated	associate	VERB
ecj-11349	101	26	with	with	ADP
ecj-11349	101	27	escitalopram	escitalopram	PROPN
ecj-11349	101	28	,	,	PUNCT
ecj-11349	101	29	venlafaxine	venlafaxine	NOUN
ecj-11349	101	30	and	and	CCONJ
ecj-11349	101	31	bupropion	bupropion	NOUN
ecj-11349	101	32	in	in	ADP
ecj-11349	101	33	depressive	depressive	ADJ
ecj-11349	101	34	patients	patient	NOUN
ecj-11349	101	35	.	.	PUNCT
ecj-11349	102	1	psychiatry	psychiatry	NOUN
ecj-11349	102	2	clin	clin	PROPN
ecj-11349	102	3	neurosci	neurosci	PROPN
ecj-11349	102	4	2012;66:457	2012;66:457	PROPN
ecj-11349	102	5	-	-	SYM
ecj-11349	102	6	59	59	NUM
ecj-11349	102	7	.	.	PUNCT
ecj-11349	102	8	11	11	NUM
ecj-11349	102	9	.	.	PUNCT
ecj-11349	103	1	lopez	lopez	ADJ
ecj-11349	103	2	-	-	PUNCT
ecj-11349	103	3	vilchez	vilchez	PROPN
ecj-11349	103	4	i	i	PROPN
ecj-11349	103	5	,	,	PUNCT
ecj-11349	103	6	jerez	jerez	PROPN
ecj-11349	103	7	-	-	PUNCT
ecj-11349	103	8	dolz	dolz	PROPN
ecj-11349	103	9	d	d	NOUN
ecj-11349	103	10	,	,	PUNCT
ecj-11349	103	11	diaz	diaz	PROPN
ecj-11349	103	12	-	-	PUNCT
ecj-11349	103	13	ricart	ricart	PROPN
ecj-11349	103	14	m	m	PROPN
ecj-11349	103	15	,	,	PUNCT
ecj-11349	103	16	et	et	PROPN
ecj-11349	103	17	al	al	PROPN
ecj-11349	103	18	.	.	PUNCT
ecj-11349	104	1	escitalopram	escitalopram	PROPN
ecj-11349	104	2	impairs	impair	VERB
ecj-11349	104	3	thrombin	thrombin	NOUN
ecj-11349	104	4	-	-	PUNCT
ecj-11349	104	5	induced	induce	VERB
ecj-11349	104	6	platelet	platelet	NOUN
ecj-11349	104	7	response	response	NOUN
ecj-11349	104	8	,	,	PUNCT
ecj-11349	104	9	cytoskeletal	cytoskeletal	ADJ
ecj-11349	104	10	assembly	assembly	NOUN
ecj-11349	104	11	and	and	CCONJ
ecj-11349	104	12	activation	activation	NOUN
ecj-11349	104	13	of	of	ADP
ecj-11349	104	14	associated	associated	ADJ
ecj-11349	104	15	signalling	signal	VERB
ecj-11349	104	16	pathways	pathway	NOUN
ecj-11349	104	17	.	.	PUNCT
ecj-11349	105	1	thromb	thromb	PROPN
ecj-11349	105	2	haemost	haemost	VERB
ecj-11349	105	3	2017;117:2312	2017;117:2312	NUM
ecj-11349	105	4	-	-	SYM
ecj-11349	105	5	21	21	NUM
ecj-11349	105	6	.	.	PUNCT
ecj-11349	106	1	12	12	NUM
ecj-11349	106	2	.	.	PUNCT
ecj-11349	107	1	atar	atar	PROPN
ecj-11349	107	2	d	d	PROPN
ecj-11349	107	3	,	,	PUNCT
ecj-11349	107	4	malinin	malinin	ADJ
ecj-11349	107	5	a	a	PRON
ecj-11349	107	6	,	,	PUNCT
ecj-11349	107	7	pokov	pokov	NOUN
ecj-11349	107	8	a	a	X
ecj-11349	107	9	,	,	PUNCT
ecj-11349	107	10	et	et	PROPN
ecj-11349	107	11	al	al	PROPN
ecj-11349	107	12	.	.	PROPN
ecj-11349	108	1	antiplatelet	antiplatelet	NOUN
ecj-11349	108	2	properties	property	NOUN
ecj-11349	108	3	of	of	ADP
ecj-11349	108	4	escitalopram	escitalopram	PROPN
ecj-11349	108	5	in	in	ADP
ecj-11349	108	6	patients	patient	NOUN
ecj-11349	108	7	with	with	ADP
ecj-11349	108	8	the	the	DET
ecj-11349	108	9	metabolic	metabolic	NOUN
ecj-11349	108	10	syndrome	syndrome	NOUN
ecj-11349	108	11	:	:	PUNCT
ecj-11349	108	12	a	a	DET
ecj-11349	108	13	doseranging	doserange	VERB
ecj-11349	108	14	in	in	ADP
ecj-11349	108	15	vitro	vitro	X
ecj-11349	108	16	study	study	NOUN
ecj-11349	108	17	.	.	PUNCT
ecj-11349	109	1	neuropsychopharmacology	neuropsychopharmacology	PROPN
ecj-11349	109	2	2007;32	2007;32	NUM
ecj-11349	109	3	:	:	PUNCT
ecj-11349	109	4	2369	2369	NUM
ecj-11349	109	5	-	-	SYM
ecj-11349	109	6	374	374	NUM
ecj-11349	109	7	.	.	NOUN
ecj-11349	109	8	13	13	NUM
ecj-11349	109	9	.	.	PUNCT
ecj-11349	110	1	tseng	tseng	PROPN
ecj-11349	110	2	yl	yl	PROPN
ecj-11349	110	3	,	,	PUNCT
ecj-11349	110	4	chiang	chiang	PROPN
ecj-11349	110	5	ml	ml	PROPN
ecj-11349	110	6	,	,	PUNCT
ecj-11349	110	7	lane	lane	PROPN
ecj-11349	110	8	hy	hy	PROPN
ecj-11349	110	9	,	,	PUNCT
ecj-11349	110	10	et	et	PROPN
ecj-11349	110	11	al	al	PROPN
ecj-11349	110	12	.	.	PROPN
ecj-11349	110	13	selective	selective	ADJ
ecj-11349	110	14	serotonin	serotonin	NOUN
ecj-11349	110	15	reuptake	reuptake	NOUN
ecj-11349	110	16	inhibitors	inhibitor	NOUN
ecj-11349	110	17	reduce	reduce	VERB
ecj-11349	110	18	p2y12	p2y12	NOUN
ecj-11349	110	19	receptor	receptor	NOUN
ecj-11349	110	20	-	-	PUNCT
ecj-11349	110	21	mediated	mediate	VERB
ecj-11349	110	22	amplification	amplification	NOUN
ecj-11349	110	23	of	of	ADP
ecj-11349	110	24	platelet	platelet	NOUN
ecj-11349	110	25	aggregation	aggregation	NOUN
ecj-11349	110	26	.	.	PUNCT
ecj-11349	111	1	thrombosis	thrombosis	NOUN
ecj-11349	111	2	res	re	NOUN
ecj-11349	111	3	2013;131:325332	2013;131:325332	NOUN
ecj-11349	111	4	.	.	PUNCT
ecj-11349	112	1	14	14	NUM
ecj-11349	112	2	.	.	PUNCT
ecj-11349	113	1	canan	canan	PROPN
ecj-11349	113	2	f	f	PROPN
ecj-11349	113	3	,	,	PUNCT
ecj-11349	113	4	ataoglu	ataoglu	PROPN
ecj-11349	113	5	a.	a.	NOUN
ecj-11349	113	6	the	the	DET
ecj-11349	113	7	effect	effect	NOUN
ecj-11349	113	8	of	of	ADP
ecj-11349	113	9	escitalopram	escitalopram	PROPN
ecj-11349	113	10	on	on	ADP
ecj-11349	113	11	platelet	platelet	NOUN
ecj-11349	113	12	activity	activity	NOUN
ecj-11349	113	13	.	.	PUNCT
ecj-11349	114	1	thrombosis	thrombosis	NOUN
ecj-11349	114	2	res	re	NOUN
ecj-11349	114	3	2011;127:57	2011;127:57	NUM
ecj-11349	114	4	.	.	PUNCT
ecj-11349	115	1	15	15	NUM
ecj-11349	115	2	.	.	PUNCT
ecj-11349	116	1	hirsh	hirsh	ADJ
ecj-11349	116	2	-	-	PUNCT
ecj-11349	116	3	rokach	rokach	NOUN
ecj-11349	116	4	b	b	NOUN
ecj-11349	116	5	,	,	PUNCT
ecj-11349	116	6	spectre	spectre	NOUN
ecj-11349	116	7	g	g	PROPN
ecj-11349	116	8	,	,	PUNCT
ecj-11349	116	9	shai	shai	PROPN
ecj-11349	116	10	e	e	PROPN
ecj-11349	116	11	,	,	PUNCT
ecj-11349	116	12	et	et	PROPN
ecj-11349	116	13	al	al	PROPN
ecj-11349	116	14	.	.	PROPN
ecj-11349	116	15	differential	differential	PROPN
ecj-11349	116	16	impact	impact	NOUN
ecj-11349	116	17	of	of	ADP
ecj-11349	116	18	selective	selective	ADJ
ecj-11349	116	19	serotonin	serotonin	NOUN
ecj-11349	116	20	reuptake	reuptake	NOUN
ecj-11349	116	21	inhibitors	inhibitor	NOUN
ecj-11349	116	22	on	on	ADP
ecj-11349	116	23	platelet	platelet	NOUN
ecj-11349	116	24	response	response	NOUN
ecj-11349	116	25	to	to	ADP
ecj-11349	116	26	clopidogrel	clopidogrel	NOUN
ecj-11349	116	27	:	:	PUNCT
ecj-11349	116	28	a	a	DET
ecj-11349	116	29	randomized	randomized	ADJ
ecj-11349	116	30	,	,	PUNCT
ecj-11349	116	31	double	double	ADJ
ecj-11349	116	32	-	-	PUNCT
ecj-11349	116	33	blind	blind	ADJ
ecj-11349	116	34	,	,	PUNCT
ecj-11349	116	35	crossover	crossover	VERB
ecj-11349	116	36	trial	trial	NOUN
ecj-11349	116	37	.	.	PUNCT
ecj-11349	117	1	pharmacotherapy	pharmacotherapy	NOUN
ecj-11349	117	2	2015;35:140	2015;35:140	NUM
ecj-11349	117	3	-	-	SYM
ecj-11349	117	4	147	147	NUM
ecj-11349	117	5	.	.	PUNCT
ecj-11349	118	1	16	16	NUM
ecj-11349	118	2	.	.	PUNCT
ecj-11349	119	1	narayana	narayana	PROPN
ecj-11349	119	2	pv	pv	PROPN
ecj-11349	119	3	,	,	PUNCT
ecj-11349	119	4	satpathy	satpathy	PROPN
ecj-11349	119	5	pk	pk	PROPN
ecj-11349	119	6	,	,	PUNCT
ecj-11349	119	7	gowda	gowda	PROPN
ecj-11349	119	8	sb	sb	PROPN
ecj-11349	119	9	,	,	PUNCT
ecj-11349	119	10	addepalli	addepalli	PROPN
ecj-11349	119	11	s.	s.	PROPN
ecj-11349	119	12	buddchiari	buddchiari	PROPN
ecj-11349	119	13	syndrome	syndrome	PROPN
ecj-11349	119	14	as	as	ADP
ecj-11349	119	15	an	an	DET
ecj-11349	119	16	initial	initial	ADJ
ecj-11349	119	17	presentation	presentation	NOUN
ecj-11349	119	18	of	of	ADP
ecj-11349	119	19	antiphospholipid	antiphospholipid	NOUN
ecj-11349	119	20	syndrome	syndrome	NOUN
ecj-11349	119	21	in	in	ADP
ecj-11349	119	22	a	a	DET
ecj-11349	119	23	male	male	NOUN
ecj-11349	119	24	.	.	PUNCT
ecj-11349	120	1	j	j	PROPN
ecj-11349	120	2	clin	clin	PROPN
ecj-11349	120	3	diagnostic	diagnostic	PROPN
ecj-11349	120	4	res	re	NOUN
ecj-11349	120	5	2022;16	2022;16	NUM
ecj-11349	120	6	:	:	PUNCT
ecj-11349	120	7	od10od12	od10od12	PROPN
ecj-11349	120	8	.	.	PUNCT
ecj-11349	121	1	17	17	NUM
ecj-11349	121	2	.	.	PUNCT
ecj-11349	122	1	maurer	maurer	NOUN
ecj-11349	122	2	-	-	PUNCT
ecj-11349	122	3	spurej	spurej	PROPN
ecj-11349	122	4	e	e	NOUN
ecj-11349	122	5	,	,	PUNCT
ecj-11349	122	6	pittendreigh	pittendreigh	ADJ
ecj-11349	122	7	c	c	NOUN
ecj-11349	122	8	,	,	PUNCT
ecj-11349	122	9	solomons	solomon	NOUN
ecj-11349	122	10	k.	k.	NOUN
ecj-11349	123	1	the	the	DET
ecj-11349	123	2	influence	influence	NOUN
ecj-11349	123	3	of	of	ADP
ecj-11349	123	4	selective	selective	ADJ
ecj-11349	123	5	serotonin	serotonin	NOUN
ecj-11349	123	6	reuptake	reuptake	NOUN
ecj-11349	123	7	inhibitors	inhibitor	NOUN
ecj-11349	123	8	on	on	ADP
ecj-11349	123	9	human	human	ADJ
ecj-11349	123	10	platelet	platelet	NOUN
ecj-11349	123	11	serotonin	serotonin	NOUN
ecj-11349	123	12	.	.	PUNCT
ecj-11349	124	1	thrombosis	thrombosis	NOUN
ecj-11349	124	2	haemost	haemost	VERB
ecj-11349	124	3	2004;91:119	2004;91:119	NOUN
ecj-11349	124	4	-	-	SYM
ecj-11349	124	5	128	128	NUM
ecj-11349	124	6	.	.	PUNCT
ecj-11349	125	1	18	18	NUM
ecj-11349	125	2	.	.	PUNCT
ecj-11349	126	1	van	van	PROPN
ecj-11349	126	2	holten	holten	PROPN
ecj-11349	126	3	tc	tc	PROPN
ecj-11349	126	4	,	,	PUNCT
ecj-11349	126	5	roest	ro	ADJ
ecj-11349	126	6	m	m	PROPN
ecj-11349	126	7	,	,	PUNCT
ecj-11349	126	8	riphagen	riphagen	PROPN
ecj-11349	126	9	j	j	PROPN
ecj-11349	126	10	,	,	PUNCT
ecj-11349	126	11	et	et	PROPN
ecj-11349	126	12	al	al	PROPN
ecj-11349	126	13	.	.	PROPN
ecj-11349	126	14	citalopram	citalopram	PROPN
ecj-11349	126	15	is	be	AUX
ecj-11349	126	16	a	a	DET
ecj-11349	126	17	more	more	ADV
ecj-11349	126	18	potent	potent	ADJ
ecj-11349	126	19	platelet	platelet	NOUN
ecj-11349	126	20	function	function	NOUN
ecj-11349	126	21	inhibitor	inhibitor	NOUN
ecj-11349	126	22	than	than	ADP
ecj-11349	126	23	paroxetine	paroxetine	NOUN
ecj-11349	126	24	in	in	ADP
ecj-11349	126	25	a	a	DET
ecj-11349	126	26	case	case	NOUN
ecj-11349	126	27	-	-	PUNCT
ecj-11349	126	28	control	control	NOUN
ecj-11349	126	29	study	study	NOUN
ecj-11349	126	30	.	.	PUNCT
ecj-11349	127	1	j	j	PROPN
ecj-11349	127	2	thromb	thromb	PROPN
ecj-11349	127	3	haemostasis	haemostasis	PROPN
ecj-11349	127	4	2012;10:1177	2012;10:1177	NUM
ecj-11349	127	5	-	-	SYM
ecj-11349	127	6	1179	1179	NUM
ecj-11349	127	7	.	.	PUNCT
ecj-11349	128	1	19	19	NUM
ecj-11349	128	2	.	.	NOUN
ecj-11349	128	3	roweth	roweth	PROPN
ecj-11349	128	4	hg	hg	NOUN
ecj-11349	128	5	,	,	PUNCT
ecj-11349	128	6	cook	cook	VERB
ecj-11349	128	7	aa	aa	NOUN
ecj-11349	128	8	,	,	PUNCT
ecj-11349	128	9	moroi	moroi	PROPN
ecj-11349	128	10	m	m	PROPN
ecj-11349	128	11	,	,	PUNCT
ecj-11349	128	12	et	et	PROPN
ecj-11349	128	13	al	al	PROPN
ecj-11349	128	14	.	.	PROPN
ecj-11349	129	1	two	two	NUM
ecj-11349	129	2	novel	novel	NOUN
ecj-11349	129	3	,	,	PUNCT
ecj-11349	129	4	putative	putative	ADJ
ecj-11349	129	5	mechanisms	mechanism	NOUN
ecj-11349	129	6	of	of	ADP
ecj-11349	129	7	action	action	NOUN
ecj-11349	129	8	for	for	ADP
ecj-11349	129	9	citalopram	citalopram	NOUN
ecj-11349	129	10	-	-	PUNCT
ecj-11349	129	11	induced	induce	VERB
ecj-11349	129	12	platelet	platelet	NOUN
ecj-11349	129	13	inhibition	inhibition	NOUN
ecj-11349	129	14	.	.	PUNCT
ecj-11349	130	1	sci	sci	PROPN
ecj-11349	130	2	rep	rep	PROPN
ecj-11349	130	3	2018;8:16677	2018;8:16677	PROPN
ecj-11349	130	4	.	.	PUNCT
ecj-11349	131	1	20	20	NUM
ecj-11349	131	2	.	.	PUNCT
ecj-11349	132	1	andrade	andrade	PROPN
ecj-11349	132	2	c	c	PROPN
ecj-11349	132	3	,	,	PUNCT
ecj-11349	132	4	sandarsh	sandarsh	PROPN
ecj-11349	132	5	s	s	PROPN
ecj-11349	132	6	,	,	PUNCT
ecj-11349	132	7	chethan	chethan	PROPN
ecj-11349	132	8	kb	kb	PROPN
ecj-11349	132	9	,	,	PUNCT
ecj-11349	132	10	nagesh	nagesh	PROPN
ecj-11349	132	11	ks	ks	AUX
ecj-11349	132	12	.	.	PROPN
ecj-11349	132	13	serotonin	serotonin	VERB
ecj-11349	132	14	reuptake	reuptake	NOUN
ecj-11349	132	15	inhibitor	inhibitor	NOUN
ecj-11349	132	16	antidepressants	antidepressant	NOUN
ecj-11349	132	17	and	and	CCONJ
ecj-11349	132	18	abnormal	abnormal	ADJ
ecj-11349	132	19	bleeding	bleeding	NOUN
ecj-11349	132	20	:	:	PUNCT
ecj-11349	132	21	a	a	DET
ecj-11349	132	22	review	review	NOUN
ecj-11349	132	23	for	for	ADP
ecj-11349	132	24	clinicians	clinician	NOUN
ecj-11349	132	25	and	and	CCONJ
ecj-11349	132	26	a	a	DET
ecj-11349	132	27	reconsideration	reconsideration	NOUN
ecj-11349	132	28	of	of	ADP
ecj-11349	132	29	mechanisms	mechanism	NOUN
ecj-11349	132	30	.	.	PUNCT
ecj-11349	133	1	j	j	PROPN
ecj-11349	133	2	clin	clin	PROPN
ecj-11349	133	3	psychiat	psychiat	PROPN
ecj-11349	133	4	2010;71:1565	2010;71:1565	NUM
ecj-11349	133	5	-	-	SYM
ecj-11349	133	6	75	75	NUM
ecj-11349	133	7	.	.	PUNCT
ecj-11349	134	1	21	21	NUM
ecj-11349	134	2	.	.	PUNCT
ecj-11349	134	3	opatrny	opatrny	PROPN
ecj-11349	134	4	l	l	PROPN
ecj-11349	134	5	,	,	PUNCT
ecj-11349	134	6	delaney	delaney	PROPN
ecj-11349	134	7	ja	ja	PROPN
ecj-11349	134	8	,	,	PUNCT
ecj-11349	134	9	suissa	suissa	PROPN
ecj-11349	134	10	s.	s.	PROPN
ecj-11349	134	11	gastro	gastro	PROPN
ecj-11349	134	12	-	-	PUNCT
ecj-11349	134	13	intestinal	intestinal	ADJ
ecj-11349	134	14	haemorrhage	haemorrhage	NOUN
ecj-11349	134	15	risks	risk	NOUN
ecj-11349	134	16	of	of	ADP
ecj-11349	134	17	selective	selective	ADJ
ecj-11349	134	18	serotonin	serotonin	NOUN
ecj-11349	134	19	receptor	receptor	NOUN
ecj-11349	134	20	antagonist	antagonist	NOUN
ecj-11349	134	21	therapy	therapy	NOUN
ecj-11349	134	22	:	:	PUNCT
ecj-11349	134	23	a	a	DET
ecj-11349	134	24	new	new	ADJ
ecj-11349	134	25	look	look	NOUN
ecj-11349	134	26	.	.	PUNCT
ecj-11349	135	1	br	br	PROPN
ecj-11349	136	1	j	j	PROPN
ecj-11349	136	2	clin	clin	PROPN
ecj-11349	136	3	pharmacol	pharmacol	PROPN
ecj-11349	136	4	2008;66:76	2008;66:76	PROPN
ecj-11349	136	5	-	-	PUNCT
ecj-11349	136	6	81	81	NUM
ecj-11349	136	7	.	.	PUNCT
ecj-11349	137	1	22	22	NUM
ecj-11349	137	2	.	.	PUNCT
ecj-11349	138	1	haghbin	haghbin	PROPN
ecj-11349	138	2	h	h	PROPN
ecj-11349	138	3	,	,	PUNCT
ecj-11349	138	4	zakirkhodjaev	zakirkhodjaev	PROPN
ecj-11349	138	5	n	n	CCONJ
ecj-11349	138	6	,	,	PUNCT
ecj-11349	138	7	husain	husain	PROPN
ecj-11349	138	8	ff	ff	NOUN
ecj-11349	138	9	,	,	PUNCT
ecj-11349	138	10	et	et	PROPN
ecj-11349	138	11	al	al	PROPN
ecj-11349	138	12	.	.	PROPN
ecj-11349	138	13	risk	risk	NOUN
ecj-11349	138	14	of	of	ADP
ecj-11349	138	15	gastrointestinal	gastrointestinal	ADJ
ecj-11349	138	16	bleeding	bleeding	NOUN
ecj-11349	138	17	with	with	ADP
ecj-11349	138	18	concurrent	concurrent	ADJ
ecj-11349	138	19	use	use	NOUN
ecj-11349	138	20	of	of	ADP
ecj-11349	138	21	nsaid	nsaid	PROPN
ecj-11349	138	22	and	and	CCONJ
ecj-11349	138	23	ssri	ssri	PROPN
ecj-11349	138	24	:	:	PUNCT
ecj-11349	138	25	a	a	DET
ecj-11349	138	26	systematic	systematic	ADJ
ecj-11349	138	27	review	review	NOUN
ecj-11349	138	28	and	and	CCONJ
ecj-11349	138	29	network	network	NOUN
ecj-11349	138	30	meta	meta	ADJ
ecj-11349	138	31	-	-	PUNCT
ecj-11349	138	32	analysis	analysis	NOUN
ecj-11349	138	33	.	.	PUNCT
ecj-11349	139	1	dig	dig	VERB
ecj-11349	139	2	article	article	NOUN
ecj-11349	139	3	[	[	X
ecj-11349	139	4	emergency	emergency	NOUN
ecj-11349	139	5	care	care	NOUN
ecj-11349	139	6	journal	journal	NOUN
ecj-11349	139	7	2023	2023	NUM
ecj-11349	139	8	;	;	PUNCT
ecj-11349	139	9	19:11349	19:11349	NUM
ecj-11349	139	10	]	]	X
ecj-11349	140	1	[	[	X
ecj-11349	140	2	page	page	NOUN
ecj-11349	140	3	91	91	NUM
ecj-11349	140	4	]	]	PUNCT
ecj-11349	140	5	non	non	ADJ
ecj-11349	140	6	-co	-co	PROPN
ecj-11349	140	7	mmerc	mmerc	PROPN
ecj-11349	140	8	ial	ial	PROPN
ecj-11349	140	9	us	us	PROPN
ecj-11349	140	10	e	e	NOUN
ecj-11349	140	11	o	o	PROPN
ecj-11349	140	12	nly	nly	ADV
ecj-11349	140	13	dis	dis	PROPN
ecj-11349	140	14	sci	sci	PROPN
ecj-11349	140	15	2023;68:1975	2023;68:1975	NUM
ecj-11349	140	16	-	-	SYM
ecj-11349	140	17	1982	1982	NUM
ecj-11349	140	18	.	.	PUNCT
ecj-11349	141	1	23	23	NUM
ecj-11349	141	2	.	.	PUNCT
ecj-11349	142	1	lee	lee	PROPN
ecj-11349	142	2	mt	mt	PROPN
ecj-11349	142	3	,	,	PUNCT
ecj-11349	142	4	park	park	PROPN
ecj-11349	142	5	ky	ky	PROPN
ecj-11349	142	6	,	,	PUNCT
ecj-11349	142	7	kim	kim	PROPN
ecj-11349	142	8	ms	ms	PROPN
ecj-11349	142	9	,	,	PUNCT
ecj-11349	142	10	et	et	PROPN
ecj-11349	142	11	al	al	PROPN
ecj-11349	142	12	.	.	PUNCT
ecj-11349	143	1	concomitant	concomitant	ADJ
ecj-11349	143	2	use	use	NOUN
ecj-11349	143	3	of	of	ADP
ecj-11349	143	4	nsaids	nsaid	NOUN
ecj-11349	143	5	or	or	CCONJ
ecj-11349	143	6	ssris	ssris	NOUN
ecj-11349	143	7	with	with	ADP
ecj-11349	143	8	noacs	noac	NOUN
ecj-11349	143	9	requires	require	VERB
ecj-11349	143	10	monitoring	monitor	VERB
ecj-11349	143	11	for	for	ADP
ecj-11349	143	12	bleeding	bleeding	NOUN
ecj-11349	143	13	.	.	PUNCT
ecj-11349	144	1	yonsei	yonsei	PROPN
ecj-11349	144	2	med	med	PROPN
ecj-11349	144	3	j	j	PROPN
ecj-11349	144	4	2020;61:741	2020;61:741	NUM
ecj-11349	144	5	-	-	SYM
ecj-11349	144	6	9	9	NUM
ecj-11349	144	7	.	.	NUM
ecj-11349	144	8	24	24	NUM
ecj-11349	144	9	.	.	PUNCT
ecj-11349	145	1	wallerstedt	wallerstedt	PROPN
ecj-11349	145	2	sm	sm	PROPN
ecj-11349	145	3	,	,	PUNCT
ecj-11349	145	4	gleerup	gleerup	PROPN
ecj-11349	145	5	h	h	PROPN
ecj-11349	145	6	,	,	PUNCT
ecj-11349	145	7	sundstrom	sundstrom	NOUN
ecj-11349	145	8	a	a	PRON
ecj-11349	145	9	,	,	PUNCT
ecj-11349	145	10	et	et	PROPN
ecj-11349	145	11	al	al	PROPN
ecj-11349	145	12	.	.	PROPN
ecj-11349	145	13	risk	risk	NOUN
ecj-11349	145	14	of	of	ADP
ecj-11349	145	15	clinically	clinically	ADV
ecj-11349	145	16	relevant	relevant	ADJ
ecj-11349	145	17	bleeding	bleeding	NOUN
ecj-11349	145	18	in	in	ADP
ecj-11349	145	19	warfarin	warfarin	NOUN
ecj-11349	145	20	-	-	PUNCT
ecj-11349	145	21	treated	treat	VERB
ecj-11349	145	22	patients	patient	NOUN
ecj-11349	145	23	--	--	PUNCT
ecj-11349	145	24	influence	influence	NOUN
ecj-11349	145	25	of	of	ADP
ecj-11349	145	26	ssri	ssri	PROPN
ecj-11349	145	27	treatment	treatment	PROPN
ecj-11349	145	28	.	.	PUNCT
ecj-11349	146	1	pharmacoepidemiol	pharmacoepidemiol	NOUN
ecj-11349	146	2	drug	drug	NOUN
ecj-11349	146	3	safety	safety	NOUN
ecj-11349	146	4	2009;18:412	2009;18:412	PROPN
ecj-11349	146	5	-	-	SYM
ecj-11349	146	6	6	6	NUM
ecj-11349	146	7	.	.	NOUN
ecj-11349	146	8	25	25	NUM
ecj-11349	146	9	.	.	PUNCT
ecj-11349	147	1	quinn	quinn	PROPN
ecj-11349	147	2	gr	gr	PROPN
ecj-11349	147	3	,	,	PUNCT
ecj-11349	147	4	singer	singer	NOUN
ecj-11349	147	5	de	de	PROPN
ecj-11349	147	6	,	,	PUNCT
ecj-11349	147	7	chang	chang	PROPN
ecj-11349	147	8	y	y	PROPN
ecj-11349	147	9	,	,	PUNCT
ecj-11349	147	10	et	et	PROPN
ecj-11349	147	11	al	al	PROPN
ecj-11349	147	12	.	.	PROPN
ecj-11349	147	13	effect	effect	NOUN
ecj-11349	147	14	of	of	ADP
ecj-11349	147	15	selective	selective	ADJ
ecj-11349	147	16	serotonin	serotonin	NOUN
ecj-11349	147	17	reuptake	reuptake	NOUN
ecj-11349	147	18	inhibitors	inhibitor	NOUN
ecj-11349	147	19	on	on	ADP
ecj-11349	147	20	bleeding	bleed	VERB
ecj-11349	147	21	risk	risk	NOUN
ecj-11349	147	22	in	in	ADP
ecj-11349	147	23	patients	patient	NOUN
ecj-11349	147	24	with	with	ADP
ecj-11349	147	25	atrial	atrial	ADJ
ecj-11349	147	26	fibrillation	fibrillation	NOUN
ecj-11349	147	27	taking	take	VERB
ecj-11349	147	28	warfarin	warfarin	NOUN
ecj-11349	147	29	.	.	PUNCT
ecj-11349	148	1	am	be	AUX
ecj-11349	148	2	j	j	PROPN
ecj-11349	148	3	cardiol	cardiol	NOUN
ecj-11349	148	4	2014;114:583	2014;114:583	NUM
ecj-11349	148	5	-	-	SYM
ecj-11349	148	6	586	586	NUM
ecj-11349	148	7	.	.	NOUN
ecj-11349	148	8	26	26	NUM
ecj-11349	148	9	.	.	PUNCT
ecj-11349	149	1	hrstic	hrstic	PROPN
ecj-11349	149	2	i	i	PROPN
ecj-11349	149	3	,	,	PUNCT
ecj-11349	149	4	kalauz	kalauz	PROPN
ecj-11349	149	5	m	m	PROPN
ecj-11349	149	6	,	,	PUNCT
ecj-11349	149	7	cukovic	cukovic	NOUN
ecj-11349	149	8	-	-	PUNCT
ecj-11349	149	9	cavka	cavka	PROPN
ecj-11349	149	10	s	s	PROPN
ecj-11349	149	11	,	,	PUNCT
ecj-11349	149	12	et	et	PROPN
ecj-11349	149	13	al	al	PROPN
ecj-11349	149	14	.	.	PROPN
ecj-11349	149	15	treatment	treatment	NOUN
ecj-11349	149	16	of	of	ADP
ecj-11349	149	17	extensive	extensive	ADJ
ecj-11349	149	18	subacute	subacute	NOUN
ecj-11349	149	19	portal	portal	ADJ
ecj-11349	149	20	,	,	PUNCT
ecj-11349	149	21	mesenteric	mesenteric	ADJ
ecj-11349	149	22	and	and	CCONJ
ecj-11349	149	23	ileocolic	ileocolic	ADJ
ecj-11349	149	24	vein	vein	VERB
ecj-11349	149	25	thrombosis	thrombosis	NOUN
ecj-11349	149	26	with	with	ADP
ecj-11349	149	27	recombinant	recombinant	ADJ
ecj-11349	149	28	tissue	tissue	NOUN
ecj-11349	149	29	plasminogen	plasminogen	NOUN
ecj-11349	149	30	activator	activator	NOUN
ecj-11349	149	31	.	.	PUNCT
ecj-11349	150	1	blood	blood	NOUN
ecj-11349	150	2	coagul	coagul	NOUN
ecj-11349	150	3	fibrinolysis	fibrinolysis	VERB
ecj-11349	150	4	2007;18:581	2007;18:581	NOUN
ecj-11349	150	5	-	-	SYM
ecj-11349	150	6	3	3	NUM
ecj-11349	150	7	.	.	NOUN
ecj-11349	150	8	27	27	NUM
ecj-11349	150	9	.	.	PUNCT
ecj-11349	151	1	steffel	steffel	PROPN
ecj-11349	151	2	j	j	PROPN
ecj-11349	151	3	,	,	PUNCT
ecj-11349	151	4	verhamme	verhamme	PROPN
ecj-11349	151	5	p	p	NOUN
ecj-11349	151	6	,	,	PUNCT
ecj-11349	151	7	potpara	potpara	PROPN
ecj-11349	151	8	ts	ts	NOUN
ecj-11349	151	9	,	,	PUNCT
ecj-11349	151	10	albaladejo	albaladejo	ADJ
ecj-11349	151	11	p	p	X
ecj-11349	151	12	,	,	PUNCT
ecj-11349	151	13	antz	antz	PROPN
ecj-11349	151	14	m	m	PROPN
ecj-11349	151	15	,	,	PUNCT
ecj-11349	151	16	desteghe	desteghe	PROPN
ecj-11349	151	17	l	l	NOUN
ecj-11349	151	18	,	,	PUNCT
ecj-11349	151	19	haeusler	haeusler	PROPN
ecj-11349	151	20	kg	kg	PROPN
ecj-11349	151	21	,	,	PUNCT
ecj-11349	151	22	oldgren	oldgren	PROPN
ecj-11349	151	23	j	j	PROPN
ecj-11349	151	24	,	,	PUNCT
ecj-11349	151	25	reinecke	reinecke	VERB
ecj-11349	151	26	h	h	PROPN
ecj-11349	151	27	,	,	PUNCT
ecj-11349	151	28	roldanschilling	roldanschille	VERB
ecj-11349	151	29	v	v	ADP
ecj-11349	151	30	et	et	NOUN
ecj-11349	151	31	al	al	PROPN
ecj-11349	151	32	:	:	PUNCT
ecj-11349	152	1	[	[	X
ecj-11349	152	2	the	the	DET
ecj-11349	152	3	2018	2018	NUM
ecj-11349	152	4	european	european	ADJ
ecj-11349	152	5	heart	heart	PROPN
ecj-11349	152	6	rhythm	rhythm	PROPN
ecj-11349	152	7	association	association	PROPN
ecj-11349	152	8	practical	practical	ADJ
ecj-11349	152	9	guide	guide	NOUN
ecj-11349	152	10	on	on	ADP
ecj-11349	152	11	the	the	DET
ecj-11349	152	12	use	use	NOUN
ecj-11349	152	13	of	of	ADP
ecj-11349	152	14	non	non	ADJ
ecj-11349	152	15	-	-	ADJ
ecj-11349	152	16	vitamin	vitamin	ADJ
ecj-11349	152	17	k	k	PROPN
ecj-11349	152	18	antagonist	antagonist	NOUN
ecj-11349	152	19	oral	oral	ADJ
ecj-11349	152	20	anticoagulants	anticoagulant	NOUN
ecj-11349	152	21	in	in	ADP
ecj-11349	152	22	patients	patient	NOUN
ecj-11349	152	23	with	with	ADP
ecj-11349	152	24	atrial	atrial	ADJ
ecj-11349	152	25	fibrillation	fibrillation	NOUN
ecj-11349	152	26	:	:	PUNCT
ecj-11349	152	27	executive	executive	ADJ
ecj-11349	152	28	summary	summary	NOUN
ecj-11349	152	29	]	]	PUNCT
ecj-11349	152	30	.	.	PUNCT
ecj-11349	153	1	kardiol	kardiol	NOUN
ecj-11349	153	2	pol	pol	PROPN
ecj-11349	153	3	2018;76:1283	2018;76:1283	PROPN
ecj-11349	153	4	-	-	SYM
ecj-11349	153	5	1298	1298	NUM
ecj-11349	153	6	.	.	PUNCT
ecj-11349	154	1	28	28	NUM
ecj-11349	154	2	.	.	PUNCT
ecj-11349	155	1	brieger	brieger	PROPN
ecj-11349	155	2	d	d	PROPN
ecj-11349	155	3	,	,	PUNCT
ecj-11349	155	4	amerena	amerena	PROPN
ecj-11349	155	5	j	j	PROPN
ecj-11349	155	6	,	,	PUNCT
ecj-11349	155	7	attia	attia	PROPN
ecj-11349	155	8	j	j	PROPN
ecj-11349	155	9	,	,	PUNCT
ecj-11349	155	10	et	et	PROPN
ecj-11349	155	11	al	al	PROPN
ecj-11349	155	12	.	.	PROPN
ecj-11349	155	13	national	national	PROPN
ecj-11349	155	14	heart	heart	PROPN
ecj-11349	155	15	foundation	foundation	PROPN
ecj-11349	155	16	of	of	ADP
ecj-11349	155	17	australia	australia	PROPN
ecj-11349	155	18	and	and	CCONJ
ecj-11349	155	19	the	the	DET
ecj-11349	155	20	cardiac	cardiac	ADJ
ecj-11349	155	21	society	society	NOUN
ecj-11349	155	22	of	of	ADP
ecj-11349	155	23	australia	australia	PROPN
ecj-11349	155	24	and	and	CCONJ
ecj-11349	155	25	new	new	PROPN
ecj-11349	155	26	zealand	zealand	PROPN
ecj-11349	155	27	:	:	PUNCT
ecj-11349	155	28	australian	australian	ADJ
ecj-11349	155	29	clinical	clinical	ADJ
ecj-11349	155	30	guidelines	guideline	NOUN
ecj-11349	155	31	for	for	ADP
ecj-11349	155	32	the	the	DET
ecj-11349	155	33	diagnosis	diagnosis	NOUN
ecj-11349	155	34	and	and	CCONJ
ecj-11349	155	35	management	management	NOUN
ecj-11349	155	36	of	of	ADP
ecj-11349	155	37	atrial	atrial	ADJ
ecj-11349	155	38	fibrillation	fibrillation	NOUN
ecj-11349	155	39	2018	2018	NUM
ecj-11349	155	40	.	.	PUNCT
ecj-11349	156	1	heart	heart	NOUN
ecj-11349	156	2	lung	lung	NOUN
ecj-11349	156	3	circ	circ	PROPN
ecj-11349	156	4	2018;27:1209	2018;27:1209	NUM
ecj-11349	156	5	-	-	SYM
ecj-11349	156	6	66	66	NUM
ecj-11349	156	7	.	.	PUNCT
ecj-11349	156	8	29	29	NUM
ecj-11349	156	9	.	.	PUNCT
ecj-11349	157	1	bezabhe	bezabhe	PROPN
ecj-11349	157	2	wm	wm	PROPN
ecj-11349	157	3	,	,	PUNCT
ecj-11349	157	4	bereznicki	bereznicki	PROPN
ecj-11349	157	5	lr	lr	PROPN
ecj-11349	157	6	,	,	PUNCT
ecj-11349	157	7	radford	radford	PROPN
ecj-11349	157	8	j	j	PROPN
ecj-11349	157	9	,	,	PUNCT
ecj-11349	157	10	et	et	PROPN
ecj-11349	157	11	al	al	PROPN
ecj-11349	157	12	.	.	PROPN
ecj-11349	157	13	five	five	NUM
ecj-11349	157	14	-	-	PUNCT
ecj-11349	157	15	year	year	NOUN
ecj-11349	157	16	trends	trend	NOUN
ecj-11349	157	17	in	in	ADP
ecj-11349	157	18	potential	potential	ADJ
ecj-11349	157	19	drug	drug	NOUN
ecj-11349	157	20	interactions	interaction	NOUN
ecj-11349	157	21	with	with	ADP
ecj-11349	157	22	direct	direct	ADJ
ecj-11349	157	23	-	-	PUNCT
ecj-11349	157	24	acting	act	VERB
ecj-11349	157	25	oral	oral	ADJ
ecj-11349	157	26	anticoagulants	anticoagulant	NOUN
ecj-11349	157	27	in	in	ADP
ecj-11349	157	28	patients	patient	NOUN
ecj-11349	157	29	with	with	ADP
ecj-11349	157	30	atrial	atrial	ADJ
ecj-11349	157	31	fibrillation	fibrillation	NOUN
ecj-11349	157	32	:	:	PUNCT
ecj-11349	157	33	an	an	DET
ecj-11349	157	34	australian	australian	ADJ
ecj-11349	157	35	-	-	PUNCT
ecj-11349	157	36	wide	wide	ADJ
ecj-11349	157	37	study	study	NOUN
ecj-11349	157	38	.	.	PUNCT
ecj-11349	158	1	j	j	PROPN
ecj-11349	158	2	clin	clin	PROPN
ecj-11349	158	3	med	med	PROPN
ecj-11349	158	4	2020;9	2020;9	NOUN
ecj-11349	158	5	.	.	PUNCT
ecj-11349	159	1	30	30	NUM
ecj-11349	159	2	.	.	PUNCT
ecj-11349	160	1	forbes	forbes	PROPN
ecj-11349	160	2	hl	hl	PROPN
ecj-11349	160	3	,	,	PUNCT
ecj-11349	160	4	polasek	polasek	PROPN
ecj-11349	160	5	tm	tm	PROPN
ecj-11349	160	6	.	.	PROPN
ecj-11349	160	7	potential	potential	ADJ
ecj-11349	160	8	drug	drug	NOUN
ecj-11349	160	9	-	-	PUNCT
ecj-11349	160	10	drug	drug	NOUN
ecj-11349	160	11	interactions	interaction	NOUN
ecj-11349	160	12	with	with	ADP
ecj-11349	160	13	direct	direct	ADJ
ecj-11349	160	14	oral	oral	ADJ
ecj-11349	160	15	anticoagulants	anticoagulant	NOUN
ecj-11349	160	16	in	in	ADP
ecj-11349	160	17	elderly	elderly	ADJ
ecj-11349	160	18	hospitalized	hospitalize	VERB
ecj-11349	160	19	patients	patient	NOUN
ecj-11349	160	20	.	.	PUNCT
ecj-11349	161	1	ther	ther	VERB
ecj-11349	161	2	adv	adv	PROPN
ecj-11349	161	3	drug	drug	PROPN
ecj-11349	161	4	saf	saf	PROPN
ecj-11349	161	5	2017;8:319	2017;8:319	PROPN
ecj-11349	161	6	-	-	PUNCT
ecj-11349	161	7	328	328	NUM
ecj-11349	161	8	.	.	PUNCT
ecj-11349	162	1	31	31	NUM
ecj-11349	162	2	.	.	PUNCT
ecj-11349	163	1	zhang	zhang	PROPN
ecj-11349	163	2	y	y	PROPN
ecj-11349	163	3	,	,	PUNCT
ecj-11349	163	4	souverein	souverein	PROPN
ecj-11349	163	5	pc	pc	PROPN
ecj-11349	163	6	,	,	PUNCT
ecj-11349	163	7	gardarsdottir	gardarsdottir	PROPN
ecj-11349	163	8	h	h	NOUN
ecj-11349	163	9	,	,	PUNCT
ecj-11349	163	10	et	et	PROPN
ecj-11349	163	11	al	al	PROPN
ecj-11349	163	12	.	.	PROPN
ecj-11349	163	13	risk	risk	NOUN
ecj-11349	163	14	of	of	ADP
ecj-11349	163	15	major	major	ADJ
ecj-11349	163	16	bleeding	bleeding	NOUN
ecj-11349	163	17	among	among	ADP
ecj-11349	163	18	users	user	NOUN
ecj-11349	163	19	of	of	ADP
ecj-11349	163	20	direct	direct	ADJ
ecj-11349	163	21	oral	oral	ADJ
ecj-11349	163	22	anticoagulants	anticoagulant	NOUN
ecj-11349	163	23	combined	combine	VERB
ecj-11349	163	24	with	with	ADP
ecj-11349	163	25	interacting	interact	VERB
ecj-11349	163	26	drugs	drug	NOUN
ecj-11349	163	27	:	:	PUNCT
ecj-11349	163	28	a	a	DET
ecj-11349	163	29	population	population	NOUN
ecj-11349	163	30	-	-	PUNCT
ecj-11349	163	31	based	base	VERB
ecj-11349	163	32	nested	nested	ADJ
ecj-11349	163	33	case	case	NOUN
ecj-11349	163	34	-	-	PUNCT
ecj-11349	163	35	control	control	NOUN
ecj-11349	163	36	study	study	NOUN
ecj-11349	163	37	.	.	PUNCT
ecj-11349	164	1	br	br	PROPN
ecj-11349	165	1	j	j	PROPN
ecj-11349	165	2	clin	clin	PROPN
ecj-11349	165	3	pharmacol	pharmacol	PROPN
ecj-11349	165	4	2020;86:1150	2020;86:1150	PROPN
ecj-11349	165	5	-	-	PUNCT
ecj-11349	165	6	64	64	NUM
ecj-11349	165	7	.	.	PUNCT
ecj-11349	165	8	32	32	NUM
ecj-11349	165	9	.	.	PUNCT
ecj-11349	166	1	quinn	quinn	PROPN
ecj-11349	166	2	gr	gr	PROPN
ecj-11349	166	3	,	,	PUNCT
ecj-11349	166	4	hellkamp	hellkamp	NOUN
ecj-11349	166	5	as	as	ADP
ecj-11349	166	6	,	,	PUNCT
ecj-11349	166	7	hankey	hankey	PROPN
ecj-11349	166	8	gj	gj	PROPN
ecj-11349	166	9	,	,	PUNCT
ecj-11349	166	10	et	et	PROPN
ecj-11349	166	11	al	al	PROPN
ecj-11349	166	12	.	.	PROPN
ecj-11349	167	1	selective	selective	ADJ
ecj-11349	167	2	serotonin	serotonin	NOUN
ecj-11349	167	3	reuptake	reuptake	NOUN
ecj-11349	167	4	inhibitors	inhibitor	NOUN
ecj-11349	167	5	and	and	CCONJ
ecj-11349	167	6	bleeding	bleed	VERB
ecj-11349	167	7	risk	risk	NOUN
ecj-11349	167	8	in	in	ADP
ecj-11349	167	9	anticoagulated	anticoagulate	VERB
ecj-11349	167	10	patients	patient	NOUN
ecj-11349	167	11	with	with	ADP
ecj-11349	167	12	atrial	atrial	ADJ
ecj-11349	167	13	fibrillation	fibrillation	NOUN
ecj-11349	167	14	:	:	PUNCT
ecj-11349	167	15	an	an	DET
ecj-11349	167	16	analysis	analysis	NOUN
ecj-11349	167	17	from	from	ADP
ecj-11349	167	18	the	the	DET
ecj-11349	167	19	rocket	rocket	NOUN
ecj-11349	167	20	af	af	NOUN
ecj-11349	167	21	trial	trial	NOUN
ecj-11349	167	22	.	.	PUNCT
ecj-11349	168	1	j	j	PROPN
ecj-11349	168	2	am	be	AUX
ecj-11349	168	3	heart	heart	NOUN
ecj-11349	168	4	assoc	assoc	PROPN
ecj-11349	168	5	2018;7	2018;7	PROPN
ecj-11349	168	6	:	:	PUNCT
ecj-11349	169	1	e008755	e008755	NOUN
ecj-11349	169	2	.	.	NOUN
ecj-11349	169	3	33	33	NUM
ecj-11349	169	4	.	.	PUNCT
ecj-11349	170	1	ahsberg	ahsberg	PROPN
ecj-11349	170	2	k	k	PROPN
ecj-11349	170	3	,	,	PUNCT
ecj-11349	170	4	hoglund	hoglund	NOUN
ecj-11349	170	5	p	p	X
ecj-11349	170	6	,	,	PUNCT
ecj-11349	170	7	kim	kim	PROPN
ecj-11349	170	8	wh	wh	PROPN
ecj-11349	170	9	,	,	PUNCT
ecj-11349	170	10	von	von	PROPN
ecj-11349	170	11	holstein	holstein	PROPN
ecj-11349	170	12	cs	cs	PROPN
ecj-11349	170	13	.	.	PROPN
ecj-11349	170	14	impact	impact	NOUN
ecj-11349	170	15	of	of	ADP
ecj-11349	170	16	aspirin	aspirin	NOUN
ecj-11349	170	17	,	,	PUNCT
ecj-11349	170	18	nsaids	nsaid	NOUN
ecj-11349	170	19	,	,	PUNCT
ecj-11349	170	20	warfarin	warfarin	NOUN
ecj-11349	170	21	,	,	PUNCT
ecj-11349	170	22	corticosteroids	corticosteroid	NOUN
ecj-11349	170	23	and	and	CCONJ
ecj-11349	170	24	ssris	ssris	NOUN
ecj-11349	170	25	on	on	ADP
ecj-11349	170	26	the	the	DET
ecj-11349	170	27	site	site	NOUN
ecj-11349	170	28	and	and	CCONJ
ecj-11349	170	29	outcome	outcome	NOUN
ecj-11349	170	30	of	of	ADP
ecj-11349	170	31	non	non	ADJ
ecj-11349	170	32	-	-	ADJ
ecj-11349	170	33	variceal	variceal	ADJ
ecj-11349	170	34	upper	upper	ADJ
ecj-11349	170	35	and	and	CCONJ
ecj-11349	170	36	lower	low	ADJ
ecj-11349	170	37	gastrointestinal	gastrointestinal	ADJ
ecj-11349	170	38	bleeding	bleeding	NOUN
ecj-11349	170	39	.	.	PUNCT
ecj-11349	171	1	scand	scand	PROPN
ecj-11349	171	2	j	j	PROPN
ecj-11349	171	3	gastroenterol	gastroenterol	PROPN
ecj-11349	171	4	2010;45:1404	2010;45:1404	PROPN
ecj-11349	171	5	-	-	SYM
ecj-11349	171	6	15	15	NUM
ecj-11349	171	7	.	.	PUNCT
ecj-11349	171	8	34	34	NUM
ecj-11349	171	9	.	.	PUNCT
ecj-11349	172	1	wang	wang	PROPN
ecj-11349	172	2	y	y	PROPN
ecj-11349	172	3	,	,	PUNCT
ecj-11349	172	4	zhang	zhang	PROPN
ecj-11349	172	5	h	h	PROPN
ecj-11349	172	6	,	,	PUNCT
ecj-11349	172	7	chai	chai	NOUN
ecj-11349	172	8	f	f	X
ecj-11349	172	9	,	,	PUNCT
ecj-11349	172	10	et	et	PROPN
ecj-11349	172	11	al	al	PROPN
ecj-11349	172	12	.	.	PUNCT
ecj-11349	173	1	the	the	DET
ecj-11349	173	2	effects	effect	NOUN
ecj-11349	173	3	of	of	ADP
ecj-11349	173	4	escitalopram	escitalopram	PROPN
ecj-11349	173	5	on	on	ADP
ecj-11349	173	6	myocardial	myocardial	ADJ
ecj-11349	173	7	apoptosis	apoptosis	NOUN
ecj-11349	173	8	and	and	CCONJ
ecj-11349	173	9	the	the	DET
ecj-11349	173	10	expression	expression	NOUN
ecj-11349	173	11	of	of	ADP
ecj-11349	173	12	bax	bax	PROPN
ecj-11349	173	13	and	and	CCONJ
ecj-11349	173	14	bcl-2	bcl-2	PUNCT
ecj-11349	173	15	during	during	ADP
ecj-11349	173	16	myocardial	myocardial	ADJ
ecj-11349	173	17	ischemia	ischemia	NOUN
ecj-11349	173	18	/	/	SYM
ecj-11349	173	19	reperfusion	reperfusion	NOUN
ecj-11349	173	20	in	in	ADP
ecj-11349	173	21	a	a	DET
ecj-11349	173	22	model	model	NOUN
ecj-11349	173	23	of	of	ADP
ecj-11349	173	24	rats	rat	NOUN
ecj-11349	173	25	with	with	ADP
ecj-11349	173	26	depression	depression	NOUN
ecj-11349	173	27	.	.	PUNCT
ecj-11349	174	1	bmc	bmc	ADJ
ecj-11349	174	2	psychiatry	psychiatry	NOUN
ecj-11349	174	3	2014;14:349	2014;14:349	PROPN
ecj-11349	174	4	.	.	PROPN
ecj-11349	174	5	35	35	NUM
ecj-11349	174	6	.	.	PUNCT
ecj-11349	175	1	jiang	jiang	PROPN
ecj-11349	175	2	w	w	PROPN
ecj-11349	175	3	,	,	PUNCT
ecj-11349	175	4	velazquez	velazquez	PROPN
ecj-11349	175	5	ej	ej	PROPN
ecj-11349	175	6	,	,	PUNCT
ecj-11349	175	7	kuchibhatla	kuchibhatla	PROPN
ecj-11349	175	8	m	m	PROPN
ecj-11349	175	9	,	,	PUNCT
ecj-11349	175	10	et	et	PROPN
ecj-11349	175	11	al	al	PROPN
ecj-11349	175	12	.	.	PROPN
ecj-11349	175	13	effect	effect	NOUN
ecj-11349	175	14	of	of	ADP
ecj-11349	175	15	escitalopram	escitalopram	PROPN
ecj-11349	175	16	on	on	ADP
ecj-11349	175	17	mental	mental	ADJ
ecj-11349	175	18	stress	stress	NOUN
ecj-11349	175	19	-	-	PUNCT
ecj-11349	175	20	induced	induce	VERB
ecj-11349	175	21	myocardial	myocardial	ADJ
ecj-11349	175	22	ischemia	ischemia	NOUN
ecj-11349	175	23	:	:	PUNCT
ecj-11349	175	24	results	result	NOUN
ecj-11349	175	25	of	of	ADP
ecj-11349	175	26	the	the	DET
ecj-11349	175	27	remit	remit	NOUN
ecj-11349	175	28	trial	trial	NOUN
ecj-11349	175	29	.	.	PUNCT
ecj-11349	176	1	jama	jama	PROPN
ecj-11349	176	2	2013;309:2139	2013;309:2139	NUM
ecj-11349	176	3	-	-	SYM
ecj-11349	176	4	49	49	NUM
ecj-11349	176	5	.	.	PUNCT
ecj-11349	177	1	36	36	NUM
ecj-11349	177	2	.	.	PUNCT
ecj-11349	178	1	ziegelstein	ziegelstein	PROPN
ecj-11349	178	2	rc	rc	PROPN
ecj-11349	178	3	,	,	PUNCT
ecj-11349	178	4	meuchel	meuchel	PROPN
ecj-11349	178	5	j	j	PROPN
ecj-11349	178	6	,	,	PUNCT
ecj-11349	178	7	kim	kim	PROPN
ecj-11349	178	8	tj	tj	PROPN
ecj-11349	178	9	,	,	PUNCT
ecj-11349	178	10	et	et	PROPN
ecj-11349	178	11	al	al	PROPN
ecj-11349	178	12	.	.	PROPN
ecj-11349	178	13	selective	selective	ADJ
ecj-11349	178	14	serotonin	serotonin	NOUN
ecj-11349	178	15	reuptake	reuptake	NOUN
ecj-11349	178	16	inhibitor	inhibitor	NOUN
ecj-11349	178	17	use	use	NOUN
ecj-11349	178	18	by	by	ADP
ecj-11349	178	19	patients	patient	NOUN
ecj-11349	178	20	with	with	ADP
ecj-11349	178	21	acute	acute	ADJ
ecj-11349	178	22	coronary	coronary	ADJ
ecj-11349	178	23	syndromes	syndrome	NOUN
ecj-11349	178	24	.	.	PUNCT
ecj-11349	178	25	am	be	AUX
ecj-11349	178	26	j	j	PROPN
ecj-11349	178	27	med	med	ADJ
ecj-11349	178	28	2007;120:525	2007;120:525	NUM
ecj-11349	178	29	-	-	SYM
ecj-11349	178	30	530	530	NUM
ecj-11349	178	31	.	.	PUNCT
ecj-11349	179	1	37	37	NUM
ecj-11349	179	2	.	.	PUNCT
ecj-11349	180	1	mathews	mathews	PROPN
ecj-11349	180	2	mj	mj	PROPN
ecj-11349	180	3	,	,	PUNCT
ecj-11349	180	4	mathews	mathews	PROPN
ecj-11349	180	5	eh	eh	INTJ
ecj-11349	180	6	,	,	PUNCT
ecj-11349	180	7	liebenberg	liebenberg	ADV
ecj-11349	180	8	l.	l.	PROPN
ecj-11349	180	9	the	the	DET
ecj-11349	180	10	mechanisms	mechanism	NOUN
ecj-11349	180	11	by	by	ADP
ecj-11349	180	12	which	which	DET
ecj-11349	180	13	antidepressants	antidepressant	NOUN
ecj-11349	180	14	may	may	AUX
ecj-11349	180	15	reduce	reduce	VERB
ecj-11349	180	16	coronary	coronary	ADJ
ecj-11349	180	17	heart	heart	NOUN
ecj-11349	180	18	disease	disease	NOUN
ecj-11349	180	19	risk	risk	NOUN
ecj-11349	180	20	.	.	PUNCT
ecj-11349	181	1	bmc	bmc	PROPN
ecj-11349	181	2	cardiovasc	cardiovasc	PROPN
ecj-11349	181	3	dis	dis	PROPN
ecj-11349	181	4	2015;15:82	2015;15:82	NUM
ecj-11349	181	5	.	.	PUNCT
ecj-11349	182	1	38	38	NUM
ecj-11349	182	2	.	.	PUNCT
ecj-11349	183	1	fernandes	fernandes	PROPN
ecj-11349	183	2	n	n	CCONJ
ecj-11349	183	3	,	,	PUNCT
ecj-11349	183	4	prada	prada	PROPN
ecj-11349	183	5	l	l	NOUN
ecj-11349	183	6	,	,	PUNCT
ecj-11349	183	7	rosa	rosa	PROPN
ecj-11349	183	8	mm	mm	PROPN
ecj-11349	183	9	,	,	PUNCT
ecj-11349	183	10	et	et	PROPN
ecj-11349	183	11	al	al	PROPN
ecj-11349	183	12	.	.	PUNCT
ecj-11349	184	1	the	the	DET
ecj-11349	184	2	impact	impact	NOUN
ecj-11349	184	3	of	of	ADP
ecj-11349	184	4	ssris	ssris	NOUN
ecj-11349	184	5	on	on	ADP
ecj-11349	184	6	mortality	mortality	NOUN
ecj-11349	184	7	and	and	CCONJ
ecj-11349	184	8	cardiovascular	cardiovascular	ADJ
ecj-11349	184	9	events	event	NOUN
ecj-11349	184	10	in	in	ADP
ecj-11349	184	11	patients	patient	NOUN
ecj-11349	184	12	with	with	ADP
ecj-11349	184	13	coronary	coronary	ADJ
ecj-11349	184	14	artery	artery	NOUN
ecj-11349	184	15	disease	disease	NOUN
ecj-11349	184	16	and	and	CCONJ
ecj-11349	184	17	depression	depression	NOUN
ecj-11349	184	18	:	:	PUNCT
ecj-11349	184	19	systematic	systematic	ADJ
ecj-11349	184	20	review	review	NOUN
ecj-11349	184	21	and	and	CCONJ
ecj-11349	184	22	meta	meta	ADJ
ecj-11349	184	23	-	-	PUNCT
ecj-11349	184	24	analysis	analysis	NOUN
ecj-11349	184	25	.	.	PUNCT
ecj-11349	185	1	clin	clin	PROPN
ecj-11349	185	2	res	res	PROPN
ecj-11349	185	3	cardiol	cardiol	NOUN
ecj-11349	185	4	2021;110:183	2021;110:183	NUM
ecj-11349	185	5	-	-	SYM
ecj-11349	185	6	93	93	NUM
ecj-11349	185	7	.	.	PUNCT
ecj-11349	186	1	39	39	NUM
ecj-11349	186	2	.	.	PUNCT
ecj-11349	187	1	iasella	iasella	NOUN
ecj-11349	187	2	cj	cj	PROPN
ecj-11349	187	3	,	,	PUNCT
ecj-11349	187	4	kreider	kreider	PROPN
ecj-11349	187	5	ms	ms	PROPN
ecj-11349	187	6	,	,	PUNCT
ecj-11349	187	7	huang	huang	PROPN
ecj-11349	187	8	l	l	PROPN
ecj-11349	187	9	,	,	PUNCT
ecj-11349	187	10	et	et	PROPN
ecj-11349	187	11	al	al	PROPN
ecj-11349	187	12	.	.	PROPN
ecj-11349	187	13	effect	effect	NOUN
ecj-11349	187	14	of	of	ADP
ecj-11349	187	15	selective	selective	ADJ
ecj-11349	187	16	serotonin	serotonin	NOUN
ecj-11349	187	17	reuptake	reuptake	NOUN
ecj-11349	187	18	inhibitors	inhibitor	NOUN
ecj-11349	187	19	on	on	ADP
ecj-11349	187	20	cardiovascular	cardiovascular	ADJ
ecj-11349	187	21	outcomes	outcome	NOUN
ecj-11349	187	22	after	after	ADP
ecj-11349	187	23	percutaneous	percutaneous	ADJ
ecj-11349	187	24	coronary	coronary	ADJ
ecj-11349	187	25	intervention	intervention	NOUN
ecj-11349	187	26	:	:	PUNCT
ecj-11349	187	27	a	a	DET
ecj-11349	187	28	retrospective	retrospective	ADJ
ecj-11349	187	29	cohort	cohort	NOUN
ecj-11349	187	30	study	study	NOUN
ecj-11349	187	31	.	.	PUNCT
ecj-11349	188	1	clin	clin	PROPN
ecj-11349	188	2	drug	drug	PROPN
ecj-11349	188	3	investig	investig	PROPN
ecj-11349	188	4	2019;39:543	2019;39:543	PROPN
ecj-11349	188	5	-	-	SYM
ecj-11349	188	6	51	51	NUM
ecj-11349	188	7	.	.	NOUN
ecj-11349	188	8	40	40	NUM
ecj-11349	188	9	.	.	PUNCT
ecj-11349	189	1	pizzi	pizzi	PROPN
ecj-11349	189	2	c	c	PROPN
ecj-11349	189	3	,	,	PUNCT
ecj-11349	189	4	mancini	mancini	PROPN
ecj-11349	189	5	s	s	PROPN
ecj-11349	189	6	,	,	PUNCT
ecj-11349	189	7	angeloni	angeloni	ADJ
ecj-11349	189	8	l	l	NOUN
ecj-11349	189	9	,	,	PUNCT
ecj-11349	189	10	et	et	PROPN
ecj-11349	189	11	al	al	PROPN
ecj-11349	189	12	.	.	PUNCT
ecj-11349	189	13	effects	effect	NOUN
ecj-11349	189	14	of	of	ADP
ecj-11349	189	15	selective	selective	ADJ
ecj-11349	189	16	serotonin	serotonin	NOUN
ecj-11349	189	17	reuptake	reuptake	NOUN
ecj-11349	189	18	inhibitor	inhibitor	NOUN
ecj-11349	189	19	therapy	therapy	NOUN
ecj-11349	189	20	on	on	ADP
ecj-11349	189	21	endothelial	endothelial	ADJ
ecj-11349	189	22	function	function	NOUN
ecj-11349	189	23	and	and	CCONJ
ecj-11349	189	24	inflammatory	inflammatory	ADJ
ecj-11349	189	25	markers	marker	NOUN
ecj-11349	189	26	in	in	ADP
ecj-11349	189	27	patients	patient	NOUN
ecj-11349	189	28	with	with	ADP
ecj-11349	189	29	coronary	coronary	ADJ
ecj-11349	189	30	heart	heart	NOUN
ecj-11349	189	31	disease	disease	NOUN
ecj-11349	189	32	.	.	PUNCT
ecj-11349	190	1	clin	clin	PROPN
ecj-11349	190	2	pharmacol	pharmacol	PROPN
ecj-11349	190	3	ther	ther	PROPN
ecj-11349	190	4	2009;86:527	2009;86:527	PROPN
ecj-11349	190	5	-	-	SYM
ecj-11349	190	6	32	32	NUM
ecj-11349	190	7	.	.	PUNCT
ecj-11349	191	1	41	41	NUM
ecj-11349	191	2	.	.	PUNCT
ecj-11349	192	1	almuwaqqat	almuwaqqat	PROPN
ecj-11349	192	2	z	z	PROPN
ecj-11349	192	3	,	,	PUNCT
ecj-11349	192	4	jokhadar	jokhadar	PROPN
ecj-11349	192	5	m	m	PROPN
ecj-11349	192	6	,	,	PUNCT
ecj-11349	192	7	norby	norby	PROPN
ecj-11349	192	8	fl	fl	PROPN
ecj-11349	192	9	,	,	PUNCT
ecj-11349	192	10	et	et	PROPN
ecj-11349	192	11	al	al	PROPN
ecj-11349	192	12	.	.	PROPN
ecj-11349	192	13	association	association	PROPN
ecj-11349	192	14	of	of	ADP
ecj-11349	192	15	antidepressant	antidepressant	ADJ
ecj-11349	192	16	medication	medication	NOUN
ecj-11349	192	17	type	type	NOUN
ecj-11349	192	18	with	with	ADP
ecj-11349	192	19	the	the	DET
ecj-11349	192	20	incidence	incidence	NOUN
ecj-11349	192	21	of	of	ADP
ecj-11349	192	22	cardiovascular	cardiovascular	ADJ
ecj-11349	192	23	disease	disease	NOUN
ecj-11349	192	24	in	in	ADP
ecj-11349	192	25	the	the	DET
ecj-11349	192	26	aric	aric	PROPN
ecj-11349	192	27	study	study	NOUN
ecj-11349	192	28	.	.	PUNCT
ecj-11349	193	1	j	j	PROPN
ecj-11349	193	2	am	be	AUX
ecj-11349	193	3	heart	heart	NOUN
ecj-11349	193	4	assoc	assoc	PROPN
ecj-11349	193	5	2019;8	2019;8	PROPN
ecj-11349	193	6	:	:	PUNCT
ecj-11349	193	7	e012503	e012503	NUM
ecj-11349	193	8	.	.	PUNCT
ecj-11349	194	1	42	42	NUM
ecj-11349	194	2	.	.	PUNCT
ecj-11349	195	1	kim	kim	PROPN
ecj-11349	195	2	jh	jh	PROPN
ecj-11349	195	3	,	,	PUNCT
ecj-11349	195	4	song	song	PROPN
ecj-11349	195	5	yk	yk	PROPN
ecj-11349	195	6	,	,	PUNCT
ecj-11349	195	7	jang	jang	PROPN
ecj-11349	195	8	hy	hy	PROPN
ecj-11349	195	9	,	,	PUNCT
ecj-11349	195	10	et	et	PROPN
ecj-11349	195	11	al	al	PROPN
ecj-11349	195	12	.	.	PUNCT
ecj-11349	196	1	major	major	ADJ
ecj-11349	196	2	adverse	adverse	ADJ
ecj-11349	196	3	cardiovascular	cardiovascular	ADJ
ecj-11349	196	4	events	event	NOUN
ecj-11349	196	5	in	in	ADP
ecj-11349	196	6	antidepressant	antidepressant	ADJ
ecj-11349	196	7	users	user	NOUN
ecj-11349	196	8	within	within	ADP
ecj-11349	196	9	patients	patient	NOUN
ecj-11349	196	10	with	with	ADP
ecj-11349	196	11	ischemic	ischemic	ADJ
ecj-11349	196	12	heart	heart	NOUN
ecj-11349	196	13	diseases	disease	NOUN
ecj-11349	196	14	:	:	PUNCT
ecj-11349	196	15	a	a	DET
ecj-11349	196	16	nationwide	nationwide	ADJ
ecj-11349	196	17	cohort	cohort	NOUN
ecj-11349	196	18	study	study	NOUN
ecj-11349	196	19	.	.	PUNCT
ecj-11349	197	1	j	j	PROPN
ecj-11349	197	2	clin	clin	PROPN
ecj-11349	197	3	psychopharmacol	psychopharmacol	PROPN
ecj-11349	197	4	2020;40:475	2020;40:475	PROPN
ecj-11349	197	5	-	-	SYM
ecj-11349	197	6	81	81	NUM
ecj-11349	197	7	.	.	PUNCT
ecj-11349	197	8	43	43	NUM
ecj-11349	197	9	.	.	PUNCT
ecj-11349	198	1	park	park	PROPN
ecj-11349	198	2	k	k	PROPN
ecj-11349	198	3	,	,	PUNCT
ecj-11349	198	4	kim	kim	PROPN
ecj-11349	198	5	s	s	PROPN
ecj-11349	198	6	,	,	PUNCT
ecj-11349	198	7	ko	ko	PROPN
ecj-11349	198	8	yj	yj	PROPN
ecj-11349	198	9	,	,	PUNCT
ecj-11349	198	10	park	park	NOUN
ecj-11349	198	11	bj	bj	NOUN
ecj-11349	198	12	.	.	PUNCT
ecj-11349	198	13	comparison	comparison	NOUN
ecj-11349	198	14	of	of	ADP
ecj-11349	198	15	risk	risk	NOUN
ecj-11349	198	16	of	of	ADP
ecj-11349	198	17	cardiovascular	cardiovascular	ADJ
ecj-11349	198	18	disease	disease	NOUN
ecj-11349	198	19	related	relate	VERB
ecj-11349	198	20	adverse	adverse	ADJ
ecj-11349	198	21	events	event	NOUN
ecj-11349	198	22	between	between	ADP
ecj-11349	198	23	selective	selective	ADJ
ecj-11349	198	24	serotonin	serotonin	NOUN
ecj-11349	198	25	reuptake	reuptake	NOUN
ecj-11349	198	26	inhibitor	inhibitor	NOUN
ecj-11349	198	27	users	user	NOUN
ecj-11349	198	28	and	and	CCONJ
ecj-11349	198	29	serotonin	serotonin	VERB
ecj-11349	198	30	norepinephrine	norepinephrine	ADJ
ecj-11349	198	31	reuptake	reuptake	NOUN
ecj-11349	198	32	inhibitor	inhibitor	NOUN
ecj-11349	198	33	users	user	NOUN
ecj-11349	198	34	in	in	ADP
ecj-11349	198	35	korean	korean	ADJ
ecj-11349	198	36	adult	adult	NOUN
ecj-11349	198	37	patients	patient	NOUN
ecj-11349	198	38	with	with	ADP
ecj-11349	198	39	depression	depression	NOUN
ecj-11349	198	40	:	:	PUNCT
ecj-11349	198	41	retrospective	retrospective	ADJ
ecj-11349	198	42	cohort	cohort	NOUN
ecj-11349	198	43	study	study	NOUN
ecj-11349	198	44	.	.	PUNCT
ecj-11349	199	1	psychiatry	psychiatry	NOUN
ecj-11349	199	2	res	re	NOUN
ecj-11349	199	3	2021;298	2021;298	NUM
ecj-11349	199	4	:	:	PUNCT
ecj-11349	199	5	113744	113744	NUM
ecj-11349	199	6	.	.	PUNCT
ecj-11349	200	1	article	article	NOUN
ecj-11349	200	2	[	[	X
ecj-11349	200	3	page	page	NOUN
ecj-11349	200	4	92	92	NUM
ecj-11349	200	5	]	]	PUNCT
ecj-11349	201	1	[	[	X
ecj-11349	201	2	emergency	emergency	NOUN
ecj-11349	201	3	care	care	NOUN
ecj-11349	201	4	journal	journal	NOUN
ecj-11349	201	5	2023	2023	NUM
ecj-11349	201	6	;	;	PUNCT
ecj-11349	201	7	19:11349	19:11349	NUM
ecj-11349	201	8	]	]	X
ecj-11349	201	9	non	non	ADJ
ecj-11349	201	10	-co	-co	PROPN
ecj-11349	201	11	mmerc	mmerc	PROPN
ecj-11349	201	12	ial	ial	PROPN
ecj-11349	201	13	us	us	PROPN
ecj-11349	201	14	e	e	NOUN
ecj-11349	201	15	o	o	NOUN
ecj-11349	201	16	nly	nly	ADV